

# **Funding Opportunities Monthly Edition July 2022 Due Dates**

#### <u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in July 2022. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
105645		ging and Fluid-Based Tumor er Therapy (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-21-290	07-May-2022	499,999 USD			
	Contact Name	Shane Woodward							
	Contact Telephone	240-276-6624							
	Contact Email	woodwars@mail.nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2022 , 05-Jun-2022 , 05-Jul-2022 , 07-Sep-2022 , 05-Oct-2022 , 05-Nov-2022 , 07-Jan-2023 , 05-Feb-2023 , 05-Mar- 2023 , 07-May-2023 , 05-Jun-2023 , 05-Jul-2023 , 07-Sep-2023 , 05-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 05- Mar-2024 , 07-May-2024 , 05-Jun-2024 , 05-Jul-2024 , 07-Sep-2024							
	Synopsis	National Cancer Institute (NCI) invit monitoring (liquid biopsy) assays dur characterization of therapy response award mechanism.	ing cancer therapy in patier	nts to determine the optir	mal use of those mod	dalities in the			
106036		nterest (NOSI): Advancing the umor Site-Activated Small Molecules	National Cancer Institute/NIH/DHHS	NOT-CA-21-101	07-May-2022	Not Specified			
	Contact Name	Sharad K. Verma, PhD							
	Contact Telephone	202-657-3694							
	Contact Email	sharad.verma@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	07-May-2022, 26-May-2022, 05-Jun 2022, 25-Oct-2022, 07-Jan-2023, 26- 25-Jun-2023, 07-Sep-2023, 26-Sep-2 2024, 16-Jun-2024, 07-Sep-2024	5-Jan-2023 , 05-Feb-2023 , 2	25-Feb-2023 , 07-May-202	23 , 26-May-2023 , 05	5-Jun-2023 ,			
	Synopsis	This Notice of Special Interest (NOSI) (DCTD) to support investigation of the	seeks to highlight the inter e development of novel the	est of NCI's Division of Ca erapies for cancer-applied	ncer Treatment and research encompas	Diagnosis sing chemistry			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		ology disciplines to support tes for eventual translation to	the discovery and testing of n the clinic.	ovel therapeutics offerin	g improved safety and	d efficacy
106733	Notice of Special Interest Nutrient Sensing Pathway Prevention	(NOSI): Dietary Effects on ys in Tumor Etiology and	National Cancer Institute/NIH/DHHS	NOT-CA-21-121	07-May-2022	Not Specified
	Contact Name Phillip	J. Daschner, MSc				
	Contact Telephone 240-2	76-6227				
	Contact Email pd93u	<u>@nih.gov</u>				
	Sponsor Website					
	Program URL <u>Link to</u>	program URL				
	Deadline Dates (ALL) Feb-20 2023 , Feb-20	023 , 25-Feb-2023 , 26-Apr-20 , 26-Sep-2023 , 05-Oct-2023 , 024 , 07-May-2024 , 05-Jun-2	12-Oct-2022, 25-Oct-2022, 023, 07-May-2023, 26-May-12-Oct-2023, 25-Oct-2023, 024, 12-Jun-2024, 25-Jun-20	2023 , 05-Jun-2023 , 12-J 28-Dec-2023 , 07-Jan-20 024 , 07-Sep-2024	un-2023 , 25-Jun-2023 24 , 05-Feb-2024 , 12-	3 , 07-Sep- Feb-2024 , 25-
	Synopsis dietar from 6	standing of the biology and n gearly tumor development. S y modulation of nutrient sen	SI) seeks to support new and nolecular mechanisms that deposite that examine sor signaling pathways during ll, organoid, and animal mode	etermine the outcome of line the tumor preventive g early tumor formation (	f key diet/nutrient/cel e or tumor-promoting initiation and maligna	I interactions effects of ant progression
106282	Mechanisms that Impact Surgery (R01 Clinical Trial	Cancer Risk after Bariatric Optional)	National Cancer Institute/NIH/DHHS	PAR-21-331	05-Jun-2022	2,500,000 USD
	Contact Name Edwar	d R. Sauter, M.D., Ph.D.				
	Contact Telephone 240-2	76-7657				
	Contact Email edwar	d.sauter@nih.gov				
	Sponsor Website					
	Program URL <u>Link to</u>	program URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		5-Jun-2022 , 05-Jul-2022 , 05-Oct-20 023 , 05-Nov-2023 , 05-Feb-2024 , 05			un-2023 , 05-Jul-202	3 , 05-Oct-
	Synopsis of ta	hrough this Funding Opportunity And f investigator-initiated studies addre alented scientists who study bariatric s weight loss and diabetes.	ssing mechanisms by which	n bariatric surgery impacts	cancer risk, and see	ks to draw ir
106261	Basic Research in Cal Trial Not Allowed)	ncer Health Disparities (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21-322	05-Jun-2022	Not Specified
	Contact Name A	nu Sharman, Ph.D.				
	Contact Telephone 24	40-276-6250				
	Contact Email st	narmananu@nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
		5-Jun-2022 , 05-Jul-2022 , 05-Oct-20 023 , 05-Nov-2023 , 05-Feb-2024 , 05			un-2023 , 05-Jul-202	3 , 05-Oct-
	in st fa Synopsis st al ex de	ational Cancer Institute (NCI) invites ito the biological/genetic causes of caudies designed to investigate biologicators associated with cancer disparinategies, (2) the development and to so designed to aid and facilitate the expertise in cancer health disparities rerived models, and methods that are IH Research Project (RO1) award me	ancer health disparities. The ical/genetic bases of cance ties, including those related esting of new methodologic growth of a nationwide columns are search who can expand a penecessary to conduct basi	ese research project gran r disparities, such as (1) m d to basic research in canc es and models, and (3) sec hort of scientists with a hig vailable resources and toc	ts (R01) will support echanistic studies o er biology or cancer ondary data analyse gh level of basic resols, such as biospecio	innovative f biological prevention es. This FOA in earch mens, patien
109682		ncer Control Research in Persistent Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-CA-22-015	06-Jun-2022 [Optional][LOI/P App]	e- 7,500,00 USD
	Contact Name SI	hobha Srinivasan, Ph.D.				
	Contact Telephone 24	40-276-6938				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		TIDEAUTHE DATE T	Funding Amount
	Contact Email Sponsor Website	ss688k@nih.gov				
	·	Link to program URL				
		06-Jun-2022 [Optional][LOI/Pre-App],	06-Jul-2022			
	Synopsis	Through this Funding Opportunity And Control Research in Persistent Poverty time and effort of transdisciplinary tecancer prevention and control research serves populations living in persistent long-term goal of this initiative is to be research and promote the implement the effects of persistent poverty.	y Areas (Persistent Poverty I ams, in collaboration with in ch program and provide sup poverty areas. For this purp uild capacity in persistent po	nitiative). The goal is to prostitutions, clinics, and comport to early-career investings, NCI will support seventies areas to foster cancer	ovide resources to some immunities/tribes, to gators that focuses ral U54 Specialized (er prevention and co	support the develop a on and Centers. The ontrol
109178		NIH Faculty Institutional Recruitment ansformation (FIRST) Program: FIRST al Trial Optional)	National Cancer Institute/NIH/DHHS	RFA-RM-22-008	12-Jun-2022 [Optional][LOI/Pre App]	10,245,00 USD
	Contact Name	Jessica M. Calzola, Ph.D.				
	Contact Telephone	240-276-7474				
	Contact Email	FIRSTNIH@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jun-2022 [Optional][LOI/Pre-App],	12-Jul-2022			
	Synopsis	The purpose of the FIRST Cohort is to community of scientists committed to cultures of inclusive excellence within recipient institutions and beyond. This an advertised research tenure-track o equivalent) level), meet the criteria for to promoting diversity and inclusive e	o diversity and inclusive exce the program has the poten s community will be built the or equivalent faculty position or NIH-defined Early Stage In	ellence (defined below). Im tial to be transformational rough recruitment of indivi (positions must be at the	plementing and sus for biomedical rese duals who: are com Assistant Professor	taining arch at the apetitive for (or

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
106264	Basic Research in ( Trial Not Allowed)	Cancer Health Disparities (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-21-323	16-Jun-2022	400,000 USD
	Contact Name	Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Email	sharmananu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2022 , 16-Jul-2022 , 16-Oct-20 2023 , 16-Nov-2023 , 16-Feb-2024 , 1			5-Jun-2023 , 16-Jul-202	23 , 16-Oct-
	Synopsis	National Cancer Institute (NCI) invites into the biological/genetic causes of a studies designed to investigate biologicators associated with cancer disparstrategies, (2) the development and talso designed to aid and facilitate the expertise in cancer health disparities derived models, and methods that ar	cancer health disparities. gical/genetic bases of can ities, including those relatesting of new methodoloe growth of a nationwide research who can expand	These research project gr cer disparities, such as (1) ted to basic research in ca gies and models, and (3) s cohort of scientists with a d available resources and	ants (R01) will suppor mechanistic studies oncer biology or cancel secondary data analys high level of basic res tools, such as biospeci	t innovative of biological r prevention es. This FOA is earch
106265	<u>Basic Research in (</u> <u>Trial Not Allowed)</u>	Cancer Health Disparities (R03 Clinical	National Cancer Institute/NIH/DHHS	PAR-21-324	16-Jun-2022	100,000 USD
	Contact Name	Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Email	sharmananu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Jun-2022 , 16-Jul-2022 , 16-Oct-20 2023 , 16-Nov-2023 , 16-Feb-2024 , 1			5-Jun-2023 , 16-Jul-202	23 , 16-Oct-
	Synopsis	This Funding Opportunity Announcer basic, mechanistic research into the k will support projects on cancer health	piological/genetic causes	of cancer health disparitie	es. These small researd	ch grants (R03)



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
		projects should propose innovative s mechanistic studies of biological fact cancer biology or cancer prevention secondary data analyses.	ors associated with cancer	disparities, including those	related to basic res	earch in		
106283	<u> </u>	mpact Cancer Risk after Bariatric al Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-332	16-Jun-2022	550,000 USD		
	Contact Telephone Contact Email Sponsor Website	edward.sauter@nih.gov						
	Doadling Dates (ALL)	16-Jun-2022 , 16-Jul-2022 , 16-Oct-2022 , 16-Nov-2022 , 16-Feb-2023 , 16-Mar-2023 , 16-Jun-2023 , 16-Jul-2023 , 16-Oct-2023 , 16-Nov-2023 , 16-Feb-2024 , 16-Mar-2024 , 16-Jul-2024						
	Synopsis	Through this Funding Opportunity Ar of investigator-initiated studies addr talented scientists who study bariatr as weight loss and diabetes.	essing mechanisms by whi	ch bariatric surgery impacts	cancer risk, and see	eks to draw ii		
098641	NCI Clinical and Tra Exploratory/Develo Optional)	anslational opmental Studies (R21 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-20-292	21-Jun-2022	275,000 USD		
	Contact Name	William C. Timmer, Ph.D						
	Contact Telephone	240-276-6130						
	Contact Email	william.timmer@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	21-Jun-2022 , 21-Jun-2022 , 20-Jul-20	)22					
	Synopsis	This Funding Opportunity Announce studies, directly related to advancem						



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
DEIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

of cancer health disparities. This includes (but is not limited to) development and testing of the following: new molecular agents or biologics for cancer treatment; management strategies for cancer-related symptoms or treatment-related toxicity; cancer screening or diagnostic tools, such as imaging techniques; cancer preventive agents or approaches; predictive and prognostic biomarkers for patient selection or stratification; clinically relevant in vivo or in vitro tumor models (including genetically engineered mouse models, patient-derived xenograft models, organoids, and cell lines); and strategies to address therapeutic outcome disparities among diverse racial/ethnic populations. In addition to novel agents, new treatment strategies may involve repurposed agents or novel combinations of interventions (including radiation), based on established mechanisms of action. Comparative oncology studies in dogs investigating strategies for treatment and diagnosis of human disease are supported as well. This FOA does not support research that focuses on basic cancer biology (such as studies of cancer-related pathways or molecular mechanisms), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to breakthroughs in particular areas, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on cancer research (preclinical or clinical).

045115	Short-Term Scientist Eychange Program		National Cancer Institute/NIH/DHHS		01-Jul-2022	Not Specified
	Contact Name	Dr. Vidya Vedham				
	Contact Telephone	240-276-7272				
	Contact Email	NCICenterforGlobalHe@mail.nih.gov	<u></u>			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
		01-Jul-2022 , 01-Oct-2022				
	Synopsis	The Short-Term Scientist Exchange P promotes collaborative research bet	rogram (STSEP) at the Center ween researchers at the NCI	r for Global Health (CGH), N and foreign cancer researd	lational Cancer Instit hers.	ute (NCI),
110275	Accelerate the Dev	SBIR Phase IIB Bridge Awards to velopment of Cancer-Relevant ard Commercialization (R44 Clinical	National Cancer Institute/NIH/DHHS	RFA-CA-22-025	05-Jul-2022 [Optional][LOI/Pre- App]	4,000,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	francakohjc@mail.nih.gov	_	Business Innovation Researc	h (SBIR) application	
	Synopsis	business concerns (SBCs) that seek a that were previously funded under S facilitate the transition of SBIR or ST partnerships between Federally-fund to facilitate and accelerate the capita Applicants must submit a Commercia funding that has already been secure the level of this independent third-pathe Phase IIB Bridge Award project p development. Clinical trials may be p	BIR or STTR Phase II award TR Phase II projects to the ded SBIR or STTR Phase II a al-intensive steps that are alization Plan, which shoul ed or is anticipated during arty funding will be equal the eriod. Proposed projects n	Is from any Federal agency. commercialization stage. The wardees and third-party inverged to commercialize reduired to commercialize reduired details on any indestruction or greater than the NCI funay address preclinical and/	The purpose of this ais FOA is expected restors and/or strat arew products and seependent third-part project period. It is ands being requeste	to promote egic partners ervices. expected that distributed throughout
110367	Research Projects Clinical Trial Optio	in Physical Sciences-Oncology (U01 nal)	National Cancer Institute/NIH/DHHS	PAR-22-147	08-Jul-2022	2,000,000 USD
	Contact Name Contact Telephone	Eric M. Johnson Chavarria, Ph.D. 240-276-7416				
	·	eric.johnsonchavarria@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2022 , 01-Nov-2022 , 03-Jul-20	023 , 01-Nov-2023 , 01-Jul-	2024 , 01-Nov-2024		
	Synopsis	This Funding Opportunity Announced Oncology Projects (PS-OP). The goal physical sciences approaches and performing transdisciplinary	of the Physical Sciences-Or rspectives with cancer res	ncology Network (PS-ON) is earch to advance our under	to foster the conve standing of cancer I	rgence of piology and



		Militaliali	ig Opportunities			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	i S G	ohysical scientists may include engine ndividually and as a collaborative Ne support transdisciplinary research tha community; (2) facilitates team scien- and (3) collectively tests physical scie solutions to address outstanding ques	twork along with other PS-Cat: (1) establishes a physical ce and field convergence at nces-based experimental ar	OPs and the Physical Science sciences perspective within the intersection of physical	s-Oncology Cente the cancer resear sciences and canc	rs (PS-OC), will ch er research;
087537		ns for Validation of Biomarker Assays NIH-Supported Research Grants ot Allowed)	National Cancer Institute/NIH/DHHS	PAR-20-074	11-Jul-2022	450,000 USD
	Contact Name S	Sumana Dey, Ph.D.				
	Contact Telephone 2	240-276-5748				
	Contact Email	sumana.dey@nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	ink to program URL				
	Deadline Dates (ALL)	11-Jul-2022 , 28-Oct-2022				
	t Synopsis	The purpose of this Funding Opportulation of the purpose of this Funding Opportulations of the clinic. Specifically, the focus of appealing the clinic of molecular/cellular/imagorognosis, monitoring, and prediction control. Applications may support the observational cohorts/consortia for the control of th	y funded NCI R01 research panslation of NCI-supported plications submitted in resping markers (referred to as not response in treatment, as acquisition of well-annotate purpose of clinical valida	projects. The applicants show methods/assays/technologie ponse to this FOA should be "markers" or "biomarkers") as well as markers for cance ated specimens from NCI-sup tion of the assay. Research p	ald propose projectes (referred to as 'on the adaption afor cancer detection and provided or other corojects proposed	ts that are 'assays") to ind clinical ion, diagnosis, linical trials or in response

as investigational assays/tools/devices.

and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application. This FOA is not intended to support early-stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
110473		nities in Established Cancer ort Studies (U01 Clinical Trial Not	National Cancer Institute/NIH/DHHS	PAR-22-162	29-Jul-2022	Not Specified
	Contact Name	Joanne Elena, PhD, MPH				
	Contact Telephone	240-276-6818				
	Contact Email	joanne.elena@nih.gov				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	29-Jul-2022 , 28-Feb-2023 , 28-Jul-20	23 , 28-Feb-2024 , 29-Jul-2	024 , 28-Feb-2025		
	Synopsis	Through this Funding Opportunity Ar to support research in established caplanned recruitment goal. Applicatio and are expected to include support addition to addressing research questions.	ncer epidemiology cohort s ns must include hypothesis for cohort maintenance, co	studies, defined as studies s-based research using da ontinued follow-up, and sl	s that have achieved ta from an establishe	their initial d cohort study
107759	Administrative Sup	nterest (NOSI): Availability of oplements to Harmonize / Map CI Human Tumor Atlas Network Data	National Cancer Institute/NIH/DHHS	NOT-CA-22-013	31-Jul-2022	40,000 USD
	Contact Name	Sean Hanlon, Ph.D.				
	Contact Telephone	240-781-3310				
	Contact Email	sean.hanlon@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Jul-2022				
	Synopsis	This Funding Opportunity Announcer Moonshot Initiative. This FOA invites single cell sequencing and spatial imathrough HTAN and/or NCI data resou	current NCI awardees to a aging datasets with HTAN d	pply for supplemental fur ata and metadata standa	nding to harmonize th	neir existing



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
104713		nter for NCCIH Multi-Site nical Trials of Mind and Body tive UG3/UH3 Clinical Trial	National Center for Complementary and PAR-21-243 Integrative Health/NIH/DHHS	20-Jun-2022	Not Specified
	Contact Name Lanay Contact Telephone 301-5 Contact Email lanay. Sponsor Website	94-9346			
	Program URL Link to		2022 , 14-Nov-2022 , 21-Feb-2023 , 10-Mar-2023 , 11-Mar-2024	20-Jun-2023 , 22-Jul-202	23 , 20-Oct-
	(e.g. e with pof hig clinical composition of the conduction of the	efficacy, effectiveness or pragrohysical and/or psychological thresearch priority. Clinical Coal trial. The objective of a Clinical trial. The objective of a Clinical endensive scientific and operate be plans for project management, and dissemination of result, milestone-driven cooperative, milestone-driven cooperative clinical project is required. But of the cli	ement (FOA) encourages applications for investigation and the complementary therapeutic inputs (often called mind and body interpretation ordinating Centers should develop and implement cal Coordinating Center application is to present the tional plan for the clinical trial. Clinical Coordinating tent, participant recruitment and retention strategets. Clinical Coordinating Center applications submite agreement (UG3/UH3) funding mechanism. In actain, submitted under PAR-21-242 proposing a data oth a Clinical Coordinating Center application and explain the submitted simultaneously for consideration by Note that the approper planning to develop an application prior to see the planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application prior to see the submitted planning to develop an application planning to	and integrative health a erventions) in NCCIH de- the proposed fully pow- the scientific rationale an ig Center applications ar- ies, performance milest tted under this FOA will idition, an accompanying analysis and data mana a corresponding Data Co CCIH. For additional info uraged to consult the No riate the Scientific/Rese	approaches signated area ered multi-si d a e expected to ones, scientification at the graduation about the cordinating rmation about the site of the cordination about the cordination are cordination are cordinated as a cordination are cordinated as a cordination are cordinated as a cordinated area are cordinated as a cordinated area area area area are cordinated area area area area area area area ar
	Feasibility Clinical Trials o	of Mind and Body Intervention esearch Topics (R34 Clinical	National Center for Complementary and PAR-21-240	20-Jun-2022	450,000



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Li Deadline Dates (ALL) TI ap th fe or do ac Synopsis in da ac ef cc tc ar	o1-496-4054 eter.murray@nih.gov  ink to program URL  0-Jun-2022 , 22-Jul-2022 , 19-Oct-20 023 , 14-Nov-2023 , 20-Feb-2024 , 12 he goal of this funding opportunity is pproaches with physical and/or psychat have been identified by NCCIH as easibility clinical trials, which will propredictiveness study, or a pragmatic evelop a competitive full-scale clinical competitive full-scale c	to support early phase clinical trianological therapeutic inputs (ofter high priority research topics. This wide data that are critical for the patrial. The data collected should be all trial, including, but not limited to bublished data; adapting an intervolographic frequency or duration; and assessing the feasibility of protol conditions. This FOA will not suppose to conduct a feasibility clinical pose	als of complementary a called mind and bod funding opportunity lanning and design of used to fill gaps in so the following: examention to a specific podetermining feasibility occolized multimodal iport randomized clinity or acceptability resmilar intervention. All for a clinical trial are	y and integrative hely interventions) for is intended to support of a subsequent clinic clientific knowledge in ining feasibility and opulation; refining ty of recruitment, interventions; or experience that has been polications that present appropriate for interventions in the present appropriate for a programment of the present appropriate for interventions in the present appro	nealth for conditions oport nical efficacy e necessary to nd g the retention and examining for determine en previously ropose solely for this
104712	Investigator-Initiated	enter for NCCIH Multi-Site d Clinical Trials of Mind and Body porative U24 Clinical Trial Required)	National Center for Complementary and PA Integrative Health/NIH/DHHS	R-21-242	20-Jun-2022	Not Specified
	Contact Telephone 30 Contact Email <u>la</u> Sponsor Website	anay Mudd, Ph.D.				



Will Fullating Opportunities									
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	20-Jun-2022, 22-Jul-2022, 19-Oct-2023, 14-Nov-2023, 20-Feb-2024, This Funding Opportunity Announc collaborating Data Coordinating Ce (Phase III and beyond) application so Clinical Coordinating Center (CCC) a provides overall project coordination consideration by NCCIH. Trials for wa high priority by the Center. For ac applicants are encouraged to consular appropriate the Scientific/Research prior to submitting to this FOA	, 11-Mar-2024 cement (FOA), utilizing the U24 enter (DCC) application that acc submitted under PAR-21-243. Tapplication. The objective of the on, and administrative, data mention and a corresponding CCC app which this FOA applies must be dditional information about the ult NCCIH website: (http://www.	grant funding mechanism companies an investigator of the DCC application must e DCC application is to pranagement, and biostatistication need to be submarelevant to the research e mission, strategic vision v.nccih.nih.gov). Applicar	m, encourages appli r-initiated multi-site to be specific to the compreher stical support for the itted simultaneously mission of NCCIH and to and research prior	cations for a clinical trial ompanion nsive plan that proposed for nd considered rities of NCCIH, to contact the			
104709	· · · · · · · · · · · · · · · · · · ·	Feasibility Clinical Trials of Mind and s (R01 Clinical Trial Required)	National Center for Complementary and Integrative Health/NIH/DH	PAR-21-241 HS	20-Jun-2022	Not Specified			
	Contact Name	Della White, Ph.D.							
	Contact Telephone	301-827-6538							
	Contact Email	della.white@nih.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	20-Jun-2022 , 22-Jul-2022 , 19-Oct- 2023 , 14-Nov-2023 , 20-Feb-2024 ,		023 , 10-Mar-2023 , 20-Jı	un-2023 , 22-Jul-202	:3 , 20-Oct-			
	Synonsis	This Funding Opportunity Announce and integrative health approaches interventions) in NCCIH-designated propose a multi-site feasibility clinic demonstrate feasibility of recruitm adherence to the intervention, as we feasibility of data collection across	with physical and/or psycholog dareas of high research priority ical trial to assess whether the lent, accrual, and randomization well as retention of participants	gical therapeutic inputs (o o. Applications submitted intervention can be deliven of participants across so of throughout the study ac	often called mind an under this FOA are ered with fidelity ac ites; demonstrate p cross sites; and/or d	expected to cross sites; articipant emonstrate			



need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	or e con sub	ffectiveness. The data collected npetitive fully powered multi-site	the published literature. This FOA will not suppose should be used to fill gaps in scientific knowled clinical trial that has the potential to make a see encouraged to contact the appropriate NCCI ication.	lge and be necessary to devignificant impact on public	velop a health Prior to
107853	Complementary and Ir	est (NOSI): National Center for stegrative Health (NCCIH) T32 or Pre- and Postdoctoral se Backgrounds	National Center for Complementary and NOT-AT-21-0: Integrative Health/NIH/DHHS	13 01-Jul-2022	Not Specified
	Contact Name Lan	•			
	Contact Telephone 301				
	Contact Email Lan Sponsor Website	ay.mudd@nin.gov			
	Program URL Link	to program URI			
		Jul-2022 , 02-Jan-2023 , 03-Jul-20	123 . 02-Jan-2024 . 01-Jul-2024		
	Synopsis grosup	SA) Institutional Research Training itional training slot to support prups that are underrepresented in	allow existing NCCIH-funded Ruth L. Kirschsteing Grant (T32) programs to apply for an adminimedoctoral and postdoctoral candidates from dother the biomedical, clinical, behavioral, and social in each fiscal year and the number awarded woility of funds.	istrative supplement to sup iverse backgrounds, includi I sciences. A very limited nu	port an ng those from ımber of
106125	Complementary and Ir Complementary and Ir	est (NOSI): National Center for stegrative Health (NCCIH) T32 stegrative Health Practitioner or Pre- and Postdoctoral	National Center for Complementary and NOT-AT-21-03 Integrative Health/NIH/DHHS	14 01-Jul-2022	Not Specified
	Contact Name Lan	ay Mudd, Ph.D.			
	Contact Telephone 301	-594-93466			
	Contact Email Lan	ay.mudd@nih.gov			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount		
	Sponsor Website							
		ink to program URL						
	` '	1-Jul-2022 , 02-Jan-2023 , 03-Jul-202			_			
	Synopsis (Na	NRSA) Institutional Research Training	g Grant (T32) programs to appl	ed Ruth L. Kirschstein National Research Service Aw apply for an administrative supplement to support dates with professional clinical complementary and				
110305		Community Research Resource: the Resident Ocular Microbiome. ot Allowed)	National Eye Institute/NIH/DHHS	RFA-EY-22-001	06-Jun-2022 [Optional][LOI/Pre- App]	Not Specified		
	Contact Name Li	isa Neuhold, Ph.D.						
	Contact Telephone 3	01-443-5401						
	Contact Email <u>In</u>	<u>neuhold@nei.nih.gov</u>						
	Sponsor Website							
	Program URL <u>Li</u>	ink to program URL						
	Deadline Dates (ALL) 0	6-Jun-2022 [Optional][LOI/Pre-App],	06-Jul-2022					
	te in Synopsis w ev m	The overall purpose of this funding operams to develop a community-based ndividuals. The data include factors revill support research projects designerye; understand their immune and nemicrobiome, omics, and clinical data the ocular of the ocular	resource of microbial data as nicrobial communities elabora ed to: delineate and characteri euro interactions and contribut to determine profiles that pror	sociated with the residen te that impact human ph ze core ocular microbial o ions to the maintenance note health of the ocular	t ocular microbiome ysiology. This annou constituents in the food of homeostasis; and surface. The front o	of healthy incement ront of the d integrate f the eye or		
110406	Program Translation	omatic Cell Genome Editing nal Coordination and Dissemination - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-RM-22-017	17-Jun-2022 [Optional][LOI/Pre- App]	Not Specified		
	Contact Telephone 3	Marrah Lachowicz-Scroggins, PhD 01-827-8229 narrah.lachowicz-scroggins@nih.gov						



			9 - pp			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website Program URL Link	to program LIPI				
		lun-2022 [Optional][LOI/Pre-App],	19-Jul-2022			
	the accorpation add sub usin can acti sub wid Ann NIH	purpose of this FOA is to support NIH Somatic Cell Genome Editing elerate the development of genome ways to regulatory approval; and ition to this TCDC, the Consortium missions, optimize genome editing genome editing technologies in didates toward IND filings and futurities that facilitate intra-consortium ission. The TCDC will develop a per activities including stewardship a ouncement (FOA) is developed as Director, Office of Strategic Coord d initiatives. The FOA will be administratives.	(SCGE) Consortium. In its sector-editing therapeutic agents disseminating successful strawill include three componers-based therapeutic leads for >1 disease) which together ware first in human clinical triam collaborations and that subublicly available online platford preservation of data general Common Fund initiative (himation (https://dpcpsi.nih.g	cond phase (FY2023-2027), is by: facilitating IND-enable ategies for initiating first in this (development of technor safety and efficacy and cowill accelerate the optimizants. The TCDC is expected to upport broad dissemination form for data collection and erated by SCGE in Phase I. attps://commonfund.nih.gogov/). All NIH Institutes and	, the SCGE programing studies; establish human clinical trianology/assays that sonduct platform clination of promising coolead consortiuming strategies for regulation of . This Funding Opponov/) through the Opponov/) through the Opponing the Opponing the Opponing the Opponing the Opponing O	will shing als. In support IND-nical trials clinical wide sulatory consortium-prtunity ffice of the
104783		<u>versity in Health-Related</u>	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-22-012	10-Jul-2022 [Optional][LOI/Pro App]	770,000 e- USD
	Contact Name Pau	l Cotton, Ph.D., RDN				
	Contact Telephone 301	-435-0202				
	Contact Email pau	l.cotton@nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
		lul-2022 [Optional][LOI/Pre-App], ( tional][LOI/Pre-App], 09-Aug-2023			3-Feb-2023 , 10-Jul-	2023
	Synopsis arch	NIH Research Education Program ning goal of this NHLBI R25 prograr avioral and clinical research workf	n is to support educational a	activities that enhance the	diversity of the bio	medical,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	com	l of individuals from diverse back pete for research opportunities i l, this FOA will support creative e	n the mission areas of importa	ance to NHLBI. To accomp	plish the stated ov	
108574	· · · · · · · · · · · · · · · · · · ·	yze: Enabling Technologies and ms for HLBS Research (R33 - yed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-010	21-Jul-2022	600,000 USD
	Contact Name Mike Contact Telephone 301- Contact Email nhlb Sponsor Website					
	Program URL Link	to program URL				
	Deadline Dates (ALL)	ul-2022 , 18-Aug-2022 , 21-Nov-2 3 , 21-Dec-2023 , 21-Feb-2024 , 1		· · · · · · · · · · · · · · · · · · ·	_	23 , 21-Nov-
	tran bloc the prel utiliz dete addi tech this of Ca	Funding Opportunity Announcer isformative platforms to catalyze od, and sleep (HLBS)-related disordenabling technology or transform iminary data, but still requires fuzation and adoption. Well-suited ection and screening, model deversing issues associated with HL anologies where the novelty resides solicitation. Applications consideratelyze innovation grants to advanduct Definition or Preclinical FOA:	next-generation predictive, directive, directive and diseases. This FOA so native platform have already but her development and rigorous applications must offer the polopment, clinical diagnosis, treated diseases and disord es in the biological or clinical tred nonresponsive to the FOA ance projects to the point when	agnostic and therapeutic blicits R33 applications we een overcome, as demor us validation to encourage etential to accelerate and eatment, control, preven- lers. Projects proposing a carget/question being pu will not be reviewed. Th	products to addrest there major feasibinstrated with supping downstream deallor transform the tion or epidemioloupplication of existing send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is FOA is part of a send are not apprint is part of a send are not apprint in the product of the p	ess heart, lung lity gaps for ortive monstration, areas of early gy, while ing copriate for suite
108576	Molecules and Biologic	yze: Product Definition for Small s - Preliminary Product/Lead 33 - Clinical Trial Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-012	21-Jul-2022	700,000 USD
	Contact Name Mike Contact Telephone 301-	•				



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber		Deadline Date	Funding Amount
	Contact Email	nhlbi_catalyze@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	21-Jul-2022 , 18-Aug-2022 , 21-N 2023 , 21-Dec-2023 , 21-Feb-202			•		23 , 21-Nov-
This Catalyze Product Definition Funding Opportunity Announcement (FOA) will provide the early stage to needed to develop and test device prototype designs, identify diagnostic disease targets and develop asset develop research tools for use in the treatment of heart, lung, blood and sleep (HLBS) diseases and disord part of a suite of Catalyze innovation grants to advance projects to the point where they can meet the en NHLBI Catalyze Preclinical program or attract independent development support from other federal or preclinical product optimization and characterization.						and develop associate eases and disorders. I an meet the entry c	ed assays, and This FOA is riteria for the
108577	Prototype Design and Identification and	Catalyze: Product Definition – Devand Testing, Diagnostic Disease T Assay Development, and Researc (R61/R33 - Clinical Trial Not Allo	arget National Heart ch Blood Institute	-	RFA-HL-23-013	21-Jul-2022	750,000 USD
	Contact Name	Mike Pieck, Ph.D.					
	Contact Telephone	301-827-7986					
	Contact Email	nhlbi_catalyze@nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	21-Jul-2022 , 18-Aug-2022 , 21-N 2023 , 21-Dec-2023 , 21-Feb-202	•	-	•		23 , 21-Nov-
	Synopsis	This Catalyze Product Definition needed to develop and test devidevelop research tools for use in part of a suite of Catalyze innovaNHLBI Catalyze Preclinical prograpreclinical product optimization	ice prototype designs on the treatment of heation grants to advance am or attract indeper	, identify diag art, lung, bloo ce projects to ident develop	nostic disease targets and and sleep (HLBS) dise the point where they c	and develop associate eases and disorders. I an meet the entry c	ed assays, and This FOA is riteria for the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108578		search Tool Testing and	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-014	21-Jul-2022	500,000 USD
	Deadline Dates (ALL) 2023 This F testin the tr of Cat Precli	27-7986 _catalyze@nih.gov	8-Apr-2024, 22-Jul-2024, 19- ment (FOA) will provide the ea evelopment for diagnostic dise and sleep (HLBS) diseases and ince projects to the point whe ndent development support fi	Aug-2024, 21-Nov-2024, rly stage translational sup ase targets, and developi disorders. This FOA is par re they can meet the enti	, 20-Dec-2024  pport needed for perent of research to fa suite  ry criteria for the N	orototype ools for use in NHLBI Catalyze
108575	Molecules and Biologics Validation, and Prelimina	e: Product Definition for Small - Target Identification and ary Product/Lead Series - Clinical Trials Not Allowed)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-011	21-Jul-2022	1,050,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link to 21-Jul 2023	27-7986 <u>catalyze@nih.gov</u>	2022 , 21-Dec-2022 , 21-Feb-20 8-Apr-2024 , 22-Jul-2024 , 19-	023 , 18-Apr-2023 , 21-Jul Aug-2024 , 21-Nov-2024 ,	l-2023 , 18-Aug-20 , 20-Dec-2024	23 , 21-Nov-



SPIN ID	Program Title	Sponsor Name	Sponsor Number	TDeadline Date	Funding Amount			
	chara Synopsis diseas can m	cterize potential therapeutic cand ses and disorders. This FOA is par seet the entry criteria for the NHL	ent (FOA) will provide the early stage translational sup didates (compound and lead series) to treat heart, lun t of a suite of Catalyze innovation grants to advance p .BI Catalyze Preclinical program or attract independen eclinical optimization and development of therapeuti	g, blood, and sleep rojects to the point t development supp	(HLBS) where they			
108514	Attract Talented Underg		National Human Genome Research Institute/NIH/DHHS	01-Jun-2022 [Optional][LOI/Pre App]	1,750,000 USD			
	Contact Name Contact Telephone Contact Email Sponsor Website	80-2280						
	Program URL Link to Deadline Dates (ALL) 01-Ju		01-Jul-2022 , 01-Jun-2023 [Optional][LOI/Pre-App], 01	-Jul-2023				
	overa backg studie mission under pursu accon Resea Under partn	rching goal of this R25 program is rounds, including those from groes or careers in research. The NIH on areas of the NIH. The overarch graduates from diverse backgroue further training and careers in the plish the stated over-arching goarch Experiences Courses for Skills graduates into the Genomic Field erships that provide research edu	R25) supports research education activities in the miss to support educational activities that encourage indicups underrepresented in the biomedical and behavior Research Education Program (R25) supports research ing goal of this NHGRI R25 program is to support educations, including those from groups underrepresented in the scientific, medical, ethical, social and/or legal area al, this FOA will support creative educational activities a Development This Genome Research Experiences to do to Promote Diversity (GREAT) Program will support of the cation programs for undergraduates enrolled at mind DeA)-eligible institutions. A partnership will include a Note that the course of the cation of the ca	viduals from diverse ral sciences, to pursu education activities cational activities that the biomedical wo s of genomics resea with a primary focu Attract Talented collaborative institutionity-serving institution	e ue further sin the at encourage orkforce, to rch. To us on: tional ions (MSIs)			

scientific areas of interest to NHGRI.

and one or more research-intensive institutions or organizations with a suitable research base for graduate-level training in

SPIN ID	Program Title	Sponsor Name	Sponsor Number	II)eadiine I)ate II	Funding Amount
095566	RFA-HG-20-037 Ad Research (R21 Clinica	dvancing Genomic Medicine al Trial Optional)	National Human Genome Research Institute/NIH/DHHS	02-Jul-2022 [Optional][LOI/Pre App]	Not Specified
	Contact Name M	As. Christine Chang			
	Contact Telephone 3	01-480-2255			
	Contact Email <u>c</u>	hristine.chang2@nih.gov			
	Sponsor Website				
	Program URL <u>Li</u>	ink to program URL			
	Deadline Dates (ALL) 0	2-Jul-2022 [Optional][LOI/Pre-App]	], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 1	.3-Aug-2023	
	Synopsis P si	nderstanding of when, where, and roposed projects should be broadly	ement (FOA) encourages applications that stimulate inno- how best to implement the use of genomic information y applicable to genomic medicine as a field, and yield fir ects are strongly encouraged to include ancestrally dive	n and technologies in ndings of significance	beyond a
095564	RFA-HG-20-036 Ad Research (R01 Clinica	dvancing Genomic Medicine al Trial Optional)	National Human Genome Research Institute/NIH/DHHS	02-Jul-2022 [Optional][LOI/Pre App]	3,000,000 USD
	Contact Name M	As. Christine Chang			
	Contact Telephone 3	01-480-2255			
	Contact Email <u>cl</u>	hristine.chang2@nih.gov			
	Sponsor Website				
	Program URL <u>Li</u>	ink to program URL			
	Deadline Dates (ALL) 0	2-Jul-2022 [Optional][LOI/Pre-App]	], 01-Aug-2022 , 11-Feb-2023 [Optional][LOI/Pre-App], 1	.3-Aug-2023	
	Synopsis P si	nderstanding of when, where, and roposed projects should be broadly	ement (FOA) encourages applications that stimulate innoting how best to implement the use of genomic information y applicable to genomic medicine as a field, and yield fir ects are strongly encouraged to include ancestrally dive	n and technologies in ndings of significance	beyond a



SPIN ID	Program Title	Sponsor Name	Sponsor Number		II)eadiine I)ate II	unding mount
109413		mmune Drivers of Autoimmune 01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-012	01-Jun-2022 [Optional][LOI/Pre- App]	3,750,000 USD
	Contact Name	Thomas R. Esch, Ph.D.				
	Contact Telephone	240-627-3565				
	Contact Email	Contact Email tesch@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App]	, 01-Jul-2022			
	Synopsis	autoimmune disease. The main object events, and changes that underlie the progression of established disease, a autoimmune disease.	e clinical manifestations of aut	oimmune diseases, inclu	ding disease flare, rei	mission, and
	DEA AL 24 025 E	xploratory Data Science Methods and	National Institute of Allergy		01-Jun-2022	
			o,			275.000
102837	Algorithm Develor	oment in Infectious and Immune-	and Infectious	RFA-AI-21-035	[Optional][LOI/Pre-	275,000 USD
102837	Algorithm Develor mediated Diseases	oment in Infectious and Immune- s (R21 Clinical Trial Not Allowed)	o,	RFA-AI-21-035		
102837	Algorithm Developmediated Diseases  Contact Name	oment in Infectious and Immune- s (R21 Clinical Trial Not Allowed)  Steve Tsang, PhD	and Infectious	RFA-AI-21-035	[Optional][LOI/Pre-	
102837	Algorithm Develor mediated Diseases Contact Name Contact Telephone	Steve Tsang, PhD 240-627-3330	and Infectious	RFA-AI-21-035	[Optional][LOI/Pre-	
102837	Algorithm Develor mediated Diseases Contact Name Contact Telephone Contact Email	Steve Tsang, PhD 240-627-3330 AI-DSFOAinquiries@nih.gov	and Infectious	RFA-AI-21-035	[Optional][LOI/Pre-	
102837	Algorithm Develor mediated Diseases Contact Name Contact Telephone Contact Email Sponsor Website	Steve Tsang, PhD 240-627-3330 AI-DSFOAinquiries@nih.gov	and Infectious	RFA-AI-21-035	[Optional][LOI/Pre-	
102837	Algorithm Develor mediated Diseases Contact Name Contact Telephone Contact Email Sponsor Website	Steve Tsang, PhD 240-627-3330 AI-DSFOAinquiries@nih.gov	and Infectious Diseases/NIH/DHHS , 01-Jul-2022 , 18-Jan-2023 [O		[Optional][LOI/Pre- App]	USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		reactions associated with transplants applications focused on the development including artificial intelligence and manalysis, visualization, and dissemina (U01) and enhancement/sustainment companion FOAs.	ment of novel computational, r achine learning approaches, th tion of relevant data and/or kr	mathematical, and statist nat can considerably impr nowledge. This contrasts	ical algorithms and ove acquisition, ma with early-stage de	methods, anagement, evelopment
102836	Science Technologi	es for Infectious and Immune- (U01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-21-020	01-Jun-2022 [Optional][LOI/Pr App]	900,000 e- USD
	Contact Telephone	Steve Tsang, PhD 240-627-3330 <u>AI-DSFOAinquiries@nih.gov</u>				
	,	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App] [Optional][LOI/Pre-App], 06-Jul-2023		ptional][LOI/Pre-App], 17	-Feb-2023 , 06-Jun	-2023
	Synopsis	The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the development of enabling data science technologies to improve the acquisition, management, analysis, visualization, and dissemination of data and knowledge for immune-mediated and infectious diseases including disease mechanism, risk prediction, epidemiology, detection and diagnosis, treatment and vaccines across the allergy, immune-mediated, and infectious-disease research continuum, aligned with the research mission of NIAID. This includes infectious diseases, emerging infections, or immune-mediated diseases that include allergy, autoimmunity, or immune reactions associated with transplantation. As a part of the trans-NIAID data science program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. This contrasts with exploratory (R21) and enhancement/sustainment (U24) efforts to generate these tools and resources that are supported by the companion FOAs.				
110267	Next-Generation In	evelopment and Optimization of nmunological Assays to Support audies and Trials (UH2/UH3 Clinical	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-020	01-Jun-2022 [Optional][LOI/Pr App]	2,500,000 e- USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		IDeadline Date	unding Amount
		. Chelsea Lane, Ph.D.				
	Contact Telephone 24					
	Contact Email <u>ma</u>	ary.lane@nih.gov				
	Sponsor Website					
		nk to program URL				
		-Jun-2022 [Optional][LOI/Pre-App],				
	Synopsis res	e purpose of this Funding Opportur search to develop and optimize nex udies and trials by the end of the Ul	t-generation immunological a			
109533		roved Drug Susceptibility Testing s (R01 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-016	08-Jun-2022 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name Ka	ren A. Lacourciere, Ph.D.				
	Contact Telephone 24	0-627-3297				
	Contact Email <u>lac</u>	courcierek@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	nk to program URL				
	Deadline Dates (ALL) 08	-Jun-2022 [Optional][LOI/Pre-App],	08-Jul-2022			
	Synopsis ted	ne purpose of this Funding Opportur chnologies for tuberculosis (TB) dru agnostics for new TB drugs.	· · · · · · · · · · · · · · · · · · ·		_	
110401		chnologies and Assays for Editing INDs (U01, Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-RM-22-014	17-Jun-2022 [Optional][LOI/Pre- App]	900,000 USD
	Contact Name Be	etty Poon, Ph.D.				
	Contact Telephone 24	0-669-5024				
	Contact Email po	oonb@mail.nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding Amount
	Program LIRI	Link to program URL				
		<u> 17-Jun-2022 [Optional][LOI/Pre-App]</u>	. 19-Jul-2022			
	Synopsis	The purpose of this Funding Opportucharacterization of technologies and genome editing therapeutics. This Fu (https://commonfund.nih.gov/) throu((https://dpcpsi.nih.gov/). All NIH Insadministered by the National Institut	nity Announcement (FOA) is to assays with the potential for unding Opportunity Announcenugh the NIH Office of the NIH Etitutes and Centers participate	tilization and adoption in nent (FOA) is developed a Director, Office of Strateg in Common Fund initiation	regulatory submissins a Common Fund in the Coordination ves. The FOA will be	nitiative
110266	Novel Therapeutics	artnerships for the Development of to Combat Select Antibiotic and Fungi (R01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-028	29-Jun-2022 [Optional][LOI/Pre- App]	3,250,000 USD
	Contact Name	Michael R. Schaefer, Ph.D.				
	Contact Telephone	240-627-3364				
	Contact Email	mschaefer@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	29-Jun-2022 [Optional][LOI/Pre-App]	, 29-Jul-2022			
	Synopsis	The purpose of this Funding Opportu projects focused on preclinical develon resistant Acinetobacter baumannii, P include a Product Development Strat encouraged.	opment of lead candidate ther seudomonas aeruginosa, Ente	apeutics and related cour robacteriaceae, or Candic	ntermeasures agains la auris. Application	t antibiotic
109723		evelopment of HIV Broadly ody Susceptibility Assays (R61/R33 lowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-22-022	04-Jul-2022 [Optional][LOI/Pre- App]	Not Specified
	Contact Name	Keith Crawford, Ph.D.				
	Contact Telephone	240-669-2816				
	Contact Email	keith.crawford@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	·	nk to program URL				
		1-Jul-2022 [Optional][LOI/Pre-App],	03-Aug-2022			
	Synopsis Pr ve	nis funding opportunity will support esigned to enable the measurement roposed studies should target early- erification and late stage validation cademia and industry is strongly end	t of HIV susceptibility to broad stage assay development and of the method. Collaborative,	ly neutralizing antibodies demonstrate feasibility a	(bNAbs) in clinica nd clinical utility,	l laboratories followed by
088718	International Research Clinical Trial Not Allo	ch in Infectious Diseases (R01 wed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-108	15-Jul-2022	625,000 USD
	Contact Name Gl	len C. McGugan, Jr., Ph.D.				
	Contact Telephone 24	40-627-3314				
	Contact Email gr	m233g@nih.gov				
	Sponsor Website					
	Program URL <u>Li</u> i	nk to program URL				
	Deadline Dates (ALL) 15	5-Jul-2022 , 19-Aug-2022				
	Synopsis or lo	ne purpose of this Funding Opportugionally relevant infectious disease ganizations must be headquartered wer-middle-income economies, and oplicant organizations will be determined.	research by international inved in foreign (non-U.S.) resourced upper-middle-income econo	estigators in resource-con e-constrained countries (i mies by World Bank Class	strained countries .e. low-income ec sification). Eligibilit	s. Applicant onomies, ty status of
091509	Innovation for HIV Va Not Allowed)	accine Discovery (R01 Clinical Trial	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-20-158	28-Jul-2022	Not Specified
	Contact Name Jo	n Warren, Ph.D.				
	Contact Telephone 24	40-627-3032				
	Contact Email JV	Varren@niaid.nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jul-2022				
	Synopsis	The purpose of this Funding Opportuon vaccine approaches to prevent acconsture of this research, this FOA supperson most R01 projects. Continued fucriteria by the end of Year 2.	quisition of or ongoing infectio ports a Go/No-Go approach to	n by HIV. In keeping with funding high risk researcl	the high risk, high h, which is signific	n impact antly different
	Global Infectious D	isease Research Administration	National Institute of Allergy			100.000
100348	<del></del>	d for Low-and Middle-Income	and Infectious	PAR-21-037	28-Jul-2022	100,000 USD
	Country Institution	s (G11 Clinical Trial Not Allowed)	Diseases/NIH/DHHS			
	Contact Name	Paula S. Strickland, Ph.D., MPH				
	Contact Telephone	240-669-2922				
	Contact Email	pstricklan@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jul-2022 , 28-Jul-2023				
	Synopsis	The purpose of this Funding Opportu middle-income countries (LMIC) to possible management of NIH grants. The ulting funding policies and Federal research income countries.	rovide senior administrators fron nate goal is to improve oversigl	om these institutions with nt of NIAID grant awards	h advanced trainir and compliance w	ng in the vith NIH
107713	Notice of Special In Opportunities on H	terest (NOSI): Promoting Research IV/AIDS in NIAMS	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-20-005	07-May-2022	Not Specified
	Contact Name	Heiyoung Park, Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	parkh1@mail.nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website					
	Program URL Link to	program URL				
	Deadline Dates (ALL) 07-Ma	ıy-2022 , 05-Jun-2022 , 16-Jun-2	.022 , 20-Jul-2022 , 07-Sep-202	22 , 05-Oct-2022 , 16-Oct	-2022 , 18-Nov-20	22 , 07-Jan-
_	<u> </u>	urpose of this announcement is kin Diseases (NIAMS) of an area n.	• • • • • • • • • • • • • • • • • • • •			
108115		(NOSI): Promoting Research atic, Musculoskeletal and Skin	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-22-012	07-May-2022	Not Specified
	Contact Name Marie	Mancini, Ph.D.				
	Contact Telephone 301-5	94-5032				
	Contact Email manci	nim2@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link to</u>	program URL				
		ıy-2022 , 05-Jun-2022 , 16-Jun-2 18-Nov-2022 , 07-Jan-2023	022 , 01-Jul-2022 , 20-Jul-202	2 , 07-Sep-2022 , 05-Oct-	2022 , 16-Oct-202	2 , 04-Nov-
	Synopsis and SI	urpose of this Notice is to annot kin Diseases (NIAMS) an interes AMS mission.				
106576	Notice of Special Interest Research Within the NIAI		National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	NOT-AR-22-007	05-Jun-2022	Not Specified
_	Contact Name Leslie	K. Derr, Ph.D.				
	Contact Telephone 301-4	02-4735				
	Contact Email <u>leslie.</u>	derr@nih.gov				
	Sponsor Website					
	Program URL Link to	program URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		III)eadiine i)ate II	Funding Amount
	Deadline Dates (ALL)	05-Jun-2022 , 16-Jun-2022 , 01-Jul-20 , 01-Nov-2022 , 12-Nov-2022 , 18-No	022 , 12-Jul-2022 , 20-Jul-2022 , v-2022 , 12-Dec-2022 , 22-Jun-2	12-Aug-2022 , 05-Oct-20 2025	022 , 16-Oct-2022 ,	25-Oct-2022
	Synopsis	The purpose of this announcement is Musculoskeletal and Skin Diseases (N mission areas.	•	•		
100387	taran da antara da a	ry Studies to Ongoing Clinical al Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-054	20-Jun-2022 [Optional][LOI/Pre App]	400,000 USD
	Contact Name	Heiyoung Park, Ph.D.				
	Contact Telephone	301-594-5032				
	Contact Email	parkh1@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Jun-2022 [Optional][LOI/Pre-App]	, 20-Jul-2022 , 18-Oct-2022 [Op	otional][LOI/Pre-App], 18	-Nov-2022	
	Synopsis	This Funding Opportunity Announcer ancillary studies related to the NIAM ongoing "parent" clinical project can will be actively collecting patient sam characterized patients, infrastructure response to this FOA will undergo an mechanism to leverage established rancillary studies will enhance the scieunderstanding of a disease or organ streatment, and prevention of disease	S mission in conjunction with post an interventional clinical triangles or clinical data. The "pareit, data, and biological samples for accelerated review and award esources and maximize the return tific content and value of the system in the NIAMS portfolio,	rivately or publicly funderal, or a clinical study such nt" project(s) should profor the ancillary study. Approcess. The objective ourn on existing investment projects, improver	ed, ongoing clinical part of as an observation of we will be a cohort of we oplications submitted for this FOA is to provents in parent project the research coming the comment of the research comment.	orojects. The all study that II- ed in vide a flexible ts. Successfumunity's
100388	<u> </u>	ry Studies to Ongoing Clinical al Trial Not Allowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-055	20-Jun-2022 [Optional][LOI/Pre App]	1,200,000 USD
	Contact Name	Heiyoung Park, Ph.D.				
	Contact Telephone	301-594-5032				



					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email park	n1@mail.nih.gov				
	Sponsor Website	<u></u>				
	Program URL Link	o program URL				
		n-2022 [Optional][LOI/Pre-App]	, 20-Jul-2022 , 18-Oct-2022 [O	ptional][LOI/Pre-App], 18	-Nov-2022	
	Synopsis Synopsis response mechancil unde	Funding Opportunity Announced ary studies related to the NIAM ing "parent" clinical project can be actively collecting patient same acterized patients, infrastructure onse to this FOA will undergo an anism to leverage established rary studies will enhance the scients and ing of a disease or organisment, and prevention of disease	S mission in conjunction with post an interventional clinical triples or clinical data. The "pare post, data, and biological samples accelerated review and award esources and maximize the retentific content and value of the system in the NIAMS portfolio,	orivately or publicly funderial, or a clinical study such that project(s) should profor the ancillary study. Apply process. The objective of the existing investments of the parent projects, improves the parent projects, improves the control of the existing investments.	ed, ongoing clinicant as an observation wide a cohort of word polications submited this FOA is to property in parent project the research cores.	I projects. The real study that rell-cted in covide a flexible ects. Successfumunity's
088239	NIAMS Clinical Trial Plan Not Allowed	ning Grant (R34) - Clinical Trial	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-20-090	01-Jul-2022	300,000 USD
	Contact Name NIAN	1S Clinical Research Team				
	Contact Telephone					
	Contact Email NIAN	1Sclinicaltrials@mail.nih.gov				
	Sponsor Website					
	Program URL Link	o program URL				
	Deadline Dates (ALL) 01-Ju	l-2022 , 01-Nov-2022				
	trials to im Synopsis grant U01 plant	Funding Opportunity Announcer . The R34 planning grant is design plementation of investigator-in for documentation that plannin clinical trial implementation appoing should facilitate the launchict within the research mission of	gned to enable the necessary pitiated clinical trials. Completion ghas been addressed is requirulication that will support the aing of a trial that is hypothesis-	lanning, design, and prep n of the agreed upon mile ed prior to submission of ctual implementation and	earation of docum estones of an R34 an application the d conduct of the s	entation prior planning rough a NIAMS tudy. The



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
100720	-	CO) Studies in Musculoskeletal, seases (RO1 Clinical Trial Not	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-053	01-Jul-2022	475,000 USD
	Contact Name Yan	Wang, M.D., Ph.D.				
	Contact Telephone 301-	-594-5032				
	Contact Email wan	gy1@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 01-J	ul-2022 , 04-Nov-2022 , 03-Mar-2	2023 , 02-Jul-2023 , 03-Nov-20	23		
	obse dise obse dise part obje ence dete	Funding Opportunity Announcer ervational (CO) studies to obtain a ases or conditions. A future clinic ervational studies supported by the ase symptoms, stages, and timing cicipants; and outcomes that are interestive biomarkers or subjective outpuraged to propose studies that a cermining the appropriate primary ents are most likely to respond to	data necessary for designing class and study may include a clinical this FOA can enhance clinical stag of disease progression; como mportant to patients. They also atcome measures for use in a feddress significant obstacles or or secondary outcome measures.	inical studies for muscul trial or an observational udy design by providing orbid conditions; available o can facilitate efforts to tuture clinical study. App questions in the design res or identifying the sta	loskeletal, rheumand I study. Research do essential informat ility of potential reso develop and/or volicants to this FOA of a clinical projectages of disease dur	cic, or skin ata from ion about search alidate are t, such as ing which
100718	NIAMS Clinical Trial Imp Agreement (U01 Clinical	plementation Cooperative al Trial Required)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-036	01-Jul-2022	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email <u>NIAI</u>	MSclinicaltrials@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 01-J	ul-2022 , 04-Nov-2022 , 03-Mar-2	2023 , 02-Jul-2023 , 03-Nov-20	23		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		II) Dadling I) ata	unding mount
	Synopsis applicat other m	ding Opportunity Announcement ator-initiated interventional cling of expected to go through a two ion for the U01 (Part 2). Investi eans may apply for a NIAMS UC of potential for high impact with	nical trials (all phases). Applion- part process, which begins we gators who have completed on without an awarded R34.	cations for clinical trials su with an R34 planning pha- all necessary pre-trial pla The NIAMS expects trials	ubmitted to the NIAN se (Part 1) followed nning and preparatio	MS are by an on through
100719	Exploratory Clinical Trial Gr Musculoskeletal and Skin D Required)	iseases (R21 Clinical Trial	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-21-045	01-Jul-2022	400,000 USD
	This Fun Synopsis research	-5032 @mail.nih.gov	ent (FOA) is designed to facili of types of exploratory studion on and goals of the NIAMS a	tate clinical trials that car es may be submitted to th	nis FOA. The trials m	ust address
109646	RFA-HD-23-007 CAPSTON Multidisciplinary Research (P50) (Clinical Trial Optiona	in Child Abuse and Neglect I	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-007	27-Jun-2022 [Optional][LOI/Pre- App]	5,500,000 USD
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Valerie I maholm Link to p 27-Jun-2	-1514 ev@mail.nih.gov	27-Jul-2022			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsi	This Request for Applications (RFA) is abuse and neglect and to foster dissefunding opportunity announcement multidisciplinary centers to serve as resource for the field. The Center(s) and effectiveness of clinical intervent and understudied types of maltreatm abuse; 3) studies examining the neur testing the development of screening specific types of abuse and neglect to are also required to propose a dissental levels, to be exposed to cutting edmaltreatment. A central goal of this cactivities such as technical assistance webinars based on information emain be tailored to the expertise of the Central goal of the Centra	emination and outreach effort (FOA) will use the specialized the CAPSTONE for research or will conduct innovative and hations; 2) longitudinal prospec- nent including abusive head to obiology of abuse and neglect gotools and clinical assessment of decrease morbidity and mor- nination and outreach core was lige educational tools and tech core will be to engage the scient, evidence-based practice, parating from the other cores.	ts that bridge research, clir research center mechanism child abuse and neglect a ligh quality research includitive studies examining the rauma, medical child abuse than an implications for health measures for early identification and to identify potentich will provide opportunation will provide opportunation and lay professional articipation in grand rounds.	nical practice and p m (P50) to call for and to serve as a na- ling: 1) trials testing clong term effects and neglect, chro th outcomes; and a fication and treath nitial comorbidities nities for students a expertise within the communities in pa s, conferences and	ational g the efficacy of specific onic sexual 4) studies nent of . The Centers and faculty at field of child articipatory seminars, or
109857	· · · · · · · · · · · · · · · · · · ·	National Centers for Translational oduction and Infertility (NCTRI) (P50) onal)	National Institute of Child Health and Human Development/NIH/DHHS	RFA-HD-23-011	28-Jun-2022 [Optional][LOI/Pr App]	e- 5,500,000 USD
	Contact Name	Ravi Ravindranath, DVM, Ph.D.				
	Contact Telephone	301-435-6889				
	Contact Emai	ravindrn@mail.nih.gov				
	Sponsor Website					
	_	Link to program URL				
	Deadline Dates (ALL	) 28-Jun-2022 [Optional][LOI/Pre-App]				
	Synopsi	The Eunice Kennedy Shriver National Infertility (FI) Branch, provides fundir provide an arena for multidisciplinare translational research programs in the National Centers for Translational Re	ng for a limited number of res y interactions among basic an lese scientific areas. The purp	earch centers in the repro d clinical scientists interes ose of this FOA is to annou	ductive sciences. T ted in establishing unce the re-compe	hese centers high quality tition of the

the Specialized Research Center (P50) award mechanism. These centers will form a national network that facilitates and

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		accelerates bidirectional knowledge t reproductive health through research		ry and clinic with the ultir	nate goal of impro	oving human
100820	Biological Testing	Facility (X01 Clinical Trial Not Allowed)	National Institute of Child Health and Human Development/NIH/DHHS	PAR-21-078	15-Jul-2022	Not Specified
	Contact Name	Daniel S. Johnston, PhD				
	Contact Telephone	301-827-4663				
	Contact Email	Daniel.Johnston@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jul-2022				
	Synopsis	The purpose of this FOA is to provide advance their contraceptive development. Applicants do n receiving NIH support at the time of a	ment program. This FOA aims on the common to the common to have current NIH for the common to the co	to position innovative and	l validated metho	ds for future
100184	Clinical Trial or Ob	ractice-Based Research Network servational Study Planning and ooperative Agreement (UG3/UH3 nal)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-20-306	07-May-2022	Not Specified
	Contact Name	Dena Fischer, DDS, MSD, MS				
	Contact Telephone	301-594-4876				
	Contact Email	dena.fischer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-May-2022 , 09-Jun-2022 , 07-Jul-20 2023 , 07-Sep-2023	022 , 07-Sep-2022 , 07-Oct-20	22 , 07-Jan-2023 , 09-Feb	-2023 , 07-May-20	023 , 09-Jun-
	Synopsis	The National Institute of Dental and C dental Practice-Based Research Netw				



		Militalian	ing Opportunities			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	clini obse agre infra and and cone stre prace	onal Coordinating Center support cal trials. This Funding Opportunitervational studies to be conducted ement mechanism. Each UG3/Ulastructure and resources for studipotential transition to a UH3 implies dependent on success in meet duct of the research, NIDCR programline the implementation of natitioners and their patients, to prings into clinical practice. This FO tal PBRN.	ity Announcement (FOA) is soled in the National Dental PBRN H3 award will support an indivy planning and implementatio plementation phase. Progression UG3 milestones, considerary priorities, and availability tional oral health research sturovide evidence useful in daily	iciting applications for clir through a milestone-driv idual project which will ut n. This FOA supports a UG on to the UH3 phase is ba ition of the dental PBRN a of funds. The main goals of dies in dental practices or patient care, and to facilit	nical trials and largen UG3/UH3 coop cilize the National G3 clinical study placed on an adminis s an appropriate woof the dental PBRN in topics of importates the translatio	ge clinical perative Dental PBRN anning phase strative review yenue for ance to an of research
106245	<u> </u>	Social Intervention Clinical Trial ntation Cooperative Agreement Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317	07-May-2022	Not Specified
	Sponsor Website	-451-3888 leme@mail.nih.gov				
	Deadline Dates (ALL) 202	to program URL May-2022, 07-Jun-2022, 07-Jul-2 3, 07-May-2023, 06-Jun-2023, 0 -2024, 07-May-2024	• •		•	
	rese FOA cond NIH	purpose of this Funding Opporturated applications to plan and implications to plan and implications for NIDCR substance Model framework, describer this FOA will initially support a	olement behavioral and social and test behavior change inter apport of clinical trials research ed in detail here and incorpora	intervention clinical trials rventions related to denta n are expected to identify ate an experimental medi	. Studies approprial, oral, or craniofa research proposal cine approach. Aw	ate for this acial Is using the vards made



under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale

SPIN ID	Program Title	Sponsor Name	Sponsor Number		TDeadline Date	Funding Amount
		data collection to assess the feasibility study procedures (e.g., acceptability procedures; preliminary testing of intinclude, at a minimum, development management system and other tools and retention strategies; and other e intervention research at all stages, from implementation and health services with humans that are considered clink Requirements for Grants and Contract	of study content or mode of detervention training and fidelity of: the final clinical protocol; the for data and quality managemessential documents. The UH3 pom early mechanistic research (Stages IV/V). This FOlical trials based on the NIH's research contents.	elivery; feasibility of proper monitoring procedures). The intervention manual conent, safety and operation phase will support the conent and intervention develops A may also support basic	osed data collection Operational plannion equivalent; the dependent of the dependent of the dependent of the dependent (e.g., Stages behavioral experiment)	ing activities ata recruitment or-initiated 0/ I) through nental studies
108878		NIDCR Dental Specialty and PhD ical Trial Not Allowed)	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-001	07-Jun-2022 [Optional][LOI/Pre App]	Not Specified
	Contact Name	Leslie Frieden, Ph.D.				
	Contact Telephone	301-496-4263				
	Contact Email	leslie.frieden@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jun-2022 [Optional][LOI/Pre-App]	, 07-Jul-2022			
	Synopsis	The purpose of the NIDCR Dental Spestructured programs that provide advactivities, and mentored research trato accelerate the process of early car facilitate their transition to independ craniofacial health.	vanced clinical training in an ap ining leading to a PhD in biomo eer dentist scientists achieving	oproved dental specialty, edical or behavioral scien g competencies in both cli	research career de ce. The programs a inical and research	velopment re expected areas, and to
109617		Advancing HIV/AIDS Research at the all and Mental Health (R21 Clinical	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-003	25-Jun-2022 [Optional][LOI/Pro App]	275,000 e- USD
	Contact Name Contact Telephone	Hiroko lida, DDS, MPH 301-594-7404				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email <u>hirok</u> Sponsor Website	o.iida@nih.gov				
	Program URL Link t					
	• •	n-2022 [Optional][LOI/Pre-App],				
	Synopsis the u	urpose of this Funding Opportur nderlying mechanisms and inter lealth, mental health and co-occ	olay of biological, psychosocia	l, behavioral, and social s		
109616		cing HIV/AIDS Research at the Mental Health (R01 Clinical	National Institute of Dental and Craniofacial Research/NIH/DHHS	RFA-DE-23-002	25-Jun-2022 [Optional][LOI/Pre App]	Not Specified
	Contact Name Hirok	o Iida, DDS, MPH				
	Contact Telephone 301-5	94-7404				
	Contact Email <u>hirok</u>	o.iida@nih.gov				
	Sponsor Website					
	Program URL <u>Link t</u>	o program URL				
	Deadline Dates (ALL) 25-Ju	n-2022 [Optional][LOI/Pre-App],	25-Jul-2022			
	Synopsis the u	urpose of this Funding Opportur nderlying mechanisms and inter lealth, mental health and co-occ	olay of biological, psychosocia	l, behavioral, and social s		
107683	Continuation or Revision Implementation Coopera Trial Required)	of NIDCR Clinical Trial ative Agreement (UH3 Clinical	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-22-068	07-Jul-2022	Not Specified
	Contact Name Dena	Fischer, DDS, MSD, MS				
	Contact Telephone					
	Contact Email 301-5	94-4876				
	Sponsor Website Link t	o sponsor website				
	Program URL <u>Link t</u>	o program URL				
	Deadline Dates (ALL) 07-Ju	l-2022 , 04-Nov-2022 , 07-Mar-2	023 , 06-Jul-2023 , 03-Nov-20	23 , 06-Mar-2024		



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Hijeadiine Hate	Funding Amount
	on on Synopsis cor rev Ap	is Funding Opportunity Announcen going clinical trials supported by th going clinical trial through a compe mplete the trial or when an extend- visions will be supported when ther pplicants are strongly encouraged to nich they are planning a competing	e National Institute of Dental and ting renewal application will be s ed period of follow-up is well just e is compelling justification for m contact the appropriate Scientif	d Craniofacial Research supported when there tified to assess longer t nodifying the scope of t fic/Research contact fo	(NIDCR). Extension is need for addition erm outcomes. Con the ongoing clinical r the ongoing clinical	of an al time to npetitive trial. al trial for
110508		tic Fibrosis Research and P30 Clinical Trial Optional)	National Institute of Diabetes and Digestive and Kidney R Diseases/NIH/DHHS	FA-DK-22-011	28-Jun-2022 [Optional][LOI/Pre- App]	3,750,000 USD
	Contact Name Th	omas Eggerman, MD, Ph. D.				
	Contact Telephone 30	1-594-8813				
	Contact Email eg	germant@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	nk to program URL				
	Deadline Dates (ALL) 28	-Jun-2022 [Optional][LOI/Pre-App],	28-Jul-2022			
	Ce Fib a F Synopsis res a s ins	is Funding Opportunity Announcementers. CF Research and Translation prosis. CF Research and Translation Pilot and Feasibility program; and an sources to support research to devente on existing research base in CF. Stitutions with documented program rrently funded CF Research and Tranding/research-programs/cystic-fib	Core Centers are designed to sup Core Centers support three prim Administrative Core with an end Plop and test new therapies for C The NIDDK currently supports sevens of research excellence in basic Inslation Centers may be found at	oport both basic and cli ary research-related ac richment program. Cor F and to foster collabo ven CF Research and Ti c and clinical CF Resear t: https://www.niddk.r	inical research on Contivities: Research Content of Con	ystic ore services; hared tutions with ocated at out the
108849		l Validation of Therapeutic Leads st to the NIDDK (R01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney P. Diseases/NIH/DHHS	AR-22-111	14-Jul-2022	Not Specified
	Contact Name Ya Contact Telephone 30	•				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		TDeadline Date	Funding Amount
	Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis	Link to program URL  14-Jul-2022, 07-Sep-2022, 14-Nov-2, 07-Sep-2024, 12-Nov-2024, 07-Jan-The goal of this Funding Opportunity justification for later stage therapeut National Institute of Diabetes and Digendocrine and metabolic diseases, lividiseases, and hematologic diseases. At www.niddk.nih.gov/research-fund priorities with the Scientific Contacts validation of therapeutic leads (that respected that there is significant now therapeutic would differentiate from to support research focused on under identifying new therapeutic uses for eand of the project period, a successful validity around a therapeutic such the preclinical efforts through other fund	222, 07-Jan-2023, 14-Jul-202 2025 Announcement (FOA) is to superson the second preclinical destive and Kidney Diseases. The rand other digestive diseases additional information concerning/research-programs and appropriate and the formula of the second process of t	pport translational resear al efforts in health-related his includes outcomes related in the programmatic areas oplicants are strongly encore of this FOA is to stimulatics, henceforth called "the name of the biotechnology and pule, or non-viral biologic as be articulated clearly in the trase processes, generating fying mechanism of action significant contribution to other stage therapeutics de	ch that provides street outcomes relevant to diabetes are besity, kidney and use at NIDDK is available ouraged to discuss restree early-stage preciperapeutic leads") supharmaceutical industrial in how the resulting and in how the resulting application. It is not in the application of the data supporting velopment and	ong t to the nd other urological e esearch inical uch as small ustries. It is lting not intended w targets, ds. At the
109584	RFA-DK-21-505 L Continuation of the	(https://sbir.nih.gov/niddk/index), sp imited Competition for the e Data Coordinating Center for the ortium (U24 Clinical Trial Optional)	in-off companies, or licensing  National Institute of Diabete and Digestive and Kidney Diseases/NIH/DHHS		17-Jul-2022 [Optional][LOI/Pre App]	13 180 000
	Contact Name Contact Telephone Contact Email Sponsor Website	Teresa L. Z. Jones, M.D.				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		ם דבנו פחווחבפנוו	Funding Amount
	The Diexpen The Dibioma Synopsis calls for the for care.	abetic Foot Consortium (DFC) abetic Foot Consortium (DFC) sive, and debilitating complicate was started to address this exters to predict healing or recorthe renewal of the Data Coolowing goals: 1) development future research may involve cle overall project coordination, goals.	is the first clinical network for tion of diabetes that leads to significant public health prob urrence of DFUs. This Limited rdinating Center (DCC) for its and validation of biomarkers inical trials and studies on th	o over 100,000 amputations olem by building a research d Competition Funding Oppos support of an expansion of for DFUs and 2) accelerate pethophysiology and previous for pathophysiology and previous for the pathophysiology and pathophysiology	in the United State infrastructure and vortunity Announcen f the mission of the advances in DFU strention of DFUs. The	s every year. alidating nent (FOA) DFC with andard e DCC will
084593	RFA-ES-19-011 Mechar Research Opportunities in Sciences (R21 Clinical Tria	n Environmental Health	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-19-011	02-May-2022	275,000 USD
	This fu unpre- enviro made featur review achiev	11-3335 @niehs.nih.gov	nent (FOA) is intended to sup e provides a limited window of rimary motivation of the FOA ental public health threats, are need for rapid review and for question to be addressed aron due dates and expediting	oport novel environmental hof opportunity to collect hu A is to understand the conse nd policy changes in the U.S funding, substantially shorte nd swiftly implemented. The peer review, council concu	man biological sam equences of natural 5. and abroad. A dist er than the typical N e shortened timefra	oles or and human- inguishing IH grant me will be
110746	RFA-ES-22-004 SBIR E-L Emergency Response (R4 Allowed)		National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-22-004	20-Jun-2022 [Optional][LOI/Pre App]	Not Specified



					_	
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Kathy Ahlmark				
	Contact Name Contact Telephone	Kathy Ahlmark				
		ahlmark@niehs,nih.gov				
	Sponsor Website					
		Link to program URL	1 20 1 1 2022			
	Deadline Dates (ALL)	20-Jun-2022 [Optional][LOI/Pre-App This Funding Opportunity Announce			. (00.0)	
	Synopsis	from small business concerns (SBCs) the health and safety training of: has personnel associated with an emerg response, and medical waste cleanu enhanced training products as define mobile device training, virtual reality from development to evaluation and hazardous materials workers. These NIEHS WTP is to prevent work relate from exposure to hazardous material and Training Branch SBIR funds.	zardous materials (HAZMAT) wo ency/disaster; emergency respo p; emergency responders in dis ed by the Worker Training Prog y, and serious gaming. These add d can enhance, supplement, imp products must complement the ed harm by training workers in h	orkers; waste treatment ponders in biological hazar asters; and worker resilier am (WTP) include, but a vanced technologies comprove, and provide health a goals and objectives of low best to protect them	d response, infect of response, infect ency training. Tech re not limited to, of aplement all phase of and safety training WTP. The major of selves and their co	support ious disease nology- online training as of training ng for bjective of the
109334	Tissues (SMaHT) P	Somatic Mosaicism across Human rogram: Genome Characterization ical Trial Not Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-RM-22-013	08-Jun-2022	Not Specified
		Amy C. Lossie, Ph.D.				
	Contact Telephone	,				
	•	SMaHT@mail.nih.gov				
	Sponsor Website					
	•	Link to program URL				
	•	08-Jun-2022 , 08-Jul-2022				
	Synopsis	This funding opportunity appounces				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	£ f c i	of new biology and disease mechanis generating state of the art, high throu from 150+ donors. The GCCs will wor comprehensive catalog of variants. The nitiative (http://commonfund.nih.go (https://dpcpsi.nih.gov/). All NIH Instituted	ughput genomic data characted k closely with the SMaHT Data his Funding Opportunity Annou v/) through the NIH Office of t itutes and Centers participate	rizing somatic variants in Analysis Center to build uncement (FOA) is develo he NIH Director, Office of in Common Fund initiativ	a set of 10-15 hur the framework fo ped as a Commor f Strategic Coordir	man tissues r a n Fund nation
109327		omatic Mosaicism across Human ogram: Tissue Procurement Center ot Allowed)	National Institute of Mental Health/NIH/DHHS	RFA-RM-22-012	08-Jun-2022	Not Specified
	Contact Telephone 3 Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis to Synopsis to See Suppose the Sup	Geetha Senthil, Ph.D.  301-402-0754  SMaHT@mail.nih.gov  Link to program URL  08-Jun-2022, 08-Jul-2022  This Funding Opportunity Announcent  Somatic Mosaicism across Human Tise  new biology and disease mechanisms  Center is to collect, process, store, and  cissues recovered from a minimum of  Announcement (FOA) is developed as  the NIH Director, Office of Strategic Common Fund initiatives. The FOA with	sues (SMaHT) Network. The pushed and all substants of the pushed by genomic variation of the Network of Ne	urpose of the SMaHT Net on in somatic tissues. The work at least 15 high qua n a diverse pool of donor: tp://commonfund.nih.go h.gov/). All NIH Institutes	work is to enable goal of the Tissue lity, well charactes. This Funding Op v/) through the Nand Centers parti	discovery of Procurement rized, human portunity IH Office of icipate in
109312		omatic Mosaicism across Human ogram: Organizational Center (U24 owed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-22-009	08-Jun-2022	Not Specified
	Contact Name J Contact Telephone 3					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		II)eadiine Date	Funding Amount
	Contact Email SM	1aHT@mail.nih.gov				
	Sponsor Website					
	· ·	ık to program URL				
	Deadline Dates (ALL) 08-					
	Mobio cod Synopsis cor And the	is Funding Opportunity Announcembraicism across Human Tissues (SM plogy and disease mechanisms med ordinate meetings, communication adult for collaboration with related nouncement (FOA) is developed as a NIH Director, Office of Strategic Common Fund initiatives. The FOA will INDS) on behalf of the NIH.	aHT) Network. The purpose o liated by genomic variation in , outreach, and other organiza programs and the wider rese a Common Fund initiative (htoordination (https://dpcpsi.ni	f the SMaHT Network is t somatic tissues. The Orga ational activities within th arch community. This Fu tp://commonfund.nih.go h.gov/). All NIH Institutes	o enable discovery anizational Center whe Network and be the nding Opportunity w/) through the NIF and Centers partic	of new vill the main I Office of ipate in
109325		matic Mosaicism across Human ram: Tool Development Projects al Not Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-22-011	08-Jun-2022 [Optional][LOI/Pre App]	1,700,000 USD
	Contact Name Jill	Morris, Ph.D.				
	Contact Telephone 303	1-496-5754				
	Contact Email SM	1aHT@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	k to program URL				
	Deadline Dates (ALL) 08-	-Jun-2022 [Optional][LOI/Pre-App],	08-Jul-2022			
	und of the Synopsis sor enl (FC	is Funding Opportunity Announcem derstanding of somatic variants as the SMaHT Network is to enable dismatic tissues. Technology and Tool hance our ability to detect and charped is developed as a Common Function of Strategic Coordination (https://www.commonecomm	part of the Somatic Mosaicism scovery of new biology and di Development Projects will de racterize somatic variants in h d initiative (http://commonfu	n across Human Tissues (S sease mechanisms media velop the next generatior uman tissues. This Fundir nd.nih.gov/) through the	SMaHT) Network. The steed by genomic vare of technologies the ng Opportunity Ann NIH Office of the NI	ne purpose riation in at will ouncement IH Director,

SPIN ID	Program	Snoncor Namo	Spansor Number		Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadine Date	Amount
		initiatives. The FOA will be administer the NIH.	ed by the National Institute o	f Neurological Diseases a	and Stroke (NINDS)	on behalf of
110192	RFA-NS-22-038 Trial Optional)	Research Program Award (R35 Clinical	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-NS-22-038	13-Jun-2022 [Optional][LOI/Pr App]	e- 6,000,000 USD
	Contact Name	Alisa Schaefer, Ph.D.				
	Contact Telephone					
	Contact Email	alisa.schaefer@nih.gov				
	Sponsor Website	:				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Jun-2022 [Optional][LOI/Pre-App], [Optional][LOI/Pre-App], 15-Jul-2024	13-Jul-2022 , 13-Jun-2023 [O	ptional][LOI/Pre-App], 13	3-Jul-2023 , 15-Jun-	2024
	Synopsis	The purpose of the NINDS Research P flexibility to Program Directors (PDs)/administrative burden of writing and investigators at most career stages the research opportunities, and mentor stay will support the overall research progen PD/PI's recent NINDS support (Part 2, security, allowing them to undertake breaks new ground. Research activities Center, will not be considered through facilitating the pursuit of longer-term opportunities as they arise, not tied to grant awards, allowing investigators to mentor and foster a diverse workforce ensure it reflects our commitment to NIH-supported scientific workforce, in enhances global competitiveness, con (see NIH's Interest in Diversity). NINDS of scientific areas, approaches, region	Principal Investigators (PIs), to managing multiple grant applie opportunity to advance their tudents and postdoctorates, was a NINDS-funded investing Section II). This greater funding research projects that require its outside of the NINDS mission this program. Benefits of the research goals; Flexible funding specific aims; Reduced time to spend more time conducting in their laboratories. The RP enhancing the diversity and in accluding individuals from undestributes to robust learning ends will work to ensure that it means to the second of t	allow them to redirect to cations and towards engin long-term research goal which support and align was gators for up to 8 years, and stability will provide ear a longer timeframe or towards, or traditionally support and include: A more stand, enabling investigators spent writing grant appling and overseeing research is a unique program for a clusiveness of the neuroexprepresented groups, for the including and improve the control of the	their time away from gaging in the lab. The als, rigorously exploowith the mission of at a level commense eligible investigators o embark upon reserved by another NIH able funding envirors to pursue research ications and managon; More time for Plan or NINDS, as such NI oscience workforce, sters scientific innores the quality of the erse research portfores.	m the his RPA affords here exciting NINDS. RPAs surate with a his increased hearch that H Institute or himment, h hing multiple DS/PIs to NDS strives to A diverse hearch his research holio in terms

SPIN ID	Program Title	Sponsor Name	Sponsor Number		TIDEAUINE DATE	unding Imount
	op exp	vestments by maximizing the ideas portunity also accepts clinical trials perimental studies with humans (Bope of this funding opportunity anr	s, only applications proposing ' ESH) will be accepted. For info	mechanistic clinical trials rmation on the types of	s or studies" or basic clinical trial that are	_
110404		D-enabling Studies of Somatic apeutic Leads (U19, Clinical Trial	National Institute of Neurological Disorders and Stroke/NIH/DHHS	RFA-RM-22-015	17-Jun-2022 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Ch	ris H. Boshoff Ph.D.				
	Contact Telephone 30:	1-496-0664				
	Contact Email chr	ris.boshoff@nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u>	ık to program URL				
	Deadline Dates (ALL) 17-	-Jun-2022 [Optional][LOI/Pre-App]	, 19-Jul-2022			
	Edi opi (In sho Synopsis poi An the	is funding opportunity announcemiting (SCGE) Phase II Program. The timization and development of gervestigational New Drug) applicatio ould demonstrate strong biological stem(s) each defined by the target tentially adaptable to target differencement (FOA) is developed as a NIH Director, Office of Strategic Common Fund initiatives. The FOA will INDS) on behalf of the NIH.	goal of this U19 FOA is to supponence editing-based therapeution submission to the U.S. Food rationale and in vitro and/or ited cell or tissue type to established pathogenic variants in the sa Common Fund initiative (htwo cordination (https://dpcpsi.ni	ort team-based research ic leads towards IND-enal and Drug Administration in vivo proof of concept (sh a genome editing ther same cell or tissue types. tps://commonfund.nih.gh.gov/). All NIH Institutes	Projects to accelerate bling studies and an (FDA). The proposed POC) data generated apeutic approach the This Funding Opportov/) through the NIH and Centers participal bling process.	te further IND d leads l in model at is tunity I Office of pate in
105757	NINDS Research Educa Trial Not Allowed)	ation Opportunities (R25 Clinical	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-21-256	14-Jul-2022	1,250,000 USD
		ephen Korn, Ph.D., Director				
	Contact Telephone 303	1-496-4188				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email korns	@ninds.nih.gov				
	Sponsor Website					
	Program URL Link t	program URL				
	Deadline Dates (ALL) 14-Ju	<del></del>				
	overa worki goal, Exper	rching goal of this R25 program orce to meet the nation's bion this FOA will support creative of tences The purpose of this fun	m (R25) supports research education is to support educational active medical, behavioral and clinical reducational activities with a prinching opportunity announcement neuroscience research educations submitted under this FOA shows	rities that complement a esearch needs. To accon nary focus on: Courses fo t is to encourage applica n programs that will sigr	nd/or enhance the mplish the stated or Skills Developmentions for the initial officiantly advance of the median control of the initial officiantly advance of the initial official	e training of a over-arching ent Research tion or the mission o
	only p exper appro	le research experience, an in-cossible from a nationally orgationce, programs must also inc	depth understanding of techniqu nized program. Within the conto lude immersive coursework and de participants from a nationally	ues, analytic approaches ext of gaining expertise p expert discussion when	and theory, and e orimarily through h appropriate. Prog	xpertise that nands-on rams
085882	only percentage on the control of th	le research experience, an in-cossible from a nationally orgation incomplete, programs must also incompriate for this FOA must includes overseen by a well-balance of the control of the c	depth understanding of techniqu nized program. Within the conto lude immersive coursework and de participants from a nationally	ues, analytic approaches ext of gaining expertise p expert discussion when	and theory, and e orimarily through h appropriate. Prog	xpertise that nands-on rams
085882	Patient Activation for Se Conditions (R01 Clinical	le research experience, an in-cossible from a nationally orgation incomplete, programs must also incompriate for this FOA must includes overseen by a well-balance of the control of the c	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise p expert discussion when recruited cohort, select	and theory, and e primarily through h appropriate. Prog ed through an app	xpertise that nands-on rams olication
085882	Patient Activation for Se Conditions (R01 Clinical	le research experience, an in-cossible from a nationally orgation, programs must also incompriate for this FOA must includes overseen by a well-balance of the comprise of the	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise p expert discussion when recruited cohort, select	and theory, and e primarily through h appropriate. Prog ed through an app	xpertise that nands-on rams olication
085882	Patient Activation for Se Conditions (R01 Clinical Contact Name Karer	le research experience, an in-cossible from a nationally orgatione, programs must also incorpriate for this FOA must includes overseen by a well-balance of the company of	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise p expert discussion when recruited cohort, select	and theory, and e primarily through h appropriate. Prog ed through an app	xpertise that nands-on rams olication
085882	Patient Activation for Se Conditions (R01 Clinical  Contact Name Contact Telephone 301-5	le research experience, an in-cossible from a nationally orgatione, programs must also incorpriate for this FOA must includes overseen by a well-balance of the company of	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise p expert discussion when recruited cohort, select	and theory, and e primarily through h appropriate. Prog ed through an app	xpertise that nands-on rams olication
085882	Patient Activation for Se Conditions (R01 Clinical  Contact Name Karer Contact Telephone 301-5 Contact Email	le research experience, an in-oossible from a nationally orgatience, programs must also incorpriate for this FOA must includes overseen by a well-balance of the complete of the corprise of t	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise p expert discussion when recruited cohort, select	and theory, and e primarily through h appropriate. Prog ed through an app	xpertise that nands-on rams olication
085882	Patient Activation for Se Conditions (R01 Clinical  Contact Name Contact Telephone Contact Email Sponsor Website Program URL Link t	le research experience, an in-cossible from a nationally orgatience, programs must also incorpriate for this FOA must includes overseen by a well-balance of the company of	depth understanding of techniques inized program. Within the content in the conte	ues, analytic approaches ext of gaining expertise pexpert discussion when recruited cohort, select  PAR-19-381	and theory, and e primarily through h appropriate. Prog red through an app 07-May-2022	xpertise that nands-on rams olication
085882	Patient Activation for Seconditions (R01 Clinical Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synonsis	le research experience, an in-ossible from a nationally orgatience, programs must also incorpriate for this FOA must includes overseen by a well-balance of the composition of the corporation of the corpo	depth understanding of techniquenized program. Within the contellude immersive coursework and de participants from a nationally deleadership committee.  National Institute of Nursing Research/NIH/DHHS  N, FAAAAI	ues, analytic approaches ext of gaining expertise pexpert discussion when recruited cohort, select  PAR-19-381  23,05-Mar-2023,07-M	and theory, and e primarily through h appropriate. Progred ted through an app 07-May-2022	xpertise that nands-on rams plication Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number			Funding Amount		
	Contact Telephone	301-594-5970						
	Contact Email	hussk@mail.nih.gov						
	Sponsor Website							
	· ·	Link to program URL						
	Deadline Dates (ALL)	07-May-2022 , 16-Jun-2022 , 16-Jul-2						
Synopsis The purpose of this Funding Opportunity Announcement is to encourage grant applications that address the patient activation on self-management of chronic conditions.								
081489	· · · · · · · · · · · · · · · · · · ·	on: Modular Budget Research Project se Scientist Scholars (R01 Clinical Trial	National Institute of Nursing Research/NIH/DHHS	PAR-19-256	06-Jul-2022	1,250,000 USD		
	Contact Name	David Banks, PhD, MPH, RN						
	Contact Telephone	301-496-9558						
	Contact Email	david.banks@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
	Deadline Dates (ALL)	06-Jul-2022						
	Synopsis	The purpose of this funding opportunity announcement (FOA) is to encourage modular budget R01 grant applications from nurse scientists who are currently or were supported within the last 3 years by an NIH Career Development (K) award. This opportunity is limited to those K awardee nurse scientists who have NIH New Investigator status. Through this opportunity, NINR seeks to enhance the transition of nurse scientists to independent investigator status.						
109174	Treatments for Alz	Health Equity and the Cost of Novel theimer's Disease and Related 33 Clinical Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-005	01-Jun-2022 [Optional][LOI/Pre App]	Not Specified		
	Contact Name	Priscilla Novak, Ph.D., MPH						
	Contact Telephone	301-401-3136						
	Contact Email	NIANovelTreatmentsRFA@nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	unding mount
	Deadline Dates (ALL) 01-J	lun-2022 [Optional][LOI/Pre-App],	. 01-Jul-2022			
	This acce (ADI mine Synopsis inte cond dem	Funding Opportunity Announcentess to new therapeutics or repurp RD). Successful applications will so ority people living with AD/ADRD, ority people living with AD/ADRD, rested in receiving novel or repurduct rigorous stakeholder engage and for new and repurposed drug deling of costs and health-related	nent (FOA) invites R61/R33 ap osed drugs for Alzheimer's dis eek to identify preferences fo assess whether cost barriers and quantify expenditures an posed drugs for AD/ADRD. Th ment with racial and ethnic m gs. If successful, grantees will	sease (AD) and Alzheimer's reharmacological treatments to pharmacological care end health-related quality constitutions for study designations are study designations. The second supports a study designation to an R33 phases to identify, transition to an R33 phases.	s disease-related de ent among racial and exist for racial and et of life (HRQoL) amon evelopment phase (F measure, and asses	mentias I ethnic hnic g people R61) to s the
109243	RFA-AG-23-014 Mech in AD/ADRD (R01 Clinic	nanisms of Brain Hypoperfusion cal Trial Not Allowed)	National Institute on Aging/NIH/DHHS	RFA-AG-23-014	01-Jun-2022 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Mire	oslaw 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone 301-	-594-7636				
	Contact Email <u>mirc</u>	oslaw.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 01-J	un-2022 [Optional][LOI/Pre-App],	01-Jul-2022			
	Synopsis cellu	Funding Opportunity Announcen ular mechanisms underlying cereb nentias (ADRD).		. ,		
		urces to Promote Coordination			01-Jun-2022	
107991	and Collaboration acros Longitudinal Behaviora Clinical Trial Not Allowe	l and Social Studies of Aging (U24	National Institute on Aging/NIH/DHHS	RFA-AG-23-003	[Optional][LOI/Pre-App]	1,600,000 USD
	Contact Name Jani	ne Simmons, M.D., Ph.D.				
	Contact Telephone 301-	-529-7254				
	Contact Email janii	ne.simmons@nih.gov				



SPIN ID	Program	Sponsor Name	Sponsor Number			Funding	
31 114 15	Title	Sponsor reame	Sponsor Humber		bedamie bate	Amount	
	Sponsor Website						
	,	nk to program URL					
		-Jun-2022 [Optional][LOI/Pre-App]	01-Jul-2022				
	on lor FO and Synopsis bas rich and tea add	This Funding Opportunity Announcement (FOA) invites applications to establish a Resource Development Network focused on the infrastructure needed to promote and support coordination, collaboration, and innovation across deeply phenotype longitudinal behavioral and social studies of aging that are rich in psychological, behavioral, and biobehavioral content. This FOA calls for investigator teams to design an innovative network that will serve the field at large and advance collaboration and coordination among studies. Network activities are expected to include: Outreach to investigators and support for meetings that will stimulate innovation and collaboration. Creation of a publicly available meta-data catalogue on a webbased platform that will identify and describe existing deeply phenotyped behavioral and social datasets characterized by rich psychological, behavioral, and biobehavioral content; identify studies with overlapping measures or compatible designs and support cross-project co-analysis. Methodological consultation services for investigators. Pilot support for collaborative teams to leverage existing deeply phenotyped longitudinal studies to answer new questions of relevance to aging and the adult lifespan, including the influence of social and behavioral factors on healthspan and biological aging; address replication and generalizability issues; and provide educational opportunities for the next generation of investigators.					
109301		eening for Cognitive Impairment: 4 Clinical Trial Optional)	National Institute on Aging/NIH/DHHS	RFA-AG-23-007	11-Jun-2022 [Optional][LOI/Pre App]	10,720,000 USD	
	Contact Name Jor	nathan W. King, Ph.D.					
	Contact Telephone 30:	1-496-3136					
	Contact Email NI	AScreeningDMFOA@nih.gov					
	Sponsor Website						
	Program URL <u>Lin</u>	nk to program URL					
	Deadline Dates (ALL) 11-	-Jun-2022 [Optional][LOI/Pre-App]	, 11-Jul-2022				
	Synopsis that tar	is Funding Opportunity Announcer at could be used to screen for defic tcomes in older adults. In particula at could be useful in the context of geting functional outcomes in pers rtners/caregivers. The goal of this	its related to decision-mak r, we are interested in inst future screening for cognit sons living with cognitive in	ing, planning, and other impruments that can track chan tive impairment and the dev opairment and/or quality of	portant higher order ges in decision-maki relopment of interve life outcomes of the	functional ing capacity intions ir care	

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	d ir a:	imensions of higher cognitive abiliti ecision-making; to develop valid and astrument development and validati s well as a set of enduring resources ormative data that will enable other	d reliable measures of those on in a racially, ethnically, ge on in a racially, ethnically, ge a. Enduring resources include	abilities; and to provide su ographically, and diagnos the measurement instrun	ipport for pilot effo tically diverse set of nents, documentati	ts during the participants
109431	taran da antara da a	oncoding RNAs in Alzheimer's Dementias (R01 Clinical Trial Not	National Institute on Aging/NIH/DHHS	RFA-AG-23-010	15-Jun-2022 [Optional][LOI/Pro App]	2,500,000 - USD
	Contact Name A	lison Yao, Ph.D.				
	Contact Telephone 3	01-827-7264				
	Contact Email <u>y</u>	aoal@nia.nih.gov				
	Sponsor Website					
		ink to program URL				
	Deadline Dates (ALL) 1	5-Jun-2022 [Optional][LOI/Pre-App]	, 15-Jul-2022			
	Synopsis A m	he goal of this Funding Opportunity nvestigate the causality, directionalist Izheimer's disease-related demention nediated by ncRNAs and to elucidated D/ADRD.	cy, mechanisms, and therape as (AD/ADRD). This FOA supp	utic potential of ncRNAs ir orts applications seeking t	n Alzheimer's diseas to discover novel m	e and echanisms
109432		oncoding RNAs in Alzheimer's Dementias (R21 Clinical Trial Not	National Institute on Aging/NIH/DHHS	RFA-AG-23-011	15-Jun-2022 [Optional][LOI/Pro App]	275,000 USD
	Contact Name A	lison Yao, Ph.D.				
	Contact Telephone 3	01-827-7264				
	Contact Email y	aoal@nia.nih.gov				
	Sponsor Website					
	Program URL <u>Li</u>	nk to program URL				
	Deadline Dates (ALL) 1	5-Jun-2022 [Optional][LOI/Pre-App]	, 15-Jul-2022			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		TDeadline Date	unding
	investig and Alzi Synopsis applicat progres	ate the causality, directionalit neimer's disease-related demo ions seeking to discover funct	Announcement (FOA) is to stire, mechanisms, and therapeurentias (AD/ADRD). This FOA subjectional roles of ncRNAs and uncestional should focus on function	tic potential of ncRNAs im upports exploratory and delerlying mechanisms invol	nplicated in Alzheime evelopmental grant lved in the pathoger	er's disease (R21) esis and
110576	RFA-AG-23-028 Neurona Proteinopathies in Alzheim Disease-Related Dementias Allowed)	er's Disease and Alzheimer's	National Institute on Aging/NIH/DHHS	RFA-AG-23-028	15-Jun-2022 [Optional][LOI/Pre- App]	Not Specified
	Contact Name Mirosla	w 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone 301-594	1-7636				
	Contact Email mirosla	w.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL Link to 1	orogram URL				
	Deadline Dates (ALL) 15-Jun-2					
	Synopsis The goa that are	l of this Funding Opportunity vulnerable to Alzheimer's dis	Announcement (FOA) is to de ease (AD) and AD-related den	fine and characterize neu nentias (ADRD) proteinop	ronal and glial cell pathies.	opulations
108315	Notice of Special Interest (I Workforce for Those Living and Alzheimer's Disease-Re		National Institute on Aging/NIH/DHHS	NOT-AG-21-049	08-Jul-2022	Not Specified
	Contact Name John W.	R. Phillips, Ph.D.				
	Contact Telephone 301-496	5-3136				
	Contact Email john.ph	illips@nih.gov				
	Sponsor Website					
	Program URL Link to 1	orogram URL				
	Deadline Dates (ALL) 08-Jul-2	022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-20	23 , 11-Mar-2024 , 09-Jul-	-2024 , 12-Nov-2024	



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis of the state of the st	This Notice of Special Interest (NOSI) and the impact of workforce factors of dementia (AD/ADRD) and their famili provide care may cite NOT-AG-21-046 cite NOT-AG-21-047 in the Agency Ronot be considered a high priority for texplore whether PAR-21-307 Dementor PAR-21-308 Pragmatic Trials for Deappropriate.	on outcomes for persons lives. Applications focused or and applications focused uting Identifier field (box 4 this NOSI. Studies proposing Care and Caregiver Supp	ring with Alzheimer's disease in care of persons living with solely on unpaid dementia of B). PLEASE NOTE: Application g dementia care intervention port intervention Research (F	e or Alzheimer's dis dementia and the care partners/care ns proposing clinic n research are enc 201 – Clinical Trial	sease-related systems that givers may cal trials will ouraged to Required)
108305	-	terest (NOSI): Novel Approaches to dying Clinical Alzheimer's Disease ntias	National Institute on Aging/NIH/DHHS	NOT-AG-21-036	08-Jul-2022	Not Specified
	Contact Name	John Hsiao, M.D.				
	Contact Telephone	301-496-9350				
	Contact Email j	<u>jhsiao@mail.nih.gov</u>				
	Sponsor Website					
	Program URL <u>I</u>	Link to program URL				
		08-Jul-2022 , 14-Nov-2022 , 10-Mar-2				
	Synoncici	The goal of this NOSI is to encourage outcomes in AD and ADRD.	the development of novel a	approaches to characterizing	g, diagnosing, and	predicting
108313		terest (NOSI): Digital Technology for I Monitoring of Alzheimer's Disease htias	National Institute on Aging/NIH/DHHS	NOT-AG-21-048	08-Jul-2022	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuan.luo@nih.gov				
	Sponsor Website					
	Program URL <u>I</u>	<u>Link to program URL</u>				
	Deadline Dates (ALL)	08-Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-	-2023 , 11-Mar-2024 , 09-Jul	-2024 , 12-Nov-20	24



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis mor	Notice of Special Interest (NOSI) itoring of cognitive and functions	encourages research on the al decline in persons with A	e use of digital technology Izheimer's disease (AD) an	for early detection ad AD-related demen	and ntias (ADRD).
108309	Notice of Special Intere Science Priority Areas in Partner/Caregiver Rese		National Institute on Aging/NIH/DHHS	NOT-AG-21-047	08-Jul-2022	Not Specified
	Contact Name Mel	ssa S. Gerald, Ph.D.				
	Contact Telephone 301-	496-3136				
	Contact Email <u>mel</u>	ssa.gerald@nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 08-J	ul-2022 , 14-Nov-2022 , 10-Mar-2	.023 , 10-Jul-2023 , 13-Nov-	2023 , 11-Mar-2024 , 09-J	ul-2024 , 12-Nov-20	24
	Synopsis the	NOSI solicits high-priority Alzheir s as set forth by the National Inst AD/ADRD research implementation mit and recommendations from	itute on Aging's Division of on milestones and are base	Behavioral and Social Res d on expert discussions fro	earch. Priority areas om the NIH 2020 De	are guided by mentia Care
108307		st (NOSI): In vivo Synaptic Disease and Related Dementias	National Institute on Aging/NIH/DHHS	NOT-AG-21-038	08-Jul-2022	Not Specified
	Contact Name John	Hsiao, M.D.				
	Contact Telephone 301	496-9350				
	Contact Email jhsia	o@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 08-J	ul-2022 , 14-Nov-2022 , 10-Mar-2	.023 , 10-Jul-2023 , 13-Nov-	2023 , 11-Mar-2024 , 09-J	ul-2024 , 12-Nov-20	24
	Synopsis (AD)	Notice of Special Interest (NOSI) and Alzheimer's disease-related, in humans.				
108114		st (NOSI): Genetic Underpinnings g as a Pathological Hub in	National Institute on Aging/NIH/DHHS	NOT-AG-21-034	08-Jul-2022	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Alzheimer's Disease ar Dementias (AD/ADRD)	nd Alzheimer's Disease-Related				
	Contact Name Ma	rilyn Miller, Ph.D.				
	Contact Telephone 301	L-496-9350				
	Contact Email <u>mil</u>	<u>lerm@nia.nih.gov</u>				
	Sponsor Website					
	Program URL <u>Lin</u> l	k to program URL				
	Deadline Dates (ALL) 08-	Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-2	2023 , 11-Mar-2024 , 09-Jul-	-2024 , 12-Nov-202	24
	mo Synopsis rela enh	e goals of this Notice of Special Intellecular, cellular, and physiological ated dementias (ADRD). Studies fundering our understanding of how pathophysiological changes assoc	processes associated with t nded under this topic will su the genetic underpinnings o	he endosomal compartmen upport research into AD/AD	t in AD and Alzhei RD pathogenesis r	mer's disease- elated to
108282	Research in Epidemiol	est (NOSI): Opportunities for ogy of Alzheimer's Disease and elated Dementias (AD/ADRD) and	National Institute on Aging/NIH/DHHS	NOT-AG-21-045	08-Jul-2022	Not Specified
	Contact Name Dal	las W. Anderson, Ph.D.				
	Contact Telephone 301	1-402-6693				
	Contact Email <u>dal</u>	las.anderson@nih.gov				
	Sponsor Website					
	Program URL <u>Lin</u> l	k to program URL				
	Deadline Dates (ALL) 08-	Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-2	2023 , 11-Mar-2024 , 09-Jul	-2024 , 12-Nov-202	24
	Synopsis rele	s Notice of Special Interest (NOSI) evant to AD/ADRD and cognitive re Il as gaps and opportunities identif	esilience, but identifies spec	ific areas that build on curre	ent efforts support	
108279	the control of the co	est (NOSI): Capturing Complexity Cellular Mechanisms Involved in ner's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-21-041	08-Jul-2022	Not Specified



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name Contact Telephone Contact Email Sponsor Website Program URL	yangj13@mail.nih.gov	novative research focused	on understanding the mole	ecular and cellular m	24 nechanisms
	Synopsis	scientific paradigms. This NOSI encor	urages individual and/or complex biology of AD to fill ely addressed in the past. A	ollaborative research projec critical knowledge gaps or to applicants are encouraged to	ts that propose inno o examine critical ar o use or develop sta	ovative reas of AD ate-of-the-art
108278		nterest (NOSI): Selective Cell and illity in Aging and Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-21-040	08-Jul-2022	Not Specified
	Contact Name	Bradley C. Wise, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	WiseB@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL) Synopsis	O8-Jul-2022, 14-Nov-2022, 10-Mar- The goal of this Notice of Special Inte (e.g., neurons and glia), neural activi (or resistant) in brain aging and AD a signatures of different types of neuro and in different stages of AD will imp types by physiological measures such networks will provide a functional in generate sophisticated data on mole	erest (NOSI) is to stimulate ty and circuits, structural a nd the mechanisms under ons and glial cells across th plicate cell processes and p n as electrophysiology and dex of selective vulnerabili	research to define and cha nd functional networks, and lying such selective vulneral te adult lifespan, in AD comp athways mediating selective connectivity and manipulatity. Applicants are encourag	racterize neural cell d brain regions that bility. Genetic and mared to other demonstrate vulnerability in AD ting neural activity in ged to use new appropersions.	populations are vulnerable nolecular entias of aging, Defining cell n circuits and oaches to



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		networks. Understanding the mechan define the disease process and to dev		nerability from cells to ne	tworks in AD is cri	tical to fully
108284		terest (NOSI): Dementia Care and Services for Persons with	National Institute on Aging/NIH/DHHS	NOT-AG-21-046	08-Jul-2022	Not Specified
	Contact Name E	Elena Fazio, Ph.D.				
	Contact Telephone 3	301-496-3136				
	Contact Email <u>e</u>	elena.fazio@nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 0	98-Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-20	023 , 11-Mar-2024 , 09-Jul	-2024 , 12-Nov-20	24
	Synopsis e	This NOSI invites applications on highereas as set forth by the National Instexpert discussions from the NIH 2020 Research on AD/ADRD, and is aligned	itute on Aging's Division of Be Dementia Care Summit, the	ehavioral and Social Resea NASEM Decadal Survey of	arch. The NOSI is b	ased on
108281		rerest (NOSI): Sensory and Motor Predictors of Preclinical Alzheimer's	National Institute on Aging/NIH/DHHS	NOT-AG-21-044	08-Jul-2022	Not Specified
	Contact Name C	Coryse St. Hillaire-Clarke, Ph.D.				
	Contact Telephone 3	801-827-6944				
	Contact Email s	thillaireclacn@mail.nih.gov				
	Sponsor Website					
	Program URL <u>L</u>	ink to program URL				
	Deadline Dates (ALL) 0	08-Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-20	023 , 11-Mar-2024 , 09-Jul	-2024 , 12-Nov-20	24
	T Synopsis c	The purpose of this Notice of Special combination of basic and clinical stud mpact the development and progress	nterest (NOSI) is to encouragies that investigate how func	e applications that propo	se either basic, cli	nical, or a



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108280	Notice of Special Intere	est (NOSI): Deciphering the Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-21-042	08-Jul-2022	Not Specified
	Contact Name Aus	tin Yang, Ph.D.				
	Contact Telephone 301	-496-9350				
	Contact Email <mark>yan</mark> ı	gj13@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 08-J	ul-2022 , 14-Nov-2022 , 10-Mar-2	.023 , 10-Jul-2023 , 13-Nov	/-2023 , 11-Mar-2024 , 09-J	ul-2024 , 12-Nov-20	24
		goal of this Notice of Special Inte oohydrate analyses to understand				
108321	Notice of Special Intere Alzheimer's Disease Ge	est (NOSI): Human Cell Biology of enetic Variants	National Institute on Aging/NIH/DHHS	NOT-AG-21-052	08-Jul-2022	Not Specified
	Contact Name Brad	dley Wise, Ph.D.				
	Contact Telephone 301	-496-9350				
	Contact Email wise	eb@mail.nih.gov				
	Sponsor Website					
	Program URL <u>Link</u>	to program URL				
	Deadline Dates (ALL) 08-J	ul-2022 , 14-Nov-2022 , 10-Mar-2	2023 , 10-Jul-2023 , 13-Nov	/-2023 , 11-Mar-2024 , 09-J	ul-2024 , 12-Nov-20	24
	Synopsis and	goal of this Notice of Special Inte other age- and disease-modifying genomic editing approaches.				
108322	Notice of Special Intere Metabolic Changes in A	est (NOSI): Role of Age-Associated Alzheimer's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-21-053	08-Jul-2022	Not Specified
	Contact Name Yih-	Woei Fridell, Ph.D.				
	Contact Telephone 01-4	196-7847				
		woei.fridell@nih.gov				
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	Link to program URL  08-Jul-2022 , 14-Nov-2022 , 10-Mar-2  This Notice of Special Interest (NOSI) peripheral tissues or in the brain affect				
108373	Notice of Special II Alzheimer's Diseas	nterest (NOSI): Infectious Etiology of Se	National Institute on Aging/NIH/DHHS	NOT-AG-21-043	08-Jul-2022	Not Specified
	Contact Name	Miroslaw 'Mack' Mackiewicz, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	mirolsaw.mackiewicz@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2022 , 14-Nov-2022 , 10-Mar-2	023 , 10-Jul-2023 , 13-Nov-202	3 , 11-Mar-2024 , 09-Jul-	2024 , 12-Nov-202	24
	Synopsis	This NOSI strongly encourages leverage brain tissue, as well as imaging data, t	ging existing cohorts with availa to address the possible links be	able samples from plasm tween infectious agents	a, cerebrospinal fl and AD.	uid (CSF), and
				E	nding	

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
109685	RFA-OD-22-003 Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed	National Institute on Drug Abuse/NIH/DHHS	RFA-OD-22-003	15-May-2022 [Optional][LOI/Pre- App]	19,000,000 USD

Contact Name Heather Kimmel, PhD Contact Telephone 301-402-0036

Contact Email <u>nidatrsprogram@nida.nih.gov</u>



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Dat
	_	Link to progran		2022		
		This Funding O Science, Enhan research progra and will facilita those program in tobacco prod collaborative e Prevention and to foster resear administered b	Optional][LOI/Pre-App], 14-Jul-2 pportunity Announcement (FO/cement, and Logistics (CASEL) in ams funded by the Food and Drate synthesis, coordination and constitutions. The overall objective of CASE duct regulatory activities and activities and activities and activities. CASEL can accelerate the Tobacco Control Act (FSPTCA). In the NIH using designated functions and Tobacco control	A) solicits applications for an Tobacco Regulatory Sciening Administration (FDA) Cerommunications of research proteins. Through leadership, advancement of science regulatory authorities. The ads from the FDA CTP for tobases.	ce. CASEL will support the enter for Tobacco Product h and career enhancement grams that can inform the coordination, and facilital elevant to the Family Smooth formed an interagency powerd under this FOA will pacco regulatory science in	e scientific ts (CTP), nt within ne FDA CTP ition of oking partnership be
109316	RFA-RM-22-010 Somatic Mosaicism across Human Tissues (SMaHT) Program: Data Na Analysis Center (UM1 Clinical Trial Not Allowed)	ational Institute	on Drug Abuse/NIH/DHHS RF	A-RM-22-010	08-Jun-2022 [Optional][LOI/Pre- No App]	t Specified
	Contact Name	Amy C. Lossie,	Ph.D.			
	Contact Telephone					
		SMaHT@mail.r	nih.gov			
	Sponsor Website					
	_	Link to program	<u>n URL</u> Optional][LOI/Pre-App], 08-Jul-2	022		
	Synopsis	This Funding O (DAC) for the S	pportunity Announcement (FO/omatic Mosaicism across Huma enable discovery of new biology	A) invites applications to es n Tissues (SMaHT) Networl	k. The purpose of the SM	laHT



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat
		somatic tissues. The Data Analysis Center behalf of the Network, including ingestion of data; 2. Developing new computation an accessible data workbench; 3. Building and variant browser, and 4. Harmonizing Announcement (FOA) is developed as a NIH Office of the NIH Director, Office of and Centers participate in Common Fun Drug Abuse (NIDA) on behalf of the NIH	on, uniform processing, and stand nal methods and bioinformatics to ng a data portal for the Network, g SMaHT resources with related p Common Fund initiative (http://c Strategic Coordination (https://d d initiatives. The FOA will be adm	dardized annotation, and pols and deploying them a including the SMaHT Variorograms. This Funding Operams of the commonfund of the popsi.nih.gov/). All NIH In	archiving as part of ant Catalog oportunity rough the astitutes
108983	RFA-DA-23-003 Investigating Transposable Elements and Mobile DNA as Targets of Integration for Establishing HIV Reservoirs in the Brain (R61/R33 - Clinical Trial Optional)	ational Institute on Drug Abuse/NIH/DHF	IS RFA-DA-23-003	03-Jul-2022 [Optional][LOI/Pre- No App]	t Specified
	Contact Name	Amy C. Lossie, PhD			
	Contact Telephone	301-827-6092			
	Contact Email	lossieac@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	03-Jul-2022 [Optional][LOI/Pre-App], 03	-Aug-2022		
	Synopsis	The purpose of this funding opportunity contributions of mobile DNA elements a maintenance in the brain. NIDA is specific genetic, and epigenetic factors in HIV in the brain in the context of addiction.	and addictive substances in HIV in irically interested in studies explor	tegration, reservoir formaing the contributions of m	ation, and nolecular,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
110736	RFA-DA-23-040 Coordinating Center for the HIV/AIDS and Substance Use Cohorts Program (U24 Clinical Trial Not Allowed)	ational Institute on Drug Abuse/NIH/DH	IHS RFA-DA-23-040	10-Jul-2022 [Optional][LOI/Pre- N App]	lot Specified
		Richard A. Jenkins, PhD			
	Contact Telephone	301-443-1923  jenkinsri@mail.nih.gov			
	Sponsor Website				
	•	Link to program URL			
	Deadline Dates (ALL) 10-Jul-2022 [Optional][LOI/Pre-App], 10-Aug-2022				
	Synopsis	The purpose of this Funding Opportunation which will coordinate research efforts and high priority research on HIV/AIDS The CC will serve as 1) a national data biological samples from the NIDA cohorthrough virtual repositories; 2) a facility substance use and SUD; and 3) the ceroutside the NIDA cohort studies progrecommittees.	across the NIDA funded lo in the context of substan and specimen resource th orts and affiliated studies, rator of current and future atral hub for organizing an	ongitudinal cohorts that address ce use and substance use disord at harmonizes and collects data and enables additional research research at the intersection of I d enabling communication withi	emerging ers (SUD). and efforts HIV and n and
082413	Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)	ational Institute on Drug Abuse/NIH/DF	IHS PAR-19-282	11-Jul-2022 N	lot Specified
	Contact Telephone	vani.pariyadath@nih.gov			



SPIN ID	Program Title	Sponso	or Name	Sponsor Number		Deadline Dat
	Program URL	Link to program URL				
	_	11-Jul-2022 , 07-Sep-20	)22 . 10-Mar-2023 .	07-Mav-2023		
	Synopsis	This Funding Opportun support clinical researc understanding the neul fundamental brain fund	ity Announcement ( h applications that a robiological mechar ction relevant to sub re encouraged to ap	FOA) uses a R61/R33 Phase exploratory and develoratory and develorisms underlying Substance use. For projects no ply under a different fund	sed Innovation Award mechar opmental in nature and focus e Use Disorders (SUD), includi ot requiring a phased researd ing mechanism (e.g., Neuroso	on ing :h
	RFA-DA-23-014					
	Avenir Award Program				44       2022	
109944	for Chemistry and Pharmacology of Na	ational Institute on Drug	Abusa/NIH/DHHS	DEA_DA_22_01/	11-Jul-2022 [Optional][LOI/Pre- No	at Specified
103344	Substance Use	ational institute on Drug	Abuse/Mili/Dillis	NI A-DA-23-014	App]	it specified
	Disorders (DP1- Clinical					
	<u>Trial Not Allowed)</u>					
	Contact Name	Sam Ananthan, Ph.D.				
	Contact Telephone	301-435-2199				
	Contact Email	sam.ananthan@nih.gov	<u>v</u>			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Jul-2022 [Optional][	LOI/Pre-App], 11-Au	ıg-2022		
	Synopsis	stage investigators prop substance use disorder their career who may la	posing highly innova s and addiction. The ack the preliminary	tive research in the area of purpose of this award is	toward the future by support of chemistry and pharmacolog to support those in an early st trant, but who propose high in field.	gy of tage of
109415	RFA-DA-23-006 Implementing Comprehensive HIV services in Syringe	ational Institute on Drug	; Abuse/NIH/DHHS	RFA-DA-23-006	12-Jul-2022 [Optional][LOI/Pre- No App]	ot Specified



SPIN ID	Program	Sponsor Name	Sponsor Number	_	Deadline Date	Funding
	Title	9.00000	<b>P</b>			Amount
	Service Program (SSP) Settings (R01 - Clinical Trial Required)					
	Contact Name	Richard A. Jenkins PhD				
	Contact Telephone	301-443-1923				
	Contact Email	jenkinsri@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-App], 11-A	ıg-2022 , 12-Jul-2023 [Optiona	al][LOI/Pre-App], 11-Aug-	2023	
	Synopsis	This Funding Opportunity Announcement of models that demonstrate how Syringe Servevidence-based HIV services. This research standalone, CBO/ASO, FQHC, health dept-the research, as well as what is feasible giv services. SSPs have a history of strong ties (PWID) and allies. Applications should demof the proposed projects and establish conthey do not currently exist.	vice Programs (SSPs) can supp should address the needs and pased) and delivery models (e. en the local or regional organi to their communities and invo onstrate substantive involven	ort expanded implements of resources of SSP setting g., fixed site, mobile) that ization of substance use a livement by people who inent of the community in	ation of gs (e.g., t partner in and HIV nject drugs all phases	
109419	RFA-DA-23-007 Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R34 - Clinical Trial Required)	ational Institute on Drug Abuse/NIH/DHHS	RFA-DA-23-007	12-Jul-2022 [Optional][LOI/Pre- 45 App]	50,000 USD	
	Contact Name	Richard A. Jenkins PhD				
	Contact Telephone	301-443-1923				
	Contact Email	jenkinsri@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Dat
			.ppl 11-Aug-2	022 12-Jul-2023 [Ontional	][[O]/Pre-Ann] 11-Aug-2	2023
	Synopsis	This Funding Opportunity Annou models to demonstrate how syri evidence-based HIV services. This standalone, CBO/ASO, FQHC, heather research, as well as what is for services. SSPs have a history of standalone, CBO/ASO, and allies. Applications stof the proposed projects and est they do not currently exist.	ncement (FOA nge service pr s research sho alth dept-base easible given t trong ties to thould demons	A) supports pilot development ograms (SSPs) can support buld address the needs and buld address the needs and buld and delivery models (e.g. he local or regional organization communities and involutate substantive involvements.	ent and testing of pilot intexpanded implementation resources of SSP settings (a., fixed site, mobile) that ation of substance use arwement by people who intent of the community in a	tervention on of (e.g., partner in nd HIV nject drugs all phases
110733	RFA-DA-23-012 Pathogenic Mechanisms influencing Blood Brain Barrier Function in HIV and Substance Use Disorders (R01 Clinical Trial Optional)	itional Institute on Drug Abuse/N	ih/dhhs rf	A-DA-23-012	12-Jul-2022 [Optional][LOI/Pre- Not App]	t Specified
	Contact Name	Da-Yu Wu, PhD				
	Contact Telephone	301-435-4649				
		wudy@nida.nih.gov				
	Sponsor Website					
	_	Link to program URL	1		35, 0, /2	
	Deadline Dates (ALL)	12-Jul-2022 [Optional][LOI/Pre-A		- •	, ,	
		This Funding Opportunity Annou substances, acting independently the involvement of these effects	y or synergisti	cally on blood brain barrier		
110056	RFA-DA-23-021 -  Developing Regulated Na Therapeutic and	itional Institute on Drug Abuse/N	IH/DHHS RF	A-DA-23-021	16-Jul-2022 [Optional][LOI/Pre- Not App]	t Specified




SPIN ID	Program Title	Sponso	r Name	Sponsor Number		Deadline Date
	Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)					
	Contact Name	Leonardo Angelone, Ph	D			
	Contact Telephone	301-827-5946				
	Contact Email	leonardo.angelone@nil	n.gov			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	Jul-2023 [Optional][LOI	Pre-App], 15-Aug-2	z-2022 , 15-Jan-2023 [Opti )23 , 15-Jan-2024 [Optiona , 15-Jan-2025 [Optional][L	al][LOI/Pre-App], 14-Feb	o-2024 , 14-Jul-
	Synopsis	applications from small commercialization, for addressing the needs of (StUD). Applications recipharmacotherapeutics including software as a and psychostimulant eraffected by this devasta or are developing technic	business concerns (the development of patients suffering facived under this FO (small molecules and medical device. This nergency and offer rating crisis. Small busicologies for different	OA) encourages Small Bus (BCs) proposing research provel, evidence-based, FD, om opioid use disorders (GA) may fall within two scient biologics) and (2) medical FOA strives to contribute the with medical products for infiness companies that development in the OUD/StUD space of	projects, directed towar A-regulated medical pro OUD) and/or stimulant tific areas, namely: (1) I therapeutic and diagn to the effort against the individuals, families, and eloped currently market sted in demonstrating t	oducts use disorders ostic devices, e national opioid d communities ted technologies that their FDA-
101328	NIDA Translational Avant-Garde Award for Development of Medication to Treat Substance Use	ational Institute on Drug	Abuse/NIH/DHHS	PAR-21-092	25-Jul-2022	5,000,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor N	umber	Deadline Dat
	Disorders (UG3/UH3 Clinical Trial Optional)				
	Contact Telephone 3 Contact Email <u>i</u> Sponsor Website	Ivan D. Montoya, M.D., M.P.H. 301-827-5936 montoya@mail.nih.gov Link to program URL			
	Deadline Dates (ALL) 2 T r c p p is A Synopsis t c a t f	The purpose of this Funding Opportung researchers with the vision and expert of Substance Use Disorders (SUDs) steprescription opiate use. Eligible applications of the Eligible application of the Eligible applications o	ise to translate resemming from tobacce ants must demonstrem in the drug devoroval. The UG3/UH will support a projects the prioritized for trade UH3 phases. Throf expanding the number of these leads, and,	earch discoveries into medications for o, cannabis, cocaine, methamphetam rate the ability to develop molecules elopment continuum. The ultimate go 3 Phased Innovation Awards Coopera ect with specific milestones to be acceptor 3 years to a project that successful at have met their milestones will be ansition to the UH3 phase. Investigate ugh this FOA, NIDA seeks to attract ember and breadth of lead molecules in for advancing them to clinical testing.	the treatment nine, heroin, or with the pal of this FOA ative omplished at fully ors responding exceptionally in the pipeline Individuals
104639	NIDA Animal Genomics Program (U01 – Clinical Nat Trial Not Allowed)	tional Institute on Drug Abuse/NIH/DF	IHS PAR-21-244	26-Jul-2022	Not Specified
	Contact Telephone 3	Amy C. Lossie, PhD 301-827-6092 ossieac@mail.nih.gov			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
	_	Link to program URL	M Mari 2024		
	Synopsis	26-Jul-2022, 02-Mar-2023, 26-Jul-2023, 0 The purpose of the NIDA Animal Genetics variants that underlie: 1. Phenotypes assortages along the substance use disorder (S of tolerance, dependence, uncontrolled us with SUD (e.g. impulsivity, novelty seeking phenotypes); and 3. Comorbidities that de linked with SUD (e.g. anxiety, stress, poor may examine any type of variant, including structural variants, and all types of mobile omics, and/or data-based approaches that uncover the function of known or newly distudies to uncover novel mechanisms that intervention and guide the development of SUD.	Program is to identify ciated with addictive bud) trajectory (e.g. inite, abstinence and related discounting, monstrate genetic cormaternal care, social disciplinations and single nucleotide var DNA. NIDA encourage integrate multi-level scovered genetic or elecontribute to SUD and	behaviors and/or vulnerabilitial/acute use, escalation of apse or recovery); 2. Behavicand other genetically-associations with phenotypes defeat, and other paradigments (SNVs), indels, large a escapplications that take general defeat, and delineate general defacilitate the discovery of	ity to distinct of use, acquisition fors associated ciated and behaviors s). Applications nd small nomics, multi- e networks, and/or pects these targets for
086925		ational Institute on Minority Health and ealth Disparities/NIH/DHHS	PAR-20-048	15-Jul-2022	2,000,000 USD
	Contact Name	Jennifer Alvidrez, PhD			
	Contact Telephone	301-594-9567			
		alvidrezjl@mail.nih.gov			
	Sponsor Website				
		Link to program URL			
	Deadline Dates (ALL)		canacity of organizat	ions in the US Affiliated Day	cific Islands to
	Synopsis	The purpose of this initiative is to build the conduct ongoing population health resear		ions in the OS-Amilated Pac	THE ISIGNAS TO



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
104784	Notice of Special Interest (NOSI): HIV Drug Resistance Assays and Actionable Data Dissemination Strategies	tional Institutes of Health/DHHS	NOT-AI-21-056	07-May-2022	Not Specified	
		Usha Sharma, PhD				
	Contact Telephone					
	Sponsor Website	usharma@niaid.nih.gov				
	· ·	Link to program URL				
	Deadline Dates (ALL) (	07-May-2022 , 05-Jun-2022 , 16-Jun-202 2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Fe 05-Jun-2023 , 16-Jun-2023 , 06-Jul-2023 2024 , 07-Jan-2024 , 05-Feb-2024 , 16-Fe 07-Sep-2024	b-2023 , 16-Feb-2023 , 17-Fo , 05-Sep-2023 , 07-Sep-2023	eb-2023 , 05-Apr-2023 , 0 , 05-Oct-2023 , 16-Oct-2	07-May-2023 <i>,</i> 2023 , 05-Jan-	
	i Synopsis S	This Notice of Special Interest (NOSI) is to and optimization of next generation meterorting. This is needed to improve the individuals and populations. Research resensitive mutation detection technologismultaneous assessment of large numb strategies for rapid acquisition, curation healthcare providers and public health countries as defined by the World Bank	thodologies for HIV-1 drug reguldance available to treatresponsive to this NOSI could es that can be integrated inters of potential mutations (in and analysis of these HIV Distriction makers. Strategies a	esistance (DR) mutation on ment and prevention prop include the development o multiplex assay system i) point of care (POC) DR R data and timely dissemi	detection and grams for both tof: (i) highly s capable of assays, or (iii) ination to	
107787	Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco	tional Institutes of Health/DHHS	NOT-OD-22-022	07-May-2022	Not Specified	



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Delivery Systems: Basic Mechanisms of Health Effects					
	Contact Name	Ron Johnson, P	h.D.			
	Contact Telephone	240-276-6250				
	Contact Emai	rjohnso2@mail	.nih.gov			
	Sponsor Website	2				
	Program URI	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)		05-Jun-2022 , 16-Jun-2022 , 2022 , 07-Jan-2023 , 05-Feb-2			, 16-Oct-
	Synopsis	research exami relevant to hun systems [e.g., h	isease Prevention and partic ning how electronic nicotine nan cells, tissues, organs, and leated tobacco products (als mining smokeless tobacco of a-responsive.	delivery systems (ENDS) aff d behaviors. Research on alt o called heat-not-burn)] will	ect normal and disease sta ernative nicotine and toba also be considered. Studie	ates acco delivery es
107763	Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects	ational Institutes	s of Health/DHHS	NOT-OD-22-023	07-May-2022 No	ot Specified
	Contact Name	Rachel Grana N	layne, PhD, MPH			
	Contact Telephone	240-276-5899				
	Contact Emai	rachel.mayne@	nih.gov			



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Dat
	Sponsor Website					
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	07-May-2022, 05-Jun-2022, 16-Jun-2022, 24-Jun-2022, 11-Jul-2022, 07-Sep-2022, 05-Oct-2022, 16-Oct-2022, 20-Oct-2022, 08-Nov-2022, 07-Jan-2023, 05-Feb-2023, 16-Feb-2023, 07-Mar-2023, 16-Jun-2023, 05-Oct-2023, 05-Nov-2023, 07-Jan-2024, 05-Feb-2024, 16-Feb-2024, 07-Mar-2024, 07-May-2024				
	Synopsis	research on elected delivery systems with a focus on basis. Studies shetiology and epidifferent popula	sease Prevention and participa ctronic nicotine delivery syste is [e.g., heated tobacco product other non-combustible nicotion nould examine population-bastidemiology of use, potential ristions. Studies exclusively examine cigars) will be considered not	ms (ENDS). Research on a cts (also called heat-not-but and tobacco products wed, clinical, and applied pasks, benefits and impacts mining smokeless tobacco	Iternative nicotine and toba urn)] will also be considered will be considered on a case revention of disease, includ on other tobacco use beha	acco d. Research e-by-case ding vior among
107248	Notice of Special Interest (NOSI): Improving Outcomes in Cancer Treatment- Related Cardiotoxicity	ational Institutes	of Health/DHHS N	OT-CA-22-001	07-May-2022 No	ot Specified
	Contact Name	Crystal Wolfrey				
	Contact Telephone	-				
	Contact Email	wolfreyc@mail.	nih.gov			
	Sponsor Website					
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	07-May-2022 , 25-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 16-Jun-2022 , 21-Jun-2022 , 24-Jun-2022 , 20-Jul-2022 , 07-Sep-2022 , 25-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 16-Oct-2022 , 24-Oct-2022 , 08-Nov-2022 , 07-Jan-2023 , 25-Jan-2023 , 05-Feb-2023 , 16-Feb-2023 , 07-Mar-2023 , 07-May-2023 , 05-Jun-2023 , 07-Jun-2023 , 16-Jun-2023 , 07-Sep-2023 , 05-Oct-2023 , 09-Oct-2023 , 16-Oct-2023 , 05-Nov-2023 , 07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024 , 07-Mar-2024 , 07-Jun-2024 , 16-Jun-2024 , 07-Sep-2024 , 08-Oct-2024				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat
	Synopsis	The purpose of this Notice of Special Interesto mitigate cardiovascular dysfunction whis of cancer treatment-related cardiotoxicity detection, prevention, and management.	le optimizing cancer outcon	mes by understanding the m	nechanisms
108660	Notice of Special Interest (NOSI): Validation of Digital Health and Artificial Intelligence Tools for Improved Assessment in Epidemiological, Clinical, and Intervention Research	lational Institutes of Health/DHHS	NOT-CA-22-037	07-May-2022 N	ot Specified
	Contact Name	Dana Wolff-Hughes, PhD			
	Contact Telephone	240-620-0673			
	Contact Emai	dana.wolff@nih.gov			
	Sponsor Website				
	Program URI	Link to program URL			
07-May-2022 , 26-May-2022 , 05-Jun-2022 , 07-Jun-2022 , 08-Jun-2022 , 15-Jun-2022 , 16-Jun-2022 , 2022 , 11-Jul-2022 , 05-Sep-2022 , 07-Sep-2022 , 05-Oct-2022 , 07-Oct-2022 , 14-Oct-2022 , 16-Oct-200   Cot-2022 , 01-Nov-2022 , 08-Nov-2022 , 14-Nov-2022 , 28-Dec-2022 , 05-Jan-2023 , 07-Jan-2023 , 05-Deadline Dates (ALL)  Deadline					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline l	Date
088861	RFA-OD-20-010 Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required )	ational Institutes of Health/DHHS	RFA-OD-20-010	09-May-2022 [Optional][LOI/Pre- Not Specified App]	_
	Contact Telephone Contact Email Sponsor Website	sergei.radaev@nih.gov			
	_	Link to program URL 09-May-2022 [Optional][LOI/Pre-App	], 08-Jul-2022		
	Synopsis	and maintain a strong cohort of new a inform the development and evaluati marketing. This program is designed twith a research and/or clinical doctor independent, tenure-track or equivale support during this transition in order Research projects must address the roug Administration (FDA) Center for and Tobacco Control Act (FSPTCA), Punith using funds made available through Announcement (FOA) is designed speindependent clinical trial, a clinical tri research and career development. Approximate the support of the	and talented independent invest on of regulations on tobacco proto facilitate a timely transition of rate degree from mentored, posternt faculty positions. This program to help awardees launch comperesearch priorities related to the rabbic Law 111-31. The awards uncigh the CTP and the FSPTCA (P.L. cifically for applicants proposing al feasibility study, or a separate oplicants not planning an indeper	oduct manufacturing, distribution, and outstanding postdoctoral researchers doctoral research positions to m will provide independent research etitive, independent research careers. regulatory authority of the Food and dated by the Family Smoking Prevention der this FOA will be administered by 111-31). This Funding Opportunity to serve as the lead investigator of an	n

SPIN ID	Program Title		Sponsor Name	Sponsor	Number		Deadline Date
088856	RFA-OD-20-009 Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)	ational Institutes	of Health/DHHS	RFA-OD-20-	009	09-May-2022 [Optional][LOI/Pre- Not App]	: Specified
		Sergei Radaev, I	PhD				
	Contact Telephone						
		sergei.radaev@	<u>nih.gov</u>				
	Sponsor Website		LIDI				
	_	Link to program	<u>r URL</u> Optional][LOI/Pre-App]	00 101 2022			
	Synopsis	The purpose of increase and mathat will inform distribution, and postdoctoral recresearch positic independent NI independent reregulatory authorated by the awards under the FSPTCA (P.L. 11 proposing research proposing research position and ancillary of trial led by a methat was a supplementation.	the Pathway to Indeposit and a strong cohort the development and d marketing. This progressearchers with a research sto independent, tends to independent, tends are search careers. Research careers. Research ority of the Food and Enter Eamily Smoking Previous FOA will be administed 1-31). This Funding Opport that does not involuncial trial. Applicants	endence Award in of new and talent evaluation of regularion of regularion is designed to the chand/or clinical the chand/or clinical this transition in projects must along Administration and Tobactered by NIH using the cortunity Annound to this FOA are peoplicants proposing	ted independent in ulations on tobacco o facilitate a timely doctorate degree f valent faculty posit in order to help avaid address the researc on (FDA) Center for too Control Act (FSP g funds made availancement (FOA) is de ependent clinical tremitted to propose g a clinical trial or a	ry Research (K99/R00) is vestigators conducting reproduct manufacturing transition of outstanding from mentored, postdoctions. This program will payardees launch competing the priorities related to the Tobacco Products (CTP) TCA), Public Law 111-31 able through the CTP and signed specifically for application, a clinical trial feasibility research experience in ancillary clinical trial as	esearch  g ctoral brovide tive, e as . The d the oplicants lity study, a clinical

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
088855	RFA-OD-20-008 Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)	ational Institutes	of Health/DHHS	RFA-OD-20-008	09-May-2022 [Optional][LOI/Pre- No App]	ot Specified
	Contact Telephone Contact Email Sponsor Website	sergei.radaev@	nih.gov			
	_	Link to program 09-May-2022 [C	<u>URL</u> Optional][LOI/Pre-App],	08-Jul-2022		
		The purpose of (K01) is to providevelopment ar and that will leat to the regulator mandated by the awards under the FSPTCA (P.L. 112 proposing reseat or a separate and clinical trial led	the Mentored Research de support and protect sperience in biomedicand evaluation of regular d to research independ authority of the Food e Family Smoking Prevols FOA will be administral. This Funding Opport that does not involved a mentor or co-ments.	n Scientist Career Developmed time (three, four, or five, behavioral, and social sciencions on tobacco product mand Drug Administration (ention and Tobacco Contropered by NIH using funds mortunity Announcement (Five leading an independent plicants to this FOA are period time time.	nent Award in Tobacco Regulato e years) for an intensive, supervisence research that will inform the anufacturing, distribution, and rust address the research prioritic FDA) Center for Tobacco Product I Act (FSPTCA), Public Law 111-3 ade available through the CTP are FOA) is designed specifically for a clinical trial, a clinical trial feasib mitted to propose research expectionical trial or an ancillary clinic D-011).	sed career e marketing es related ts (CTP) as 1. The nd the pplicants illity study, rience in a
088863	RFA-OD-20-011 Mentored Research Scientist Career Development Award in	ational Institutes	of Health/DHHS	RFA-OD-20-011	09-May-2022 [Optional][LOI/Pre- No App]	ot Specified



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Date
	Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)					
	Contact Name	Sergei Radaev, PhD				
	Contact Telephone	240-276-5630				
	Contact Email	sergei.radaev@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
Deadline Dates (ALL) 09-May-2022 [Optional][LOI/Pre-App], 08-Jul-2022						
	The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regular (K01) is to provide support and protected time (three, four, or five years) for an intensive, super development experience in biomedical, behavioral, and social science research that will inform development and evaluation of regulations on tobacco product manufacturing, distribution, an and that will lead to research independence. Research projects must address the research prior to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Prod Synopsis  Synopsis  Synopsis  Synopsis  Synopsis  Synopsis  The purpose of the Mentored Research Scientist Career Development Award in Tobacco Product					rvised career the d marketing ities related ucts (CTP) as -31. The and the r applicants ity study, or a planning an
105957	Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PA	R-21-305	10-May-2022	Not Specified
	Contact Name	Mary Evans, Ph.D.				
	Contact Telephone	301-594-4578				
	Contact Email	evansmary@mail.nih.gov				



SPIN ID	Program Title	Sponsor Na	me	Sponsor Number		Deadline Dat
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	10-May-2022, 09-Jun-2022 2022, 10-Jan-2023, 09-Feb- 09-Aug-2023, 08-Sep-2023, 2024, 09-Apr-2024, 08-May	-2023 , 09-Mar-20 , 09-Oct-2023 , 10	23 , 11-Apr-2023 , 09-May -Oct-2023 , 11-Dec-2023 ,	-2023 , 09-Jun-2023 , 11-J 09-Jan-2024 , 09-Feb-2024	ul-2023 ,
	Synopsis	This Funding Opportunity Artime-sensitive research to exbehaviors (e.g., dietary intakan effort to prevent or reducempirical study are, by their applications submitted to the program offers an uncommothe research is initiated with FOA are not eligible for resultances of unforeseen circumstances of the sensitive research is initiated.	valuate a new police, physical activity ce obesity. This FC very nature, only his FOA must demonand scientifically minimum delay. Ubmission. It is into the application delay.	cy or program that is likely, sedentary behavior, and A is intended to support ravailable through expeditionstrate that the evaluation y-compelling research opport these reasons, applicated that eligible applicated date; however, administrate that the evaluation of the expedition o	to influence obesity related for sleep) and/or weight of esearch where opportunited review and funding. All an of an obesity-related poportunity that will only bestions submitted to this time tions selected for funding strative requirements and	ted outcomes in ties for l blicy or available if ne-sensitive s will be
102271	RFA-OD-21-002 Tobacco Regulatory Science (R01 Clinical Trial Optional)	ational Institutes of Health/D	HHS RF	A-OD-21-002	15-May-2022 [Optional][LOI/Pre- 2,5 App]	500,000 USD
	Contact Name	Rachel Grana Mayne, PhD				
	Contact Telephone	240-276-5899				
	Contact Email	granar@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-May-2022 [Optional][LOI	J/Pre-App], 14-Jul-	2022 , 17-Dec-2022 [Optio	nal][LOI/Pre-App], 14-Feb	)-2023
	Synopsis	The purpose of this Funding biomedical and behavioral roto protect public health. Res	esearch that will p	rovide scientific data to in	form regulation of tobacc	o products



SPIN ID	Program Title	Sponsor Name	Sponsor Number	r	Deadline Dat
		authority of the Food and Drug Adminithis FOA will be administered by NIH ufamily Smoking Prevention and Tobaccexpected to generate findings and data manufacture, distribution, and market	sing funds that have beer to Control Act (P.L. 111-3 a that are directly relevan	n made available through FDA CTP 1). Research results from this FOA t in informing the FDA's regulation	and the are
109686	RFA-OD-22-004 Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional)	ational Institutes of Health/DHHS	RFA-OD-22-004	15-May-2022 [Optional][LOI/Pre- 4,i App]	000,000 USD
	Contact Name	Rachel Grana Mayne, PhD, MPH			
	Contact Telephone	240-276-5899			
	Contact Email	Rachel.Mayne@nih.gov			
	Sponsor Website				
	Program URL	<u>Link to program URL</u>			
	Deadline Dates (ALL)	15-May-2022 [Optional][LOI/Pre-App],			
	Synopsis	The purpose of this Funding Opportunion of Regulatory Science (TCORS) to support to inform regulation of tobacco product Research Objectives related to the regulation of tobacco Products (CTP). The awards unade available through FDA CTP and the Research results from this FOA are expinforming the FDA's regulation of the reprotect the public health.	ort biomedical and behavets to protect public healt ulatory authority of the Fonder this FOA will be admine Family Smoking Preverenced to generate finding	ioral research that will provide sci h. Research Projects must address ood and Drug Administration (FDA ninistered by NIH using funds that ntion and Tobacco Control Act (P.I s and data that are directly releva	ientific data s the A) Center for have been L. 111-31). ant in

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
108959	RFA-NS-22-027 BRAIN Initiative: Targeted BRAIN Circuits Planning Projects – TargetedBCPP (R34 Clinical Trials Not Allowed)	ational Institutes	of Health/DHHS	RFA-NS-22-027	01-Jun-2022 [Optional][LOI/Pre- No App]	ot Specified	
		Karen K David, F	PhD				
	Contact Telephone		NIII COV				
		BRAINCircuits@	NIH.GUV				
	Sponsor Website	Link to program	LIDI				
	-	01-Jun-2022 [O May-2023 [Opti	ptional][LOI/Pre-App], 01-J onal][LOI/Pre-App], 30-Jur	ul-2022 , 06-Sep-2022 [Option n-2023 , 04-Sep-2023 [Optiona n-2024 , 02-Sep-2024 [Optiona	il][LOI/Pre-App], 04-Oct-20	)23 , 29-	
	May-2024 [Optional][LOI/Pre-App], 28-Jun-2024, 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024  This R34 FOA solicits applications that offer a limited scope of aims and an approach that will establish feasibility, validity, or other technically qualifying results that, if successful, would support, enable, and/or lay the groundwork for a potential, subsequent Targeted BRAIN Circuits Projects - TargetedBCP R01, as described in the companion FOA (RFA-NS-22-026). Applications should be adventurous, exploratory research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior.					, and/or lay as described a projects	
108955	RFA-NS-22-026 BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)	ational Institutes	of Health/DHHS	RFA-NS-22-026	01-Jun-2022 [Optional][LOI/Pre- No App]	ot Specified	
	Contact Name	Karen K David, F	PhD				

Icahn School of Medicine at Mount Sinai

Funding Amount

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Da
		BRAINCircuits@	NIH.GOV			
	Sponsor Website	Link to program	LIDI			
01-Jun-2022 [Optional][LOI/Pre-App], 01-Jul-2022 , 06-Sep-2022 [Optional][LOI/Pre-App], 06-Oct-2022 , 20   Deadline Dates (ALL) May-2023 [Optional][LOI/Pre-App], 30-Jun-2023 , 04-Sep-2023 [Optional][LOI/Pre-App], 04-Oct-2023 , 20   May-2024 [Optional][LOI/Pre-App], 28-Jun-2024 , 02-Sep-2024 [Optional][LOI/Pre-App], 02-Oct-2024						
	Synopsis	mental experier support advent Applications are such as sensation communication to experimenta aim to improve stimuli and/or but Diverse species be chosen base	nce and behavior using innourous projects that can real expected to address circuion, perception, attention, reports of the moderate and should produce the understanding of circuion experimental systems are	rojects that seek to underst vative, methodologically-int ze a potentially transformat function in the context of sasoning, intention, decision hould link theory, data analyst predictive models (concept so of the central nervous system and/or manipulating data cross-species/comparat the specific question at har	egrated approaches. The go live outcome within 5 years pecific behaviors or neural making, emotion, navigation risis, and/or computational actual cual or quantitative). Projectem by systematically contractional actual ynamic patterns of neural active approach are welcome	oal is to systems, on, approaches ts should rolling activity. and should
110290	RFA-OD-22-010 Clinical Trials Development for Co- Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)	ational Institutes	of Health/DHHS	RFA-OD-22-010	01-Jun-2022 [Optional][LOI/Pre- No App]	t Specified
	Contact Name	Laurie M. Ryan,	Ph.D.			
	Contact Telephone	301.496.9350				



Contact Email ryanl@mail.nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor Numbe	er	Deadline Dat			
	Sponsor Website	· 	·					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jun-2022 [Optional][LOI/Pre-App] Jun-2024 [Optional][LOI/Pre-App], 0:		3 [Optional][LOI/Pre-App], 01-Jul-2	023 , 01-			
	The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring heat conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. To total project period for an application submitted in response to this FOA may not exceed five years. This Fox provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.							
110282	RFA-OD-22-007 INvestigation of Co- occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Clinical Trial Readiness (R21 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	RFA-OD-22-007	01-Jun-2022 [Optional][LOI/Pre- 27 App]	'5,000 USD			
	Contact Name	Laurie M. Ryan, Ph.D.						
	Contact Telephone	301.496.9350						
	Contact Email	ryanl@mail.nih.gov						
	Sponsor Website							
	Program URL	Link to program URL						
Deadline Dates (ALL)    Deadline Dates (ALL)								

SPIN ID	Program Title		Sponsor Name	Sponsor Numb	ber	Deadline Dat
	Synopsis	(INCLUDE) Projection funding Opport projects that adapplications that movement of concurring condition for the condition	ect seeks to improve hea unity Announcement (F dress critical needs for t are intended to facilitate andidate therapeutics of tions, and to increase the clinical outcome assess	alth and quality-of-life (OA) invites researcher clinical trial readiness in the Down syndrome reading to the Community of th	ifespan to Understand Down syndro for individuals with Down syndrome is to submit applications for support in Down syndrome. This initiative sec esearch by enabling efficient and effectionical trials for Down syndrome and ess through development and testing dopment and testing of novel trial measures of the co-occurring conditions are clinical trials.	e. This of clinical eks ective d its co- s of ethods and
110376	RFA-OD-22-008 Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome- related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)	ational Institutes	of Health/DHHS	RFA-OD-22-008	01-Jun-2022 [Optional][LOI/Pre- 20 App]	00,000 USD
	Contact Name	Huiqing Li, PhD				
	Contact Telephone	301-435-0554				
		Huiqing.Li@nih.	gov			
	Sponsor Website					
	Program URL Deadline Dates (ALL)	11			023 [Optional][LOI/Pre-App], 30-Jun	-2023 , 01-
	Synopsis	The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions. Development of approaches,				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat
		tools, or algorithms appropriate for an within the research community throug		•	a sharing:
108852	RFA-NS-22-018 HEAL Initiative: Discovery and Functional Evaluation of Human Pain-associated Genes & Cells (U19 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	RFA-NS-22-018	07-Jun-2022 [Optional][LOI/Pre- 7,5 App]	500,000 USD
		D.P. Mohapatra, PhD			
	Contact Telephone				
	Contact Email Sponsor Website	dp.mohapatra@ni.gov			
	•	Link to program URL			
	Deadline Dates (ALL)	07 Jun 2022 [Ontional][I OI/Bro Ann]		otional][LOI/Pre-App], 11-Oct-2	2022 , 07-
	Synopsis	The purpose of this funding opportunito generate comprehensive datasets for epigenetic signatures, and molecular/orand processing. This FOA will support of high-throughput approaches on tissue Program to Reveal and Evaluate Cells-Human Pain (PRECISION Human Pain). collaboration and coordination of resellinitiative: Human Pain-associated General Pain and integrate datasets general paramonize, and integrate datasets general paramonize.	or the discovery and character cellular pathways that underlie concerted multidisciplinary teas involved in human pain proctogene Information that Spec U19 Centers will operate as a arch activities. U19 Centers wes & Cells Data Coordination a	rization of functional genetic e e human pain transduction, tra am science efforts that apply I essing as part of the NIH HEAL ify Intricacies, Origins, and the cooperative network to prom ill also coordinate with the U2 and Integration Center that wil	elements, ansmission, arge-scale Initiative's Nature of note
108853	RFA-NS-22-021 HEAL Initiative: Human Pain- associated Genes & Cells Data Coordination	ational Institutes of Health/DHHS	RFA-NS-22-021	07-Jun-2022 [Optional][LOI/Pre- 5,0 App]	)00,000 USD



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat			
	and Integration Center (U24 Clinical Trial Not Allowed)							
	Contact Name D.P. Mohapatra, PhD							
	Contact Telephone	e 301-496-9964						
	Contact Emai	il dp.mohapatra@ni.gov						
	Sponsor Website	е						
	Program URI	L Link to program URL						
	Deadline Dates (ALL	.) 07-Jun-2022 [Optional][LOI/Pre-App]	, 07-Jul-2022 , 11-Sep-2022 [Օլ	otional][LOI/Pre-App], 11-Oct	:-2022			
The goal of this funding opportunity announcement is to support a Human Pain-associated Genes Data Coordination and Integration Center as part of the NIH HEAL Initiative's Program to Reveal a Cells-to-gene Information that Specify Intricacies, Origins, and the Nature of Human Pain (PRECISI Pain). The Data Coordination and Integration Center will curate, harmonize, and integrate compre omics and cellular function datasets generated by companion U19 Centers for Discovery and Function Evaluation of Human Pain-associated Genes & Cells, which include the characterization of function elements, epigenetic signatures, and molecular/cellular pathways that underlie human pain signa Synopsis  Synopsis  Synopsis  The Human Pain-associated Genes & Cells Data Coordi Integration Center will lead efforts to establish spatial and semantic standards for managing heter human pain-associated data types and information, collect and register multimodal human pain-adata to common neural tissue coordinate systems, and establish a web-accessible information system be widely used throughout the research community. A central goal of the PRECISION Human Interwork is to generate comprehensive, integrated datasets, maps, and other resources on human cellular function phenotypes underlying the heterogeneity, pathogenesis and susceptibility to speconditions.					and Evaluate SION Human ehensive - nctional onal genetic al dination and erogeneous -associated ystem that in Pain an genes and			
103396	RFA-MH-21-180 BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific N Access and Manipulation to Broaden Distribution of	National Institutes of Health/DHHS	RFA-MH-21-180	12-Jun-2022 [Optional][LOI/Pre- N App]	lot Specified			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Fundin	
	Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)						
	Contact Telephone	Douglas S. Kim, Ph.D. 301-827-6463 douglas.kim@nih.gov					
	Sponsor Website						
	Program URL  Link to program URL  Deadline Dates (ALL) 12-Jun-2022 [Optional][LOI/Pre-App], 12-Jul-2022						
	This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative is intended to support the establishment of facilities at minority-serving institutions (MSIs) and Institutional Development Award (IDeA)-eligible institutions for scaled production and distribution of brain cell type-specific access and manipulation reagents. Reagents will be initially developed in pilot resource projects for brain cell type-specific access and manipulation across vertebrate species from the BRAIN Initiative Armamentarium project. Awardees under this FOA will work with the other Armamentarium awardees to manufacture and distribute the resources for use throughout the neuroscience community. It is envisioned that the awardees will work both with the Armamentarium community as well as with the neuroscience research community to optimize the new reagents. The types of reagents to be produced and distributed could include but are not limited to viral vectors, nucleic acid constructs, and nanoparticles designed for selective access to and manipulation of brain cell types. Such reagents will enable neuroscientists to probe circuit function with high precision in experimental animals and ex vivo human tissue and cells. Facilities are needed to contribute to the production and distribution of BRAIN Initiative Armamentarium project reagents broadly to neuroscience users.						
109251	RFA-NS-22-048 BRAIN Initiative Connectivity across Scales (BRAIN National Nationa	ational Institutes of Health/DHHS	RFA-NS-22-048	13-Jun-2022 [Optional][LOI/Pre- No App]	ot Specified		



SI	PIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
31	טו אווי	Title	Sponsor Name		Deadine Date	Amount

Brain (UM1 Clinical Trial Not Allowed)

Contact Name Edmund Talley

Contact Telephone 301-496-1917

Contact Email BRAIN-CONNECTS-Inquiries@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-Jun-2022 [Optional] [LOI/Pre-App], 13-Jul-2022, 13-Jun-2023 [Optional] [LOI/Pre-App], 13-Jul-2023

This Funding Opportunity Announcement (FOA) solicits applications for Comprehensive Centers to develop the research capacity and technical capabilities to map mouse brain connectivity, with goals of brain-wide coverage and comprehensive mapping of local and long-range cell-to-cell connectivity at the level of synaptic connections. Proposals may focus on a sub-volume of the central nervous system (CNS), provided the volume is sufficiently large to demonstrate feasibility of collecting, reconstructing, analyzing, integrating, disseminating, and interpreting synapse-level connectivity maps of entire brains. The resulting feasibility data from these awards are expected to inform NIH decisions on program continuation in a potential subsequent five-year funding period for production of brain-wide wiring diagrams. Applications may propose limited testing and optimization using additional species beyond mouse for testbed technology development, if strong scientific and cost justification is provided. Applications must address the following five required research activity elements: (1) Sample Processing and Data Acquisition, (2) Data Processing and Management, (3) Integration and Dissemination, (4) Research Discovery, and (5) Feasibility Metrics and Milestones. Successful Centers will establish and scale complete pipelines from sample collection through

Synopsis

Management, (3) Integration and Dissemination, (4) Research Discovery, and (5) Feasibility Metrics and Milestones. Successful Centers will establish and scale complete pipelines from sample collection through data integration and dissemination, using state-of-art methods. They will automate and streamline processes for sample collection and data acquisition, optimize protocols for data management, and develop solutions for highly accurate circuit reconstruction. They will incorporate toolsets and infrastructure for seamless integration with other datasets of the same and different modalities, and for easy-access dissemination to the research community for collaborative annotation and analyses. They will apply their data to address research questions of high significance for understanding the relationship between structure and function of brain circuits. Centers will be integrated into the BRAIN CONNECTS Network, consisting of projects from this FOA and its companion announcements, as a coordinated effort aimed at developing wiring diagrams that can span entire brains across multiple scales.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
109253	RFA-NS-22-049 BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Na Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	RFA-NS-22-049	13-Jun-2022 [Optional][LOI/Pre- No App]	ot Specified
	Contact Telephone Contact Email	BRAIN-CONNECTS-Inquiries@nih.gov			
	_	Link to program URL	2022 42 Jun 2022 [Om	sianalli Ol/Dra Anni 12 kd 2	022 42
	Deadline Dates (ALL)	13-Jun-2022 [Optional][LOI/Pre-App], 13-Jun-2024	Il-2024  Int (FOA) supports Specialized e atlases of brain connectivity ects using other species are aches that can be generalized ruction, analysis, integration, ipelines, to enable faster, movide wiring diagrams. Proposibe expected to complement eveloping and optimizing curproaches. Funded projects we specialized Projects from the rdinated effort aimed at device.	Projects to develop current of y, with an emphasis on humanalso permitted, if their use is wacross species. Applications not dissemination, and interpretore precise, and more cost-effals are encouraged to develope Comprehensive Centers solicities integrated into the BRA is FOA, and Comprehensive C	or emerging n, non- vell justified nay address ation of fective p distinct ited by the ng entirely IN enters from

SPIN ID	Program Title		Sponsor Name	Sponse	or Number		Deadline Date
109249	RFA-NS-22-047 BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Comprehensive Centers for Human and Non-Human Primate Brain (UM1 Clinical Trial Not Allowed)	ational Institutes	s of Health/DHHS	RFA-NS-2	2-047	13-Jun-2022 [Optional][LOI/Pre- No App]	t Specified
		Edmund Talley					
	Contact Telephone						
			CTS-Inquiries@nih.gov				
	Sponsor Website						
	•	Link to program					
		This Funding Op the research ca connectivity, what the level of a provided the vo- integrating, diss feasibility data potential subse may propose line technology devi following five re Processing and Metrics and Mil through data in	ptional][LOI/Pre-App], 13- pportunity Announcement pacity and technical capal ith goals of brain-wide cov exonal projections. Propose plume is sufficiently large to exeminating, and interpretification these awards are explained testing and optimizate elopment, if strong scientical equired research activity elemanagement, (3) Integrate lestones. Successful Cente etegration and dissemination emple collection and data	c (FOA) solicicities to maderage and coals may focute of demonstration of the coals and cost and cost and cost are will estaboon, using states.	its applications for Complete phuman and non-homomprehensive mappers on a sub-volume of ate feasibility of collete phenomenate feasibility of collete phenomenate form NIH decisions of duction of brain-wide dditional species bey justification is provided as Sample Processing as semination, (4) Reseatish and scale complete-of-art methods. The sample processing as the sample phenomenate complete phenomenate phenomenate states and scale complete phenomenate phenomenate states and scale complete phenomenate ph	omprehensive Centers to uman primate (NHP) braining of region-to-region of the central nervous systecting, reconstructing, armaps of entire brains. The program continuation is wiring diagrams. Applications must accord human and NHPs for ded. Applications must accord Data Acquisition, (2) arch Discovery, and (5) Feete pipelines from sample they will automate and standing and sample a	o develop in onnectivity tem (CNS), nalyzing, e resulting in a cations or testbed ddress the Data easibility e collection treamline

SPIN ID	Program Title	Sponsor Name	Sponsor Numb	er	Deadline Da
		solutions for highly accurate circuit reciseamless integration with other datase dissemination to the research commundata to address research questions of hand function of brain circuits. Centers when the projects from this FOA and its companion wiring diagrams that can span entire broads.	ts of the same and differ ity for collaborative and high significance for und will be integrated into the on announcements, as	erent modalities, and for easy-access notation and analyses. They will app derstanding the relationship between ne BRAIN CONNECTS Network, consi a coordinated effort aimed at develo	s lly their n structure isting of
097805	RFA-MH-20-600 BRAIN Initiative: Data Archives for the BRAIN Na Initiative (R24 Clinical Trial Optional)	ational Institutes of Health/DHHS	RFA-MH-20-600	14-Jun-2022 [Optional][LOI/Pre- No App]	t Specified
	Contact Name	Ming Zhan, Ph.D.			
	Contact Telephone	301-827-3678			
	Contact Email	ming.zhan@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jun-2022 [Optional][LOI/Pre-App], 1	.4-Jul-2022 , 14-Jun-202	23 [Optional][LOI/Pre-App], 14-Jul-20	023
	Synopsis	This Funding Opportunity Announcement to capture, store, and curate data relativith the research community to incorpore creation of such tools is not part of this data, but the creation of such standard by creating a community resource data broadly available and accessible to the	ed to BRAIN Initiative a orate tools that allow u FOA. The data archives s is not part of this FOA archive with appropria	ctivities. The data archives teams wi sers to analyze and visualize the dat s will use appropriate standards to d a. A goal of this program is to advanc te standards and summary informat	III work ta, but the escribe the te research
110790	Education Program on Translational Devices (R25 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PAR-22-146	29-Jun-2022 [Optional][LOI/Pre- 1,2 App]	250,000 USD
	Contact Name	Brooks Gross, Ph.D.			



Funding Amount

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Sponsor Website Program URL Deadline Dates (ALL)	Link to program 29-Jun-2022 [O The NIH Resear NIH. The overa enhance the tra To accomplish to primary focus of applications to medical device challenges, and include a plan f obtain guidance scientists, and	n URL ptional][LOI/Pre-App], 29- rch Education Program (R2 prching goal of this R25 programing of a workforce to me the stated over-arching go pen: Courses for Skills Developed and implement a development, translation (3) best-practices and resorrextended engagement a from faculty members and entire including senior post-do	est the nation's biomedic eet the nation's biomedic eal, this FOA will support of opment This FOA invites short course focused on and commercialization, of ources for each stage in to opportunities for participater the conclusion of the ctoral fellows, independents interested in develop	cation activities in the mission ational activities that complem cal, behavioral and clinical resected to the cativities of the cativities	ent and/or earch needs. with a 5) ul neural tegic oose to th and ld address a
110286	Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)	1	s of Health/DHHS	RFA-OD-22-009	01-Jul-2022 N	lot Specified
	Contact Name Contact Telephone	Charlene Schra 301-402-3793	mm, Ph.D.			



Contact Email schrammc@nih.gov

SPIN ID	Program Title	Sponsor Name	Sponsor I	Number	Deadline Dat		
	_	Link to program URL					
		The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) is soliciting Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. Applications are welcome in all topics relevant to Down syndrome-related research or its co-occurring conditions. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in research related to Down syndrome.					
110100	RFA-AI-22-025 Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed)	lational Institutes of Health/DHHS	RFA-AI-22-02	04-Jul-2022 25 [Optional][LOI/Pre- I App]	Not Specified		
		Diane Lawrence, Ph.D.					
	Contact Telephone						
		l <u>lawrencedi@niaid.nih.gov</u>					
	Sponsor Website						
	•	Link to program URL 04-Jul-2022 [Optional][LOI/Pre-App]	03-Δμσ-2022				
	Synopsis	The purpose of this Funding Opport	unity Announcemen	t (FOA) is to support basic research to do oir cells that promote survival and resist			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Da
		induced and immune-mediated cell de infected cells to eradication strategies	·	rapeutic targets that could ser	nsitize HIV-
110503	RFA-AI-22-024 Limited Interaction Targeted Epidemiology: Viral Suppression (LITE-VS) (UG3/UH3 Clinical Trial Optional)	ational Institutes of Health/DHHS	RFA-AI-22-024	04-Jul-2022 [Optional][LOI/Pre- No App]	ot Specified
		Gerald B. Sharp, Dr.P.H.			
	Contact Telephone				
		GSharp@niaid.nih.gov			
	Sponsor Website				
	_	Link to program URL			
	Deadline Dates (ALL)	04-Jul-2022 [Optional][LOI/Pre-App], (	-		
	Synopsis	The purpose of this Funding Opportune enroll large, digitally-maintained coho adequately virally suppressed. Application enrollment of participants who report suppression (VS). The goal is to follow of HIV care engagement and viral suppression that drive changes in care engagement strategies for improved methods of so should seek to inform future interventional suppression, and additionally havend.	rts of people with HIV-1 (PWH nts will need to employ sampl prior gaps in HIV care engage the research cohort over time pression, as well as the tempor t, antiretroviral adherence, an reening, enrollment, and reter tions to promote sustained en	) in the United States who are ling strategies that ensure ment ment and/or lack of sustained to prospectively investigate t ral antecedents and multilevel d viral suppression. Researche ntion of cohort participants. P gagement in HIV care and sust	e not aningful I viral crajectories I factors ers may test rojects tained HIV
109643	FCOResources to Advance Pediatrics and Na HIV Prevention Science	ational Institutes of Health/DHHS	75N93021R00020	07-Jul-2022 No	ot Specified
	Contact Name	Robert Corno			



SPIN ID	Program Title	Spons	sor Name	Sponsor Number		Deadline Dat
	Contact Telephone	240-669-5151				
	Contact Email	robert.corno@nih.go	<u>v</u>			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jul-2022				
Synopsis RESOURCES TO ADVANCE PEDIATRICS AND HIV PREVENTION SCIENCE (RAPPS) Please see the att for the RFP (75N93021R00020)						
108318	Notice of Special Interest (NOSI): Sex and Gender Differences in Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD)	ational Institutes of He	ealth/DHHS	NOT-AG-21-050	08-Jul-2022	Not Specified
	Contact Name	Amelia Karraker, Ph.D	).			
	Contact Telephone	301-496-3131				
	Contact Email	amelia.karraker@nih.	.gov			
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Jul-2022 , 14-Nov- 2024	2022 , 10-Mar-202	3 , 10-Jul-2023 , 13-Nov-202	23 , 11-Mar-2024 , 09-Jul-2	2024 , 12-Nov-
	Synopsis	progression, diagnosidementias (ADRD). Stwell-being) among perelevant. Broad areas neuroscientific (e.g., rengagement), social (	s, and clinical prese tudies that examine cople living with AD of interest include neural systems and e.g., history of mal	earch to clarify sex and generation of Alzheimer's disease sex and gender differences /ADRD as well as AD/ADRD biological (e.g., hormonal, functions), behavioral (e.g. reatment or adversity, parament status), psychological	ase (AD) and Alzheimer's of a sin outcomes (e.g., clinica caregiving-related outcongenetic, metabolic, comor , physical activity, substanenthood, marital status, ed	disease-related al, functional, mes are also rbidity-related), nce use, social ducational



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
		socio-emotional functioning and self-r provider knowledge and attitudes abo and processes that separately, or toge operate differently by sex and gender. may drive sex and gender differences	ut dementia) and healthcare ther, may drive observed diff Studies that account for met	system-level (e.g., access erences by sex and gend	s to care) factors er and/or may
108113	Notice of Special Interest (NOSI): Health Disparities and Alzheimer's Disease	ational Institutes of Health/DHHS	NOT-AG-21-033	08-Jul-2022	Not Specified
	Contact Telephone Contact Email Sponsor Website	martinda@mail.nih.gov			
	Program URL Deadline Dates (ALL)	Link to program URL 08-Jul-2022, 14-Nov-2022, 10-Mar-20 2024	023 , 10-Jul-2023 , 13-Nov-20.	23 , 11-Mar-2024 , 09-Jul	-2024 , 12-Nov-
	Synopsis	This Notice of Special Interest (NOSI) edisparities in AD/ADRD, using diverse of		examine mediators and n	noderators of
108050	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R21 Clinical Trial Optional)	ational Institutes of Health/DHHS	PAR-22-094	08-Jul-2022	275,000 USD
	Contact Telephone Contact Email Sponsor Website	sanoj.suneja@nih.gov			



SPIN ID	Program Title		Sponsor Name		Sponsor Number		Deadline Dat
	Deadline Dates (ALL) 08-Jul-2022, 14-Nov-2022, 10-Mar-2023, 10-Jul-2023, 13-Nov-2023, 11-Mar-2024, 09-Jul-2024, 12-Nov-2024						, 12-Nov-
	Synopsis	animal models, (ADRD) that nee	techniques, etc. to adved additional preliminal arch field. The priority t	ance res	search on Alzheimer's dise vith broader disseminatio	te applications proposing ease (AD) and its related do in to establish them for mo a series of Notices publish	ementias ore general
108049	Research on Current Topics in Alzheimer's Disease and Its Related Dementias (R01 Clinical Trial Optional)	ational Institutes	of Health/DHHS	РА	R-22-093	08-Jul-2022 No	t Specified
	Contact Name	Sanoj K. Suneja,	Ph.D				
	Contact Telephone	301-402-7710					
	Contact Email	l <u>sanoj.suneja@n</u>	<u>iih.gov</u>				
	Sponsor Website	2					
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	08-Jul-2022 , 14 2024	-Nov-2022 , 10-Mar-20	23 , 10	Jul-2023 , 13-Nov-2023 , 1	.1-Mar-2024 , 09-Jul-2024	, 12-Nov-
	Synopsis	current topics ir	n Alzheimer's disease (A	AD) and	its related dementias (AD	te applications proposing RD). Further information opposited to totall the contraction to totall subsequent to totall subsequent to the contractions are sub	n the high-
108374	Notice of Special Interest (NOSI): Sleep Disorders and Circadian Clock Disruption in Alzheimer's Disease and other Dementias of Aging	ational Institutes	of Health/DHHS	NC	0T-AG-21-051	08-Jul-2022 No	t Specified
	Contact Name Miroslaw 'Mack' Mackiewicz, Ph.D.						



SPIN ID	Program	_	Sponsor Name	Sponsor Number	_	Deadline Date		
	Title							
	Sponsor Website	mirolsaw.mack						
	Program URL	-	nk to program URL					
Deadline Dates (ALL)  O8-Jul-2022 , 14-Nov-2022 , 10-Mar-2023 , 10-Jul-2023 , 13-Nov-2023 , 11-Mar-2024 , 09-Jul  2024  The aim of this NOSI is to advance basic and clinical research on the causes and consequence deficiency and circadian clock dysfunction in AD/ADRD, and the roles of sleep and the circad modifiers of the onset and progression of neurodegeneration.					1-Mar-2024 , 09-Jul-2024	, 12-Nov-		
					•	•		
109825	RFA-DA-23-004 Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 - Clinical Trial Not Allowed)	ational Institutes	s of Health/DHHS	RFA-DA-23-004	12-Jul-2022 [Optional][LOI/Pre- No App]	t Specified		
	Contact Name	John Satterlee,	Ph.D.					
	Contact Telephone							
		satterleej@nida	a.nih.gov					
	_	Link to program	<u>1 URL</u> ptional][LOI/Pre-App], 11-Aug	;-2022				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
	Synopsis	The National Institute on Drug Abuse (N sequencing data sets for at least one bramethamphetamine, or cannabinoid use	in region relevant to persis		
104333	Chronic, Non- Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)	ational Institutes of Health/DHHS	PAR-21-230	13-Jul-2022 N	ot Specified
	Contact Name	Susannah Allison, Ph.D.			
	Contact Telephone	240-627-3861			
	Contact Email	allisonsu@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2022 , 13-Jul-2023			
	Synopsis	This funding opportunity announcement Diseases and Disorders Across the Lifesp D43 program for institutional research to defined by the World Bank classification in the U.S and an eligible LMIC or may in externally funded research and/or resea institutional research training program is the LMIC institutions, and to train in-coulifespan, with the long-range goal of devitheir countries. Interdisciplinary research topical applications, the main focus of remission and/or interests of at least one FOA. Other NCD topics and types of train	an: Fogarty International Relations programs in low-and system). Applications may volve just LMIC institutions rich training programs by the expected to sustainably stantry experts to develop an eloping and implementing in training that cuts across Nesearch training covered in of the participating NIH ICs	tesearch Training Award (NCD-d middle-income countries (LN be for collaborations between if there is a previous track require lead LMIC institution. The parengthen the NCD research call conduct research on NCDs are evidence-based interventions NCDs is encouraged. However, the application must be relevant, other than FIC, as stated by example of the second countries.	-LIFESPAN) MICs, as in institutions cord of roposed apacity of cross the relevant to for more ant to the each in this



Funding Amount

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat
		This Funding Opportunity Announcement the lead investigator of an independent of proposing to gain research experience in and career development.	clinical trial; or proposing	a separate ancillary clinical tr	ial; or
109744	Chronic, Non- Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)	ational Institutes of Health/DHHS	PAR-22-104	13-Jul-2022	Not Specified
	Contact Name	Kathleen Michels, Ph.D.			
	Contact Telephone	301-496-1653			
		FIC-NCD@mail.nih.gov			
	Sponsor Website				
	_	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2022 , 13-Jul-2023 , 15-Jul-2024			
	Synopsis	the LMIC institutions, and to train in-cour lifespan, with the long-range goal of deve their countries. Interdisciplinary research topical applications, the main focus of res	an: Fogarty International aining programs in low-active just LMIC institution in the training programs by expected to sustainably atry experts to develop a eloping and implementing training that cuts across	Research Training Award (NCI nd middle-income countries (I y be for collaborations betweens if there is a previous track rathe lead LMIC institution. The strengthen the NCD research nd conduct research on NCDs gevidence-based intervention NCDs is encouraged. Howeven the application must be rele	D-LIFESPAN) LMICs, as en institutions record of proposed capacity of across the as relevant to er, for more



mission and/or interests of at least one of the participating NIH ICs, other than FIC, as stated by each in this

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Dat
		FOA. Other NCD topics and types of tr This Funding Opportunity Announcem the lead investigator of an independer proposing to gain research experience and career development.	ent (FOA) allows appointment clinical trial; or proposing	nt of Trainees (D43) prop a separate ancillary clinic	oosing to serve as cal trial; or
091401	NIH Science Education Partnership Award (SEPA) (R25 - Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PAR-20-153	13-Jul-2022	1,250,000 USD
	Contact Name	Tony Beck, Ph.D.			
	Contact Telephone	301-480-4623			
	Contact Email	beckl@mail.nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	13-Jul-2022			
	Synopsis	The NIH Research Education Program NIH. The overarching goal of this R25 enhance the training of a workforce to To accomplish the stated over-arching primary focus on: Courses for Skills De Methods Development Outreach Info at: https://www.nigms.nih.gov/Researchplicants are strongly encouraged to appropriateness of the intended projection.	program is to support educate program is to support educate meet the nation's biomedic goal, this FOA will support of evelopment Research Experientation on current SEPA program of the sepa solution with the SEPA Scient	tional activities that come al, behavioral and clinical active educational active ences Mentoring Activition between the case of the content and helps://www.itific/Research Contact to	nplement and/or al research needs. vities with a es Curriculum or nihsepa.org be advised on the
091934	Mechanisms and Consequences of Sleep Disparities in the U.S. N (R01 - Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PAR-20-164	14-Jul-2022	Not Specified
	Contact Name	Rina Das, Ph.D.			



**Funding Amount** 

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Sponsor Website Program URL Deadline Dates (ALL)	dasr2@mail.nih Link to program 14-Jul-2022 The purpose of underlying mecl		mong U.S. populations th		
110541	FCODiagnostics Pre- Clinical Services Na Program	ational Institutes	of Health/DHHS NI	HAI75N93022R00008	14-Jul-2022 No	t Specified
	Contact Name	Ignacio Reyes				
	Contact Telephone	3014357574				
	Contact Email	ignacio.reyes@r	nih.gov			
	Sponsor Website					
	Program URL	Link to program	URL			
	Deadline Dates (ALL)	14-Jul-2022				

Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Microbiology and Infectious Diseases, has a requirement to support a preclinical services program that will advance the development of promising candidate diagnostic products for a wide array of infectious Synopsis diseases. Description Research supported by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), strives to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research for the investigation, control and prevention of diseases caused by all infectious agents other than HIV. Support for basic and applied research to develop and evaluate therapeutics, vaccines, and diagnostics is provided through a variety of research grants and contracts. DMID also supports an array of

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the



	PIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
,		Title	Sponsor ivallie		Deadine Date	Amount

research resources and services to assist investigators, including programs that provide or make available genomic data and technologies; organisms and state-of-the-art reagents; biocontainment facilities; and preclinical and clinical translational research services https://www.niaid.nih.gov/research/microbiology-andinfectious-diseases-resources. NIAID supports nearly all stages of the in vitro diagnostic (IVD) product development pipeline from planning and design, through development, verification, and manufacturing using multiple support services contracts. The purpose of this program is to offer a comprehensive array of capabilities with the intent of providing to product developers a discrete subset of services that will propel new IVD products toward regulatory clearance. This resource is intended to be applied to any/multiple product(s) at any/multiple stage(s) requiring access to services in support of IVD development need rather than to carry a single IVD product candidate through the entire product development pathway. These services are intended to help a wide variety of investigators (including academics and start-up or mature companies) in a number of scientific areas to obtain critical data needed to attract additional funding, gain prospective partnerships (either for further development or to support clinical validation studies), fulfill regulatory requirements, and complete necessary studies to satisfy regulatory requirements. The development and introduction of new IVD products to detect, identify, and characterize potential agents of bioterrorism, antimicrobial-resistant pathogens, emerging and re-emerging infectious pathogens, as well as infectious pathogens prevalent in resource-limited countries remain a high public health priority. To assist in filling these public health gaps, the NIAID requires a nontraditional, proactive, and product developmentoriented program to provide IVD product development support for promising assay technologies that emerge from academia, as well as start-up or mature biotech companies. The suite of services shall encompass those activities commonly associated with the development of IVD tests for infectious disease required for FDA 510(k) clearance, Premarket Approval (PMA), and Emergency Use Authorization (EUA) or pre-EUA authorization. Foreign (ex-US) product developers that request support for Diagnostic pre-clinical services needs to receive approval for the service request from NIAID-authorized officials before the contractor can be evaluated and/or compete for a task order(s) to produce the service. Since the rapid diagnosis of infectious disease-causing pathogens and/or toxins is crucial for implementing proper treatment and patient management, the commercial development of new diagnostics is a high priority. For that purpose, this solicitation includes services to support the development of new diagnostics for infectious disease-causing pathogens and/or toxins. NIAID anticipates awarding one or more Indefinite Delivery, Indefinite Quantity (IDIQ) contracts to organizations that best meet the overall qualifications for fulfilling the technical requirements of the Task Areas listed in this solicitation. Offerors may propose on any or all Task Areas. The Government anticipates making awards to those organizations with the best qualifications in each Task Area. Organizations will be considered for contracts only in the Task Area(s) they include in the proposal. Sample

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deadine Date	Amount

Task Orders are provided in the RFP solely to evaluate offeror responses and capabilities. Task Orders for specific tasks will be issued after award of the Base Contract. The Task Areas of this solicitation are as follows: Task Area A- Product Development Processes and Documentation Task Area B- Recombinant Proteins and Monoclonal Antibodies Task Area C- Biochemical Reagents: Nucleic Acids and Oligonucleotides Task Area D- Clinical Specimens and Bacterial Isolates Task Area E- Next-Gen Sequencing, Immunoassays, Nucleic Acid Amplification Assays Task Area F- Pre-Pilot and Pilot-Scale GMP Manufacturing Services Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about April 15, 2022 and may be accessed through SAM.gov. This notice does not commit the Government to award a contract or Task Order. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted via the NIAID electronic Contract Proposal Submission (eCPS) website. The content of the disc and online proposals must be identical. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website https://ecps.nih.gov/ and then click on "How to Submit." Please Note: When opening or downloading the solication in the Chrome browser, select "Open with system viewer" to allow the links in Section J of the RFP to work properly.

RFA-MD-22-009 --Innovative Multi-Level Approaches and Strategies to Prevent, Test and Treat HIV in **Primary Care Settings** 110442 in Health Disparity

Populations in

Required)

**Geographic Hot Spots** in the United States (R01 - Clinical Trial

National Institutes of Health/DHHS

RFA-MD-22-009

15-Jul-2022 [Optional][LOI/Pre- 2,500,000 USD App]

Contact Name Rick Berzon, DrPH, PA

Contact Telephone 301-594-8949

Contact Email Rick.berzon@nih.gov

Sponsor Website



SPIN ID	Program Title	Sponsor Name		Sponsor Number		Deadline Dat
	_	<u>Link to program URL</u> 15-Jul-2022 [Optional][LOI/Pre-	App], 15-Aug-2	022		
	Synopsis	This initiative will support reseatest and treat HIV among healtl geographic areas with a high ra	n disparity popu	ulations or subgroups within	_	•
086488	Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional)	ational Institutes of Health/DHH	S PA	R-20-035	19-Jul-2022 2,1	.00,000 USD
	Contact Name	Shelley Su, Ph.D.				
	Contact Telephone	301-402-3869				
	Contact Email	shelley.su@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	19-Jul-2022 , 07-Nov-2022				
	Synopsis	This Funding Opportunity Anno at the National Institutes of Headloohol Abuse and Alcoholism (Institute (NCI). The intent of this associated behaviors, and publisimilar to, those observed in sintranslational pipeline, consisting and epidemiological studies. The Exploratory/Developmental Phasany of these translational stage integrated into another stage defined the National Stage of the National Institute of the National Stage of the National Institute of the National Stage of the National Institute of the National Institute of the National Institute of the National Institutes of Headlook Ins	alth (NIH), a tra NIAAA), the Na s FOA is two-fo c health consect igle drug use; (2 g of basic sciency ese dual object ased Award (R6 s during the R6	ns-NIH partnership compositional Institute on Drug Abold: (1) characterize how the quences arising from polysus) promote integrative polyce research in animals, humives will be accomplished v 1/R33) mechanism, where 1 phase and these findings	sed of the National Instituuse (NIDA), and the National Instituuse (NIDA), and the National Instituuse (NIDA), and the National Institute (NIDA), and the National Institute (NIDA), and the NIDA) in th	onal Cancer ons, or are g a estigations, can occur in orward-
108531	RFA-TR-22-013 Emergency Awards: HEAL Initiative- New Innovator Award (DP2	ational Institutes of Health/DHH	S RF.	A-TR-22-013	23-Jul-2022 [Optional][LOI/Pre- 1,5 App]	00,000 USD



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Title					
	Clinical Trial Not Allowed)					
	Contact Nam	ne Steven Pittenge	er, Ph.D			
	Contact Telephor	ne 301-827-5810				
	Contact Ema	ail steven.pittenge	er@nih.gov			
	Sponsor Websit	te				
	Program UF	RL Link to progran	n URL			
	Deadline Dates (AL	L) 23-Jul-2022 [O	ptional][LOI/Pre-App], 22-Au	g-2022 , 22-Apr-2023 [O	ptional][LOI/Pre-App], 22-May	<i>y</i> -2023
	Synops	emergency issu Nationwide as Health Emerge Helping End Ad independent Earesearch conce concepts on br and/or overdos	ued by the Secretary, HHS. Pl the Result of the Opioid Crisi ncy Exists Nationwide as the ddiction Long-Term (HEAL) No arly Stage Investigator of exc epts with the potential to pro load, important problems in I	ease see Determination is as renewed in Renewa Result of the Continued iw Innovator Award suppeptional creativity who pluce a major impact, testiomedical research relating unexpected converge	esponse to the declared publichat a Public Health Emergence I of the Determination that a Reconsequences of the Opioid Coports a postdoctoral or newly proposes novel, original and in state of the Opioid Coports apostdoctoral or newly proposes novel, original and in state of the Opioid use disordernce of disciplines, new scientific paradigms, or advance of disciplines, new scientific paradigms.	ey Exists Public Crisis. The sightful ance key er (OUD),
102922	Notice of Special Interest (NOSI): Administrative Supplements for the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project	National Institute	s of Health/DHHS	NOT-OD-20-024	23-Jul-2022 No	ot Specified
	Contact Name Contact Telephone					



SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Contact Email					
	Sponsor Website					
	·	k to program URL				
	Deadline Dates (ALL) 23					
	Th wi su Synopsis NI Th m	e Office of the Dire th relevant active N oplement application I INvestigation of O is Notice is solicitin	ector of the National Institutes of the National Institutes of NIH-supported grants from the possible for funded projects to meet Co-occurring conditions across to administrative supplements for National Page 1,803,821,824,901,920, P30,901,803,821,824,901,920, P30,901,803,821,824,901,920,920,920,920,920,920,920,920,920,920	participating Institutes liste t new NIH Down syndrome the Lifespan to Understand or the following	d above to submit admini research objectives relate Down syndromE (INCLUD	istrative ed to the DE) Project.
109943	RFA-CA-22-017 Small Business Transition Grant For Early Career Scientists (R42 Clinical Trial Not Allowed)	National Institute	s of Health/DHHS RF	A-CA-22-017	23-Jul-2022 [Optional][LOI/Pre- No App]	t Specified
	Contact Na	me Monique Pond	, Ph.D.			
	Contact Telepho	one 240-276-5014				
	Contact Er	nail <u>monique.pond</u>	@nih.gov			
	Sponsor Web	site				
		JRL Link to progran				
	Deadline Dates (A		ptional][LOI/Pre-App], 22-Aug-2			
	Syno	Institute of Bio intend to supporting the businesses and together to addrawd funding support	unding Opportunity Announcen medical Imaging and Bioengine ort early-career academic scien transfer of technology from acl universities are drivers of tech vance innovative ideas into process basic research in university in U.S. small businesses through	ering (NIBIB), and National tists interested in transition ademic laboratories into so nological innovation in the ducts that can benefit the Laboratories, the NIH also su	Institute on Drug Abuse ( ning to entrepreneurship wall businesses. Both small United States (U.S.), often J.S. population. While mo upports innovative techno	(NIDA) while also II n working ost NIH blogy



SPIN ID	Program Title	Sponsor Name	Sponsor Nu	mber	Deadline Dat
		right expertise to take the product into	a small business, ar ss both challenges si	multaneously by having two equally im	
110096	Implementation Research to Reduce Noncommunicable Disease (NCD) Burden in Low- and Middle- Income Countries (LMICs) and Tribal Nations During Critical Life Stages and Key Transition Periods (R01 Clinical Trial Optional)	ational Institutes of Health/DHHS	PAR-22-132	27-Jul-2022 No	t Specified
	Contact Name	Brad Newsome, Ph.D.			
	Contact Telephone	301-480-8389			
	Contact Email	brad.newsome@nih.gov			
	Sponsor Website				
		Link to program URL			
	Deadline Dates (ALL)	27-Jul-2022 , 10-Aug-2022			
	Synopsis	the Global Alliance for Chronic Disease addressing risk factors for common no middle-income countries (LMICs) and A United States. This Funding Opportunit understanding, developing, and impler adaptation, integration, scale-up, and guidelines. In addition, studies to adva measures into application are encoura	es (GACD), invite appliancemmunicable dise American Indian/Alasty Announcement (Finenting strategies for sustainability of evidence dissemination arged. Specifically, this	tes and Centers (ICs), in collaboration we lications for implementation research for asses (NCDs) in World Bank-defined low ska Native (AI/AN) Tribal Nation population of Supports innovative approaches to or overcoming barriers to the adoption, ence-based interventions, tools, policies and implementation research methods as FOA invites applications that propose dhood, adolescence, pregnancy, older a	ocused on - and tions in the identifying, s, and nd



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date
		key transitions between life stages to r behaviors. All applications must be wit above (see "Components of Participati Bank-defined LMIC institutions only.	hin the scope of the mission	on of one of the Institutes/Ce	enters listed
088687	Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PAR-20-107	28-Jul-2022	5,000,000 USD
	Contact Name	Candice Beaubien, M.P.H.			
	Contact Telephone	240-627-3098			
	Contact Email	candice.beaubien@nih.gov			
	Sponsor Website				
		<u>Link to program URL</u>			
	Deadline Dates (ALL)	28-Jul-2022			
	Synopsis	The purpose of this Funding Opportunion Developmental Centers for AIDS Reseasupport to enhance HIV/AIDS research readily obtained otherwise through mosupport to assist investigators in the deinterdisciplinary collaboration across a	orch (D-CFAR) program to post. D-CFARs provide core factore traditional funding measurely	orovide administrative and sh cilities, expertise, resources, chanisms. Additionally, D-CF ive standard CFAR. The progr	nared research and services not ARs provide
088686	Centers for AIDS Research (P30 Clinical Trial Not Allowed)	ational Institutes of Health/DHHS	PAR-20-106	28-Jul-2022	Not Specified
	Contact Name	Candice Beaubien, M.P.H.			
	Contact Telephone	240-627-3098			
	Contact Email	candice.beaubien@nih.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	28-Jul-2022			



### **NIH Funding Opportunities**

Funding

Amount

SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date
	Synopsis	AIDS Research ( s research. CFAR: through more t	(CFAR) program to provide s provide core facilities, ex	Announcement (FOA) is to invadent administrative and shared resertise, resources, and services. The program emphasize	esearch support to enhance es not readily obtained othe	HIV/AIDS erwise
110353	Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)	lational Institutes	s of Health/DHHS	PAR-22-161	29-Jul-2022 No	t Specified
	Contact Name	Tram Kim Lam,	Ph.D., MPH			
	Contact Telephone	240-276-6970				
	Contact Emai	lamt@nih.gov				
	Sponsor Website	е				
	Program URI	Link to program	<u>n URL</u>			
	Deadline Dates (ALL	) 29-Jul-2022 <i>,</i> 28	3-Feb-2023 , 28-Jul-2023 , 2	8-Feb-2024 , 29-Jul-2024 , 28	3-Feb-2025	
Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-base cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship.  Synopsis Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks an outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement.						ng tion-based ip. gy cohorts r risks and d

SPIN ID Program Title		Sponsor	Name		ponsor lumber	Deadline Date	Funding Amount
FCONSF Convergence Accelera	ator 2022 Cohort Phases 1 and 2 for Trac	cks H. I.	National Science	NSFBAA	<b>A</b> - 3	31-May-2022	
and J Broad Agency Announcem			Foundation	CA22-0		LOI/Pre-App]	Not Specified
Contact Name	Ben Patterson						
Contact Telephone							
Contact Emai	bpatters@nsf.gov						
Sponsor Website	Link to sponsor website						
Program URI							
Deadline Dates (ALL)	31-May-2022 [LOI/Pre-App], 20-Jul-202	22					
Synopsis	challenges through use-inspired convecentered design, user discovery, as we Accelerator program seeks to transitio aligned with specific research themes-Materials for Global Challenges; and Trchosen in concordance with the theme potential for significant national impact awardees receive resources to further resources to accelerate their projects. prototypes and sustainability plans. Th for-profit businesses, non-profit organi of research projects that will support t two-phase program. Both phases of the program solicitation that can be found provide increased opportunities for program July 20,2022, offerors must first subsequences.	Il as team n basic res —Track H: rack J: Foo es identifie t. The NSF develop t Phase 2 an ne purposo izations, a he strateg e program here: (Inso oposals th	science and integration search and discovery interpretation of the Nutrition Security. It does not convergence to their convergence and institutions of higher convergence researched in the convergence of the NSF convergence of the NSF convergence researched in the convergence of the NSF convergence researched in the convergence resear	of multice to practice for Periodeation tor imple rich ideas ant resouccelerator education. The NSF hare despondent of this pagemic entitice.	disciplinar e – to solv sons with vergence process t ments a t and to ide proces lead or is to process con, and the converge cribed in rallel functies. Note	ry research, the Ove high-impact so Disabilities; Track Accelerator track hat aligns with to wo-phase programmify importanting to deliverably ovide research opicir partners, to ence Accelerator this BAA and the ding opportunity	Convergence ocietal challenges ck I: Sustainable of themes are opics that have the am. Phase 1 partnerships and e research oportunities to U.S. conduct a variety implements a corresponding of BAA is to
110655 Dear Colleague Letter: Geoscier Students (GEO-REPS) Suppleme	nce Research Experiences for Post-Bacca ntal Funding Opportunity	<u>laureate</u>	National Science Foundation	NSF 22-	-072 C	)1-Jul-2022	Not Specified
Contact Name Contact Telephone	Amanda S. Adams 703) 292-8521						



SPIN ID	Program Title	Sponsor Name	•	Deadline	Funding
		Sponsor Name	Number	Date	Amount

Contact Email amadams@nsf.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 01-Jul-2022

NSF GEO invites Principal Investigators (PIs) of active awards to submit a supplemental funding request to support the research training of post-baccalaureate students. For the purposes of this DCL, a post-baccalaureate student is defined as an individual who has a bachelor's degree but is not currently enrolled in another degree program. The GEO Research Experience for Post-Baccalaureate Students (GEO-REPS) DCL encourages requests for supplemental funding to existing awards for the purpose of supporting research experiences for post-baccalaureate students who desire to engage in research or who want to pursue a career in STEM but did not have access to opportunities to begin or complete a research experience as an undergraduate student due to pandemic-related interruptions. The sponsor expects that PIs will provide REPS participants with an independent but guided research project and professional development to better prepare them for graduate education or entry into the STEM workforce. Ideally, REPS participants will be involved in the development of their research project. High-quality mentoring for participants is very important in supporting post-baccalaureate scholars. Synopsis| Mentors are strongly encouraged to sustain interaction with the participant(s) throughout the duration of the supplemental

funding. Mentors are also encouraged to help connect research experiences to scholars' long-term career goals and to support the scholars' transition to graduate school or the STEM workforce. PIs are encouraged to use the resources available at their own institution or at the GEO REU Resource Center to design a program that aims to develop further the participants' competency as a research scholar. At a minimum, PIs are expected to provide training in ethics and the responsible conduct of research and to inform participants of institutional policies or code of conduct on sexual harassment. NSF GEO is particularly interested in increasing the participation of historically excluded or under-involved groups in geoscience research and education such as persons with disabilities, individuals from underrepresented racial and ethnic communities, LGBTQIA+ individuals, and women. Proposals submitted in response to this DCL are strongly encouraged to substantively involve participants who are members of these groups. Proposers are also strongly encouraged to consider involving veterans of the U.S. Armed Forces as part of NSF's broader effort to promote veteran involvement in STEM research and education.

106094

NSF-Simons Research Collaboration on a National Institute for Theory and Mathematics in Biology (NITMB)

**National Science** Foundation

21-607

18-Jul-2022

50,000,000 USD

Contact Name Zhilan J. Feng

Contact Telephone 703-292-7523

Contact Email NITMB@nsf.gov



SPIN ID	Program Title	Spo	nsor Name	Spons Numl		Funding Amount
	•	Link to sponsor website Link to program URL  18-Jul-2022 The purpose of the NSF-Simons Collaborati support a research institute to enable inno facilitate new developments of biology inspect to advance the understanding of challenging	vative research at the inters pired mathematical theories	section of math	ematical and biologi	cal sciences to
110617	Future of Semiconductors- Team Teaming Grants)	ning for Co-Design Research Capacity (FuSe	National Science Foundation	22-589	18-Jul-2022	100,000 USD
	Sponsor Website	703-292-7843  sabasu@nsf.gov  Link to sponsor website  Link to program URL  18-Jul-2022  The goal of this solicitation is to cultivate a to utilize a holistic, co-design approach to f semiconductor technologies. Proposals are Teaming grants are expected to support ca	undamental research and e sought to support team-for pacity building across the co nd possibly future center ac ty networks to develop strat ational research center leve	ducation and to rmation to artion o-design platfor ctivity. Teaming degies that add el. Teaming gran	raining, to enable rap culate co-design vision rm, which positions ing grants can also supp ress the innovative co	nid progress in new ns for the future. nvestigators for catalytic odesign capacity of
110559	IUSE/Professional Formation of Departments	Engineers: Revolutionizing Engineering	National Science Foundation	22-587	18-Jul-2022	3,000,000 USD
	Contact Telephone	Jumoke Ladeji-Osias 703-292-7708 jladejio@nsf.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor	Deadline	Funding
SPIN ID	Program true		Number	Date	Amount

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 18-Jul-2022

The Directorates for Engineering (ENG) and Education and Human Resources (EHR) are funding projects as part of the RED program, in alignment with the Improving Undergraduate STEM Education (IUSE) framework and Professional Formation of Engineers (PFE) initiative. These projects are designing revolutionary new approaches to engineering education, ranging from changing the canon of engineering to fundamentally altering the way courses are structured to creating new departmental structures and educational collaborations with industry. A common thread across these projects is a focus on organizational and cultural change within the departments, involving students, faculty, staff, and industry in rethinking what it means to provide an engineering program. In order to continue to catalyze revolutionary approaches, while expanding the reach of those that have proved efficacious in particular contexts, the RED program supports three tracks: RED Innovation, RED Adaptation and Implementation (RED A&I) and RED Two-Year. RED Innovation projects will develop new, revolutionary approaches and change strategies that enable the transformation of undergraduate engineering education. RED Adaptation and Implementation projects will adapt and implement evidence-based organizational change strategies and actions to the local context, which helps propagate this transformation of undergraduate engineering education. RED Two-Year projects will develop radically new approaches among multiple two-year institutions to expand the path to engineering and engineering technology education. Projects in all tracks will include consideration of the cultural, organizational, structural, and pedagogical changes needed to transform the department to one in which students are engaged, develop their technical and

professional skills, and establish identities as professional engineers or technologists. The focus of projects in all tracks should be on the department's disciplinary courses and program. RED project initiatives are expected to be institutionalized at the

Synopsis

National Science Faculty Early Career Development Program 110556 22-586 25-Jul-2022 400,000 USD Foundation

Contact Name

Contact Telephone 703-292-5111

Contact Email nsf-ccc@nsf.gov

Sponsor Website Link to sponsor website

end of the funding period.

Program URL Link to program URL

Deadline Dates (ALL) 25-Jul-2022



SPIN ID	Program Title		Sponsor	Name		ponsor Iumber	Deadline Date	Funding Amount
	Synopsis	CAREER: The Faculty Early Career Deve Science Foundation's most prestigious role models in research and education pursued by early-career faculty should research. NSF encourages submission of especially encourages women, member apply. PECASE: Each year NSF selects in from among the most meritorious rece	who have the po ir department of adership in integulty at all CAREE alty at all CAREE and persons with	otential to servor or organization grating educat ER-eligible orga n disabilities to	ve as academic n. Activities cion and anizations and			
090458	Historically Black Colleges and U	niversities Undergraduate Program (HB	CU-UP)	National Science Foundation	20-559	26-Jul-: [LOI/Pr	2022 e-App]	Not Specified
	Contact Name	Carleitta L. Paige-Anderson						
	Contact Telephone	703-292-2816						
	Contact Email	cpaigean@nsf.gov						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	26-Jul-2022 [LOI/Pre-App], 13-Sep-202	2 [LOI/Pre	e-App], 04-Oct-2022 , 10-	Nov-202	22 , 22-Nov-202	2	
	Synopsis	HBCU-UP provides awards to strengthe	en STEM ເ	ındergraduate education	and res	earch at HBCUs		

SPIN ID	Program Title	Sponsor Name	9	Sponsor Number	Deadline Date	Funding Amount
107694	Combatting COVID-19 Grant Prog	gram_	Department of State	SCA52522GR30000	CC 04-May-202	22 100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	ottawa-pa@state.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-May-2022 , 06-Jul-2022				
	Synopsis	The Public Affairs Section (PAS) of to competition for organizations and is between the United States and Car \$100,000.	individuals to submit app	lications to carry out progra	ams to strengthen I	oilateral ties
109854	Lung Cancer Research Program Research Award	-Investigator-Initiated Translational	Department of the Arm	y W81XWH-22-LCRP	-IITRA 04-May-202 [LOI/Pre-Ap	600 000 1181
	Contact Name					
	Contact Telephone	301-682-5507				
	Contact Email	help@eBRAP.org				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-May-2022 [LOI/Pre-App], 27-Jul	-2022			
	Synopsis	The FY22 LCRP Investigator-Initiate develop promising ideas in lung car basic science and clinical observation population-based studies, or a clini move a concept or observation for translational research as a one-way mesothelioma will not be accepted and clinical science.	ncer into clinical applicati ons. Observations that dr cian's firsthand knowled ward into clinical applicat y continuum from bench	ons. Translational research ive a research idea may ori ge of patient care. The ultin ion. However, Principal Inv to bedside. Research applic	may be defined as ginate from a labor nate goal of transla estigators (PIs) sho ations only in the a	an integration of atory discovery, tional research is to uld not view rea of



SPIN ID	Program Title	Sponsor Nam	ne Spo	onsor Number	Deadline Date	Fun	ding Amount
	Research and Development Awar	<u>rd</u>			[LOI/Pre-A	App]	USD
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
		Link to program URL					
		16-May-2022 [LOI/Pre-App], 28					
	Synopsis	This MMRDA mechanism is into development efforts relevant to medical product development abeneficiaries, and/or the Ameri assistance agreements (grants a Funding from this award mechan translational and technology deforms of promising drug and vaccine of	o the above FY22 JWMRP Focus and healthcare solutions for mil ican public. The USAMRDC will i and cooperative agreements), r anism may be used for a wide ra evelopment, clinical studies (inc	s Areas with the highe litary Service Member implement this resear research contracts, or ange of research projectuding correlative stud	est potential to augments, Veterans, their fan The program through Other Transaction Ag ects spanning preclini dies and initial safety	ent and milies, of the aware greemed is to all the area and end and end area and area	d accelerate other MHS varding of ents (OTAs). Idies, fficacy testing
110468	Kidney Cancer Research Program Investigators – Postdoctoral and		Department of the Army	W81XWH-22-K0	CRP-PCFA 23-Jun-202 [LOI/Pre-A		195,000 USD
	Contact Name						
	Contact Telephone	301-682-5507					
	Contact Email	help@eBRAP.org					
	Sponsor Website						
	-	Link to program URL					
	, <i>,</i>	23-Jun-2022 [LOI/Pre-App], 14-					
	Synopsis	The KCRP's vision is to eliminat promote rigorous, innovative, hamerican public. Within this co Overarching Strategic Goals to: strategies for the treatment of collaboration in the area of kids	nigh-impact research in kidney on ontext, the KCRP is interested in (1) increase understanding of t kidney cancer; (3) improve pati	cancer for the benefit supporting research a the biology of kidney cant care for kidney ca	of Service Members, and clinical care that a cancer; (2) develop no ancer; and (4) grow th	Veteraddressovel the field	ans, and the sses the KCRP erapeutic and increase



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		doctoral or medical school graduate and/or clinical fellowship and allow cancer research. Applicants must deadvancements in kidney cancer research pursue a career in kidney cancer resuccessful independent career in ki	s them to obtain the nemonstrate that the prearch and/or patient cases	ive, high-impact kidney car ecessary experience for an oposed research has high pare. Applicants for this awa	ncer research during independent career ootential to lead to, ord must also exhibit	their postdoctoral as a leader in kidney or make, significant a strong desire to
109887	Breast Cancer Research Program	Breakthrough Award Level 4	Department of the A	rmy W81XWH-22-BC	RP-BTA4 27-Jul-202	Not Specified
	Sponsor Website	301-682-5507 help@eBRAP.org				
	•	Link to program URL				
	Deadline Dates (ALL) Synopsis	The intent of the Breakthrough Award breakthroughs in breast cancer. The Breakthrough Award will have the primpact may be near-term or long-teapproach that is fundamentally bet expected to identify the breast cancersearch. Research Scope: The Breat to support major (but not all) stage It is the responsibility of the Princip The funding level should be selected amount of the budget.	e critical components of cotential for a major in erm, but must move bester than interventions cer patients or at-risk is akthrough Award is stres of research that will I had Investigator (PI) to s	of this award mechanism are appact and accelerate progressions a minor advancement already approved or in cline adviduals who would ultimuctured with four different ead to clinical application. elect the level that aligns were application.	re: Impact: Research ess toward ending but and have the pote ical development. Appately benefit from to funding levels. The Each level has a definition to the scope of the	supported by the reast cancer. The ntial to lead to a new oplications are he proposed levels are designed ned research scope. proposed research.
109839	Amyotrophic Lateral Sclerosis Re Development Award	search ProgramClinical Biomarker	Department of the A	rmy W81XWH-22-AL: CBDA	SRP- 28-Jul-202	2 500,000 USD
	Contact Name Contact Telephone					



SPIN ID	Program Title	Sponsor Name	9	Sponsor Number	Deadline Date	Funding Amount
	Contact Email	help@eBRAP.org				
	Sponsor Website					
	•	Link to program URL				
	Deadline Dates (ALL)					
	Synopsis	The intent of the FY22 ALSRP Clinic biorepositories to better define su trials. Applications should focus on Biomarkers may be predictive/coh analysis can be relevant to a specif genetic mutation) and does not ha these projects should be made brodata platforms when possible.	btypes, assess prognosis, the development and im ort-selective, prognostic, ic therapeutic or class of ve to broadly apply to all	or predict therapeutic resuprovement of clinical bior and/or pharmacodynamic therapeutics, or to a specipatients. Analysis of resultance	ponse and to impro markers to enrich cli c. Biomarker develop fic type of ALS (such ts and/or biosample	ve value of clinical nical trials in ALS. oment or data n as a particular es collected under
109826	Amyotrophic Lateral Sclerosis Re Award	search ProgramTherapeutic Idea	Department of the Arm	ny W81XWH-22-ALS	RP-TIA 28-Jul-2022	Not Specified
	Contact Name					
	Contact Telephone	301-682-5507				
	Contact Email	help@eBRAP.org				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	28-Jul-2022				
	Synopsis	The FY22 ALSRP Therapeutic Idea A promote new ideas aimed at drug projects should include a well-form potential to improve ALS treatment inclusion of preliminary data is not innovative approach. Projects that therapeutic development, are not	or treatment discovery the nulated, testable hypothe at and/or advance a novel prohibited, the strength focus primarily on investi	nat are still in the early stands is is based on strong scient treatment modality. Prelication should in igating the pathophysiologone.	ges of development ific rationale that ho minary data are not not rely on prelimin	. All research olds translational required. While the ary data, but on the
109823	Amyotrophic Lateral Sclerosis Re Development Award	search ProgramTherapeutic	Department of the Arm	ny W81XWH-22-ALS	RP-TDA 28-Jul-2022	1,000,000 USD



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Name								
	Contact Telephone	301-682-5507							
	Contact Email	help@eBRAP.org							
	Sponsor Website								
		Link to program URL							
	Deadline Dates (ALL)	28-Jul-2022							
	Synopsis	The FY22 ALSRP Therapeutic Development of through U.S. Food and Drug Admin expected to be empirical in nature include collaborators with substant Examples of activities that will be so screening or by other means, include sister compounds. • Validation of expreliminary data with more time por Manufacturing Practice production distribution, metabolism, and excressystems.	istration (FDA) Investigate and product-driven. Appial experience in the releupported by this award iding optimization of pote arly pilot studies, includitionts or additional dosesmethods. • IND-enabling	tional New Drug (IND)-ena dicants with limited ALS ex evant ALS model systems, on include: • Confirmation of ency and pharmacological ing the use of multiple ALS . • Studies on formulation g studies, to include comp	bling studies. The propertience are strong endpoints, and path candidate therapeur properties and testing model systems and and stability leading ound characterizations.	roposed studies are ly encouraged to ophysiology. tics obtained from ng of derivatives and l/or replicating to Good on; absorption,			
103766	Notice of Special Interest (NOSI): Grants to PAR-18-604 Vet-LIRN N (Vet-LIRN)	Add COVID-19 Capacity Building  Network Capacity-Building Projects	Food and Drug Administration/DHHS	NOT-FD-21-014	11-Jul-2022	Not Specified			
	Contact Name	Rene Vasquez, Grants Managemen	t Specialist						
	Contact Telephone	301-796-3546							
	Contact Email	rene.vasquez@fda.hhs.gov							
	Sponsor Website								
	Program URL	Link to program URL							
	Deadline Dates (ALL)	11-Jul-2022 , 10-Jul-2023							
	Synopsis	The purpose of this notice is to info (Vet-LIRN), about a special interest				Response Network			
108743	Notice of Special Interest (NOSI):	Add COVID-19 Capacity Building	Food and Drug	NOT-FD-22-006	11-Jul-2022	2 Not			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
	Grants to PAR-18-604 Vet-LIRN N	Jetwork Capacity-Building Projects Adminis	stration/DHHS		Specified
	Contact Name	Dr. Olgica Ceric			
	Contact Telephone	240-4025419			
	Contact Email	olgica.ceric@fda.hhs.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	11-Jul-2022 , 15-Apr-2023 , 10-Jul-2023			
	Synopsis	The purpose of this notice is to inform poten (Vet-LIRN), about a special interest in applica	itial applicants to the Veterinary Laborations focusing on COVID-19 animal dia	atory Investigation and	d Response Network

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
110437 Seed Grants		ALS Association	17-May-2022 [LOI/Pre-App	50 000 1180
			[ЕОЈ/ГТЕ-АРР	<u> </u>
Contact Name				
Contact Telephone				
Contact Email	researchgrants@alsa-national.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	17-May-2022 [LOI/Pre-App], 19-Jul-2022			
Synopsis	The ALS Association's Seed Grant prograr significant impact in ALS but limited preliminary data	minary data. These 1-year awards w	vith a maximum budget of	550,000
Applicant Types	;			
Funding Limit	50,000.00 maximum			
Limited Submission	No			
110441 Clinical Trial Awards (CTA) Prog	gram_	ALS Association	07-Jul-2022	1,000,000 USD
Contact Name				
Contact Telephone				
Contact Email	researchgrants@alsa-national.org			
	Link to sponsor website			
·	Link to program URL			
Deadline Dates (ALL)				
Dead.inc Dates (ALL)	10. 34. 2022			



SPIN ID	Program Title	Sponsor Name	Spon	sor Number	Deadline Date F	unding Amount
	Synancis	The ALS Association's Clinical Trials Award treatments and cures for amyotrophic lat	ls program suppor	ts early-stage interve	entional clinical trials	o discover new
	Syllopsis	treatments and cures for amyotrophic lat	eral sclerosis (ALS)			
	Applicant Types					
	_	1,000,000.00 maximum				
	Limited Submission	No				
055304	Drug Development Program		Alzheimer's Drug	Discovery Foundation	20-May-202	
	stag bevelopment trogram		7 (IZHEIII EI 3 DI UG	Discovery Fouridation	'' [LOI/Pre-Ap	p] USD
	Contact Name	Jonathan Sabbagh				
	Contact Telephone	212-901-8000				
	Contact Email	jsabbagh@alzdiscovery.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-May-2022 [LOI/Pre-App], 22-Jul-2022	, 30-Sep-2022 [LOI,	/Pre-App], 02-Dec-20	)22	
	Synopsis	The Drug Development RFP seeks to supp Alzheimer's disease and related demential deliver a compound with strong potential novel drug mechanisms and modes of act dementia. For this reason, amyloid target for this RFP.	s to IND-enabling s for clinical and cor ion related to the l	studies. The propose mmercial application piology of aging and	d studies should be s . This funding opport other emerging thera	ructured to unity prioritizes peutic areas for
	Applicant Types					
	Funding Limit	600,000.00 maximum				
	Limited Submission	No				
055305	Program to Accelerate Clinical	Trials (PACT)	Alzheimer's Drug	Discovery Foundatio	n 20-May-202 n [LOI/Pre-Ap	



SPIN ID	Program Title	9	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Fund	ing Amount
	Contact Name	Alessio Travaglia						
	Contact Telephone	_						
	Contact Email	atravaglia@alzdis	scovery.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	<u>JRL</u>					
	Deadline Dates (ALL)	20-May-2022 [LC	ol/Pre-App], 22-Jul-2022 , 30-Sep	o-2022	2 [LOI/Pre-App], 02-Dec-2	022		
	Synopsis	interventions and symptomatic age action related to	oports IND-enabling studies and devices for Alzheimer's disease nts will be considered. This function the biology of aging and other each cholinesterase inhibito	e (AD) ding o emerg	and related dementias. B pportunity prioritizes dive ing therapeutic areas for o	oth disease-modify erse drug mechanis dementia. For this i	ing an ms and	d d modes of
	Applicant Types							
	Funding Limit	3,000,000.00 ma	ximum					
	Limited Submission	No						
061078	Request For Proposal: Preventi	on Pipeline	Alzhei	mer's	Drug Discovery Foundatio	on 20-May-2 [LOI/Pre-		Not Specified
	Contact Name	Yuko Hara, PhD, i	Assistant Director, Aging and Alz	zheim	er's Prevention			
	Contact Telephone	212-901-7991						
	Contact Email	yhara@alzdiscov	ery.org					
	Sponsor Website	Link to sponsor w	<u>vebsite</u>					
	Program URL	Link to program l	<u>JRL</u>					
		•	ol/Pre-App], 22-Jul-2022 , 30-Sep					
	Synopsis	The ADDF seeks t	o support prevention drug disco	overy	not covered by most rese	arch funders or the	ir curr	ent RFPs.



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Fund	ing Amount
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
059477	Neuroimaging and CSF Biomark	ker Development Program	Alzheimer's	Drug Discovery Foundatio	n 20-May-2 n [LOI/Pre-		600,000 USD
	Contact Name						
	Contact Telephone	212-901-7992					
	Contact Email	grants@alzdiscovery.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	20-May-2022 [LOI/Pre-App], 22-	Jul-2022 , 30-Sep-202	2 [LOI/Pre-App], 02-Dec-20	)22		
	Synopsis	The aim of this RFP is to further Alzheimer's disease and related advantage over other relevant b	dementias. This RFP p	rioritizes biomarkers with	a defined context o		
	Applicant Types						
	Funding Limit	600,000.00 maximum					
	Limited Submission	No					
081154	Korb-Exford Dry Eye Career Dev	velopment Grant	American A	cademy of Optometry	01-Jul-20	22	25,000 USD
	Contact Name	Jennifer Rubin, Grants and Awar	ds Manager				
	Contact Telephone	321-319-4872					
	Contact Email	AAOAwards@aaoptom.org					
	Sponsor Website	Link to sponsor website					



SPIN ID Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
Program UR	L Link to program URL			
Deadline Dates (ALL				
Synopsi	The Korb-Exford Dry Eye Career Development the broad area of dry eye. The stipend is s	nent Grant is designed to support an in \$25,000.	dividual to further t	their knowledge in
Applicant Type	s			
Funding Limi	it 25,000.00 maximum			
Limited Submission	n No			
006566 Research and Training Scholar	<u>rships</u>	American Association of Obstetricians Gynecologists Foundation	and 01-Jul-20.	22 360,000 USD
Contact Name	e Angeles Alvarez Secord, MD, MHSc			
Contact Telephone	e 919-684-3765			
Contact Emai	il angeles.secord@duke.edu			
Sponsor Website	e <u>Link to sponsor website</u>			
Program UR	L Link to program URL			
Deadline Dates (ALL	.) 01-Jul-2022			
Synopsi	The American Association of Obstetrician Board of Obstetrics and Gynecology (ABO academic physician leaders in the field of through the support of advanced scientifis of Obstetrics and Gynecology in the Unite candidate of proven ability who exhibits scareer. Research training may focus on basinterventions and prevention, epidemiological	OG) and Society for Maternal-Fetal Medic Obstetrics and Gynecology and to stim ic training. The Scholarship Award is to ed States or Canada to provide research significant talent, original thought and e asic or translational research, disease pa	icine (SMFM) seek to ulate their scholarly be used in an acade of training and exper evidence of dedicati	to identify future y development, emic Department rience for a ion to an academic
Applicant Type	s			



	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
	Funding Limit Limited Submission	120,000.00 per year No			
016278	Mastership		American College of Physicians	01-Jul-2022	Not Specified
	Contact Name				
	Contact Telephone	800-523-1546			
	Contact Email	awards@acponline.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2022			
		ACP Bylaws state that Masters sha	II he Fellows who have been selected bec	auco of "porconal characto	
	Synopsis	1	nering the purposes of the ACP, eminence	•	• •
	Synopsis Applicant Types	honor, contributions towards furth other attainments in science or in	nering the purposes of the ACP, eminence	•	• •
	Applicant Types	honor, contributions towards furth other attainments in science or in	nering the purposes of the ACP, eminence	•	• •
	Applicant Types	honor, contributions towards furth other attainments in science or in 0.00 see detail	nering the purposes of the ACP, eminence	•	• •
016301	Applicant Types Funding Limit	honor, contributions towards furth other attainments in science or in 0.00 see detail No	nering the purposes of the ACP, eminence	•	• •
016301	Applicant Types Funding Limit Limited Submission	honor, contributions towards furth other attainments in science or in 0.00 see detail No	nering the purposes of the ACP, eminence the art of medicine."	in practice or in medical re	Not
016301	Applicant Types Funding Limit Limited Submission  Alvan R. Feinstein Memorial Av  Contact Name	honor, contributions towards furth other attainments in science or in 0.00 see detail No	nering the purposes of the ACP, eminence the art of medicine."	in practice or in medical re	Not
016301	Applicant Types Funding Limit Limited Submission  Alvan R. Feinstein Memorial Av  Contact Name	honor, contributions towards furth other attainments in science or in 0.00 see detail No  ward  800-523-1546 ext2714	nering the purposes of the ACP, eminence the art of medicine."	in practice or in medical re	Not
016301	Applicant Types Funding Limit Limited Submission  Alvan R. Feinstein Memorial Av  Contact Name Contact Telephone Contact Email	honor, contributions towards furth other attainments in science or in 0.00 see detail No  ward  800-523-1546 ext2714	nering the purposes of the ACP, eminence the art of medicine."	in practice or in medical re	Not



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Deadline Dates (ALL)	01-Jul-2022			
Synopsis	The award is to be given to an American in activities that Dr. Feinstein has broadly patients' clinical conditions. This award is	defined as clinical epidemiology or		•
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
016288 Edward R. Loveland Memorial of the Health Field	Award for a Distinguished Contribution in	American College of Physicians	01-Jul-2022	Not Specified
Contact Name				
Contact Telephone	800-523-1546			
Contact Email	awards@acponline.org			
Sponsor Website	<u>Link to sponsor website</u>			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2022			
Synopsis	The Edward R. Loveland Memorial Award layperson or lay organization for a disting	I for a Distinguished Contribution in guished contribution in the health fie	the Health Field is bestoweld.	ed to a
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
016281 James D. Bruce Memorial Awar	rd for Distinguished Contributions in	American College of Physicians	01-Jul-2022	Not Specified
Contact Name				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Contact Telephone	800-523-1546				
	Contact Email	awards@acpon	line.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)	01-Jul-2022				
	Synopsis	The James D. Bodistinguished co	ruce Memorial Award for Distinguished on tributions in preventive medicine.	d Contributions in Preventi	ve Medicine is besto	owed for
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
016279 <u>J</u>	ohn Phillips Memorial Award f	for Outstanding	Work in Clinical Medicine American C	College of Physicians	01-Jul-202	Not Specified
	Contact Name					
	Contact Telephone	800-523-1546				
	Contact Email	awards@acpon	line.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>uRL</u>			
	Deadline Dates (ALL)	01-Jul-2022				
	Synopsis		s Memorial Award for Outstanding Wo medicine which has been innovative a			nding, lifetime
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
016294 Nicholas E. Davies Memorial So Humanities and History of Med	cholar Award for Scholarly Activities in th	e American College of Physicians	01-Jul-202	Not 2 Specified
Contact Name				
Contact Telephone	800-523-1546			
Contact Email	awards@acponline.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2022			
	The Nicholas F. Davies Memorial Schola	r Award for Scholarly Activities in the	<b>Humanities and History</b>	of Medicine is
Synopsis	given for outstanding scholarly activities in medicine.	•	•	
Synopsis Applicant Types	given for outstanding scholarly activities in medicine.	•	•	
Applicant Types	given for outstanding scholarly activities in medicine.	•	•	
Applicant Types	given for outstanding scholarly activities in medicine.  0.00 see detail	•	•	
Applicant Types Funding Limit	given for outstanding scholarly activities in medicine.  0.00 see detail  No	•	•	ns to humanism
Applicant Types Funding Limit Limited Submission	given for outstanding scholarly activities in medicine.  0.00 see detail  No  ience as Related to Medicine	s in history, literature, philosophy, and	d ethics and contribution	ns to humanism
Applicant Types Funding Limit Limited Submission  016284 Harriet P. Dustan Award for Sc	given for outstanding scholarly activities in medicine.  0.00 see detail  No  ience as Related to Medicine	s in history, literature, philosophy, and	d ethics and contribution	ns to humanism
Applicant Types Funding Limit Limited Submission  016284 Harriet P. Dustan Award for Sc  Contact Name Contact Telephone	given for outstanding scholarly activities in medicine.  0.00 see detail  No  ience as Related to Medicine	s in history, literature, philosophy, and	d ethics and contribution	ns to humanism
Applicant Types Funding Limit Limited Submission  016284 Harriet P. Dustan Award for Sc  Contact Name Contact Telephone Contact Email	given for outstanding scholarly activities in medicine.  0.00 see detail No  ience as Related to Medicine  800-523-1546	s in history, literature, philosophy, and	d ethics and contribution	ns to humanism
Applicant Types Funding Limit Limited Submission  016284 Harriet P. Dustan Award for Sc  Contact Name Contact Telephone Contact Email Sponsor Website	given for outstanding scholarly activities in medicine.  0.00 see detail No  ience as Related to Medicine  800-523-1546  awards@acponline.org	s in history, literature, philosophy, and	d ethics and contribution	ns to humanism



SPIN ID Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
Synopsis	The Harriet P. Dustan Award for Science related to medicine. Scientists of any couphysical, or social, shall be eligible for thi	intry and in any field, whether non-clini	~	
Applicant Types Funding Limit Limited Submission	0.00 see detail	3 awara.		
016282 Alfred Stengel Memorial Award College of Physicians	d for Outstanding Service to the American	American College of Physicians	01-Jul-202	Not Specified
Contact Name				
Contact Telephone	800-523-1546			
Contact Email	awards@acponline.org			
Sponsor Website	<u>Link to sponsor website</u>			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2022			
Synopsis	The Alfred Stengel Memorial Award for Coutstanding service to the American Coll		llege of Physicians is	bestowed for
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
030810 AGA-Caroline Craig Augustyn a Cancer	nd Damian Augustyn Award in Digestive	American Gastroenterological Associa	tion 19-Jul-202	22 40,000 USD
Contact Name				
Contact Telephone	301-222-4012			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
Contact Emai	il awards@gastro.org			
Sponsor Website	Link to sponsor website			
Program UR	L Link to program URL			
Deadline Dates (ALL	) 19-Jul-2022			
Synopsi		ear to an early career investigator who cu conducting research related to digestive		ral or non-federal
Applicant Type	s			
Funding Limi	t 40,000.00 maximum			
Limited Submission	n No			
041049 R. Robert and Sally Funderbur	g Research Award in Gastric Cancer	American Gastroenterological Associa	ation 19-Jul-20	22 100,000 USD
Contact Name	е			
Contact Telephone	e 301-222-4012			
Contact Email	il <u>awards@gastro.org</u>			
Sponsor Website	Link to sponsor website			
Program UR	L <u>Link to program URL</u>			
Deadline Dates (ALL	) 19-Jul-2022			
Synopsi	This AGA Research Foundation award p investigator working on novel approach	provides \$50,000 per year for two years (the sin gastric cancer research.	:otaling \$100,000) t	o an established
Applicant Type	s			
Funding Limi	t 50,000.00 per year			
Limited Submission	n No			
001181 Joan F. Giambalvo Fund for th	e Advancement of Women	American Medical Association Founda	ation 15-Jul-20	22 10,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadlin	e Date	Funding Amount
	Contact Name							
	Contact Telephone	800-262-3211						
	Contact Email	wps@ama-assn	n.org					
	Sponsor Website	Link to sponsor	website					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	15-Jul-2022						
	Synopsis	research advan	mbalvo Fund for the Advan cing the study of women ir ues affecting women physio	the medica	I profession and strengthe			
	Applicant Types							
	Funding Limit	10,000.00 maxi	mum					
	Limited Submission	No						
075269	Cutting Edge Research Grant Pi	<u>rogram</u>		American So	ociety for Dermatologic Su	rgery	01-Jul-202	2 40,000 USD
	Contact Name							
	Contact Telephone	847-956-9139						
	Contact Email	847-956-0900						
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	01-Jul-2022						
	Synopsis		550,000 in grants will be aw ate a broad scope of resear		•			•
	Applicant Types							



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	Funding Limit Limited Submission	40,000.00 maximum No				
023279	Short-Term Research/Training	<u>Fellowship</u>	Asian Pacifi	c Society of Respirology	31-Jul-202	2 6,000 USD
	Contact Name					
	Contact Telephone	+81-3-5684-3370				
	Contact Email	apsrinfo@theapsr.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Jul-2022 , 30-Nov-2022				
	Synopsis	The APSR is funding a scholarship medicine in the APSR region; sup respiratory medicine; and contrib APSR region. The Asian Pacific Soprofessionals actively engaged in is initially for one month and can	porting the exchange outing to the develop ciety of Respirology ( clinical and basic res	e in the APSR region of you ment of research and scie APSR) offers for the curre earch in respiratory medic	ung respirologists act nce of respiratory monty nt year, scholarship s	ively involved in edicine in the chemes for
	Applicant Types					
	Funding Limit	1,000.00 per month				
	Limited Submission	No				
060378	Avian Health Fund Grant		Association	of Avian Veterinarians	15-Jul-202	2 10,000 USD
	Contact Name	Robert Groskin				
	Contact Telephone	720-458-4111				
	Contact Email	grants.awards.scholarships@aav.	org			
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Program URL	Link to program	ı URL						
	Deadline Dates (ALL)	15-Jul-2022							
	Synopsis	species) are now of interest inclu pharmacokineti relating to aviar companion specipurposes of this owner or perso	proposals for research projects addressing clinical aspects of captive bird health (companion and zoological cies) are now being accepted for consideration for funding by the Association of Avian Veterinarians (AAV). Area terest include, but are not limited to, diagnostic testing, disease treatment, drug macokinetics/pharmacodynamics, and practice management. Preference will be given to grant submissions cing to avian species traditionally kept as companions or to projects in which the major findings are relevant to panion species, however strong proposals relating only to zoological species will also be considered. For the poses of this grant, companion birds are defined as "species normally maintained in or near the household of the error person who cares for such animals" and can include companion poultry and species used for falconry. In the limited to \$10,000.00 US for individual projects.						
	Applicant Types								
	Funding Limit	10,000.00 maxi	mum						
	Limited Submission	No							
067925	Grants Program		Barnett	(Gordon J) Foundation	31-Jul-20	20,000 USD			
	Contact Name								
	Contact Telephone								
	Contact Email	fdnsvcs.fl@sunt	trust.com						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u> URL</u>						
	Deadline Dates (ALL)	31-Jul-2022							
	Synopsis	The Gordon J. B educational pur	sarnett Memorial Foundation was e poses or the prevention of cruelty	established for religious, char to children or animals.	itable, scientific, lite	rary, and			



Applicant Types

SPIN ID Program Title		Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Funding I Limited Submis	Limit 20,000.00 max	ximum			
013871 BLR Literary Prizes	'		Bellevue Literary Review	01-Jul-2022	Not Specified
Contact N	ame				
Contact Teleph	none 212-263-3973				
Contact E	mail <u>info@BLRevie</u>	w.org			
Sponsor We	osite Link to sponso	or website			
Program	URL Link to progra	m URL			
Deadline Dates (	ALL) 01-Jul-2022				
Synd	opsis The annual Be mind, and the	llevue Literary Review F body.	Prizes award outstanding writing relate	d to themes of health, heal	ing, illness, the
Applicant T	ypes				
Funding I	imit 0.00 see detai	I			
Limited Submis	ssion No				
079141 Exceptional Project Grants	<u>i</u>		Breast Cancer Alliance, Inc.	22-Jul-2022	100,000 USD
Contact N	ame				
Contact Teleph	none 203-861-0014				
Contact E	mail <u>researchgrant</u>	s@breastcanceralliance	.org		
Sponsor We	osite <u>Link to sponso</u>	or website			
Program	URL Link to progra	m URL			



SPIN ID Program Title		Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount		
Deadline	Dates (ALL) 22-Jul-2022							
	Synopsis careers who recognizes of	er Alliance invites clinical doct se primary focus is breast can reative, unique and innovativ Jnited States. This is a one ye	cer to apply e research ar	for an Exceptional Project nd is open to applicants at	Grant. This award			
Appl	icant Types							
Fu	nding Limit 100,000.00	per year						
Limited	Submission Yes							
059797 Young Investigator	Grant Program		Breast Canc	er Alliance, Inc.	22-Jul-20	22 125,000 USD		
Cor	ntact Name							
Contact	Telephone 203-861-003	L4						
Со	ntact Email <u>researchgra</u>	nts@breastcanceralliance.org						
Spons	sor Website Link to spon	sor website						
Pr	ogram URL Link to prog	ram URL						
Deadline	Dates (ALL) 22-Jul-2022							
	research sci	on breast cancer, to apply for funding for the Young Investigator Grant. This is a two-year grant for a total of						
Appl	icant Types							
Fu	nding Limit 125,000.00	see detail						
Limited	Submission Yes							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	inding Amount
006102	Undergraduate Clinical Case Or	ral Presentation Prize	British Society for Restorative Dentistr	y 31-Jul-2022	Not Specified
	Contact Name				
	Contact Telephone				
	Contact Email	info@bsrd.org.uk			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jul-2022			
	Synopsis	Final year undergraduates are invited to their case in form of an oral presentation		oest entry will be invite	ed to present
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
045367	Partnering Opportunity for Late	e Stage Preclinical Projects (CLIN1)	California Institute for Regenerative Medicine	31-May-202	6,000,000 USD
	Contact Name				
	Contact Telephone	510-340-9101			
	Contact Email	clinical@cirm.ca.gov			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-May-2022 , 30-Jun-2022 , 31-Jul-2022	2		
	Synopsis	The mission of California Institute for Re with unmet medical needs. The objective	generative Medicine (CIRM) is to acceler e of this program announcement is to cr	rate stem cell treatme eate a highly competit	nts to patients ive partnering



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fu	nding Amount
Applicant Type:	initiate clinical trial start-up with a proposed IND filing within 24 mcs	etion of an IND or IDE filing with the Food ar romising stem or progenitor cell-based or ge its projects under this program to advance ra onths.	ene therapy treatment	that addresses
Funding Limi Limited Submissior	t 6,000,000.00 maximum			
045538 Partnering Opportunity For Cli	1	California Institute for Regenerative Medicine	31-May-2022	Not Specified
Contact Name	e			
Contact Telephone	510-340-9101			
Contact Emai	Clinical@cirm.ca.gov			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL	) 31-May-2022 , 30-Jun-2022 , 31-Jul-2	2022		
Synopsis	with unmet medical needs. The obje opportunity to accelerate the comples therapy treatment that addresses an agency, but will also devote significal experts to actively advance the projest.	r Regenerative Medicine (CIRM) is to acceler ctive of this program announcement is to cr etion of a clinical trial for a promising stem of unmet medical need. Under this program, on the internal resources and leverage its extern ect. The result of a successful application will be program and gives it the greatest opportun	eate a highly competiti or progenitor cell-based CIRM will act not only a nal team of world-class I be the formation of a	ve partnering I or gene is a funding subject matter
Applicant Types	s			
Funding Limi	t 0.00 see detail			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date Fund	ling Amount
	Limited Submission	No			
064953 <u>C</u>	linician Scientist Fellowship		Cancer Research UK	14-Jul-2022	Not Specified
	Contact Name	Dr Marjolein Schaap			
	Contact Telephone	0300 1231022			
	Contact Email	fellowships@cancer.org.uk			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jul-2022			
		The Clinician Scientist Fellowship support through a period of postdoctoral training with the exception of clinical trials and c	g. Applications are considered from ar		
	Applicant Types				
	_	0.00 see detail			
	Limited Submission	No			
110569 <u>C</u>	Chris4Life Research Program	Early Career Investigator Awards	Colorectal Cancer Alliance	09-Jun-2022 [LOI/Pre-App]	150,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	research@ccalliance.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jun-2022 [LOI/Pre-App], 25-Jul-2022			



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
	Synopsis	The Colorectal Cancer Alliance research with the potential for In this cycle, proposals will be attract early career faculty wis supporting the next generation and original, preclinical, transference scientists within the first five senior investigator is required.	or high impact on preve e accepted for Early Care ith original ideas into th on of CRC research lead slational, and/or early cl years of their first acad	ntion, diagnosis, treatment eer Investigator Awards. Ea e field of colorectal cancer ers. Awardees will be provid inical research projects. Ear	., or survivorship of c rly Career Investigat research, thereby re ded funding to accor rly Career Investigato	olorectal cancer. or Awards aim to cruiting and nplish innovative ors are defined as
	Applicant Types					
	Funding Limit	75,000.00 per year				
	Limited Submission	No				
110567	Chris4Life Research Program	Pilot Awards	Colorectal	Cancer Alliance	25-Jul-202	100,000 USD
	Contact Name					
	Contact Telephone					
	Contact Email	research@ccalliance.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-Jul-2022				
	Synopsis	The Colorectal Cancer Allianc research with the potential for In this cycle, proposals will be potentially transformative ide translational goals. Resources which may then leverage add	or high impact on preve e accepted for Pilot Awa eas that do not have ext s for such "high-risk, hig	ntion, diagnosis, treatment ords. Pilot Awards support s tensive preliminary data but h-reward" projects are imp	, or survivorship of c enior investigators w t articulate a clear hy	olorectal cancer. who propose ypothesis and



SPIN ID	Program Title	Sı	ponsor Name	Sponsor Numb	er Deadl	ine Date Fun	ding Amount
	Applicant Types						
	Funding Limit	50,000.00 per yea	r				
	Limited Submission	No					
059521 <u>G</u>	Grants Program		(	Conservation, Food and Hea	alth Foundation	01-Jul-2022 [LOI/Pre-App]	20,000 USD
	Contact Name	Prentice Zinn					
	Contact Telephone	617-391-3091					
	Contact Email	pzinn@gmafound	ations.com				
	Sponsor Website	Link to sponsor we	<u>ebsite</u>				
	Program URL	Link to program U	<u>RL</u>				
	Deadline Dates (ALL)	01-Jul-2022 [LOI/F	Pre-App], 05-Sep-2022				
	Synopsis	distribution of foo helps build the ca generation of loca leadership and pro capacity of local o	ed, and promote public he pacity of organizations ar al solutions to complex promote professional deve	etion seeks to protect nature ealth in Asia, Africa, Latin And nd coalitions with grants that oblems. The foundation sup lopment in the conservation is a particular problem or quand geographic areas.	merica, and the Mat support researce ports projects the ancient, and agricultural, and	liddle East. The f th or improve the at demonstrate l d health sciences	oundation learning and ocal develop the
	Applicant Types						
	Funding Limit	20,000.00 on aver	age				
	Limited Submission	Yes					
000055 <u>R</u>	Research Fellowship Awards		(	Crohn's & Colitis Foundation	n of America	05-May-2022 [LOI/Pre-App]	174,750 USD



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Fund	ling Amount			
	Contact Name	Orlando Green								
	Contact Telephone	646-943-7501								
	Contact Email	ogreen@crohnscolitisfoundation.org								
	Sponsor Website	<u>Link to sponsor website</u>								
	Program URL	Link to program URL	orogram URL							
	Deadline Dates (ALL)	05-May-2022 [LOI/Pre-App], 20-Jul-2022	2022 [LOI/Pre-App], 20-Jul-2022							
	Synopsis	Research Fellowship Awards are intended skills related to basic research investigation ulcerative colitis.		·	•		•			
	Applicant Types									
	Funding Limit	58,250.00 per year								
	Limited Submission	No								
001440	Career Development Awards		Crohn's & C	olitis Foundation of Ameri	ca 05-May- [LOI/Pre		156,000 USD			
	Contact Name									
	Contact Telephone	646-943-7501								
	Contact Email	mmbesch@crohnscolitisfoundation.org								
	Sponsor Website	<u>Link to sponsor website</u>								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	05-May-2022 [LOI/Pre-App], 20-Jul-2022								
	Synopsis	Career Development Awards are intended career of independent investigation and r		potential basic/translation	nal researchers to t	ransitio	on to a			
	Applicant Types									



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Funding Limit	52,000.00 per year			
	Limited Submission	Yes			
000628 \$	Senior Research Awards		Crohn's & Colitis Foundation of Amer	ica 05-May-2 [LOI/Pre-/	
	Contact Name	Orlando Green			
	Contact Telephone	646-943-7501			
	Contact Email	ogreen@crohnscolitisfoundation.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	05-May-2022 [LOI/Pre-App], 20-Jul-2022	!		
	Synopsis	Senior Research Awards are intended to data to become competitive for funds from	provide established researchers with foom other sources such as the National I	unds to generate suf Institutes of Health (	ficient preliminary NIH).
	Applicant Types				
	Funding Limit	115,830.00 per year			
	Limited Submission	No			
083322 <u>C</u>	Crohn's & Colitis Foundation/N	ASPGHAN IBD Young Investigator Award	Crohn's & Colitis Foundation of Amer	ica 05-May-2 [LOI/Pre-/	
	Contact Name				
	Contact Telephone	646-943-7505			
	Contact Email	grant@crohnscolitisfoundation.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			



SPIN ID	Program Title	Spor	nsor Name		Sponsor Number	Deadline	e Date Fund	ding Amount
	Deadline Dates (ALL)	05-May-2022 [LOI/Pr	re-App], 20-Jul-2022					
	Synopsis	available to research epidemiological, or b in their submission for	fellows or junior factors factors for fellows or junior factors fellows fellow	ulty. Application of the color	N Foundation and the Cons must propose origin ediatric inflammatory betion Career Developme ohn's & Colitis Foundation	al clinical, owel disea nt or Rese	translational, ase. Applicants I arch Fellowship	must indicate Award, if
	Applicant Types							
	Funding Limit	0.00 see detail						
	Limited Submission	No						
063869	Litwin IBD Pioneers Initiative			Crohn's & Co	litis Foundation of Ame	rica	05-May-2022 [LOI/Pre-App]	Not Specified
	Contact Name	Orlando Green						
	Contact Telephone	800-932-2423						
	Contact Email	ogreen@crohnscoliti	isfoundation.org					
	Sponsor Website	Link to sponsor webs	<u>site</u>					
	Program URL	Link to program URL						
	Deadline Dates (ALL)	05-May-2022 [LOI/Pr	re-App], 20-Jul-2022					
	Synopsis	impact the treatmen identification of clinic innovative pilot resea Pioneers supports re	t of IBD patients in th cally relevant subsets arch so that scientists searchers who are ex	ne near future s, treatments, s can test their sploring all pos	inical and translational. The program encourage and cures for inflammate initial ideas and general sible opportunities for and funds innovative and	es novel re tory bowel ate prelimi diagnostic	esearch into the I diseases (IBD) nary data. Litwi and therapeuti	diagnosis, and funds In IBD



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
		relevant focus. Additionally, the program as countries outside the United States.	m is open to investigators from other dis	sciplines new to the I	BD field, as well			
	Applicant Types							
		0.00 see detail						
	Limited Submission							
092281	Damon Runyon-Rachleff Innova	ation Award	Damon Runyon Cancer Research Fou	ndation 01-Jul-202	400,000 USD			
	Contact Name							
	Contact Telephone	212-455-0520						
	Contact Email	awards@damonrunyon.org						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Jul-2022						
	Synopsis	The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact ou understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Stage 1 award will be for two years, \$200,000 per year (\$400,000 total) with the opportunity for up to two additional years of funding (up to four years total for \$800,000). Stage 2 support for years three and four will be granted to those awardees who demonstrate progress on their proposed research during years one and two of the award.						
	Applicant Types							
	Funding Limit	200,000.00 per year						
	Limited Submission	No						
084903	Trauma Research Scholarship		Eastern Association for the Surgery o Trauma Foundation	f 12-May-2 [LOI/Pre- <i>l</i>	Δ() ()()() (15()			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount			
	Contact Name									
	Contact Telephone	312-202-5508								
	Contact Email	managementof	fice@east.org							
	Sponsor Website <u>Link to sponsor website</u>									
	Program URL	RL Link to program URL								
	Deadline Dates (ALL)	12-May-2022 [LOI/Pre-App], 20-Jul-2022								
	Synopsis	substance to ha	he intent of the Trauma Research Scholarship is basic or applied trauma related research project of sufficient ubstance to have potential for further funding sources as initial studies are produced and published (e.g. basic cience, clinical, epidemiology, injury prevention, burns). The scholarship amount is \$40,000 for one year only.							
	Applicant Types									
	Funding Limit	40,000.00 maxii	mum							
	Limited Submission	No								
103754	EBAA High Impact Research Gr	ant_	E	ye Bank As	ssociation of America	01-Jul-20	22 50,000 USD			
	Contact Name	Stacey Gardner,	Director of Education							
	Contact Telephone	202-775-4999								
	Contact Email	stacey@restore	sight.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	01-Jul-2022								
	Synopsis	and knowledge	ssociation of America (EBAA in sight restoration, eye bar pical Therapies to Improve C	king and c	ornea transplantation. In 2	2022, EBAA will fun				
	Applicant Types									



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fund	ding Amount
Funding Limit	50,000.00 maximum			
Limited Submission				
058675 Seeding Solutions Research Gr	rants .	Foundation for Food and Agriculture Research	13-Jul-2022	1,000,000 USD
Contact Name				
Contact Telephone	202-624-0700			
Contact Email	grants@foundationfar.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	13-Jul-2022			
Synopsis	research to benefit farmers, consum	re Research (FFAR) invites applications for invites, and the environment. FFAR seeks to awatts that emphasize a commitment to cross-s	ard approximately ten m	
Applicant Types	5			
Funding Limit	1,000,000.00 maximum			
Limited Submission	No			
001781 William T. Grant Scholars Prog	ram	Grant (William T.) Foundation	15-Jun-2022 [LOI/Pre-App]	350,000 USD
Contact Name				
Contact Telephone	212-752-0071			
Contact Email	info@wtgrantfdn.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-App], 06-Jul-2022			
Synopsis	The William T. Grant Scholars Program so program funds five-year research and modisciplines, methods, and content areas.	·	• .	
Applicant Types				
Funding Limit	350,000.00 maximum			
Limited Submission	Yes			
058140 Harvard Medical School Fellow Care	vship in General Medicine and Primary	Harvard Medical School	02-Jul-2022	Not Specified
Contact Name	Jessica Pham			
Contact Telephone	617-643-9433			
Contact Email	GIMFellowship@bidmc.harvard.edu			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)				
Synopsis	The Harvard Medical School Fellowship i prepare talented physicians for careers in	n General Medicine and Primary Care on academic medicine.	offers 2-year academic	fellowships to
Applicant Types				
Funding Limit	0.00 not provided			
Limited Submission	No			
081163 SWOG/Hope Foundation Impa	ct Award	Hope Foundation for Cancer Researc	h 01-Jul-2022 h [LOI/Pre-Ap	,
Contact Name	Johanna Horn, President & CEO			



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadlin	e Date Fur	nding Amount		
	Contact Telephone	734-998-7150								
	Contact Email	jo@thehopefou	indation.org							
	Sponsor Website	Link to sponsor	nk to sponsor website							
	Program URL	Link to program	nk to program URL							
	Deadline Dates (ALL)	01-Jul-2022 [LO	-Jul-2022 [LOI/Pre-App]							
	Synopsis	The SWOG/Hope Foundation Impact Award is a funding program that encourages novel and innovative SWOG research by supporting early and conceptual stages of these projects. The work proposed should use resources for completed SWOG trials or be directly translatable to future clinical trials in SWOG and the National Clinical Trials Network (NCTN). These studies may involve scientific risk but potentially lead to a breakthrough in a particular are or to the development of novel techniques, agents, methodologies, models, or applications that could have a may impact on cancer research. It is expected that support via this mechanism will lead to subsequent extramural support of the sources, and will be a metric of success for this grant program. In addition, publications citing SWOG at The Hope Foundation will be further metrics for success.								
	Applicant Types									
	Funding Limit	250,000.00 max	kimum							
	Limited Submission	No								
033209	HD Human Biology Project Fell	<u>owship</u>		Huntington's	Disease Society of Amer	ica, Inc.	06-May-2022 [LOI/Pre-App			
	Contact Name	Leora Fox								
	Contact Telephone	212-242-1968 x	219							
	Contact Email	lfox@hdsa.org								
	Sponsor Website	Link to sponsor	<u>website</u>							
	_	Link to program								
	Deadline Dates (ALL)	06-May-2022 [L	.OI/Pre-App], 08-Jul-2022							



SPIN ID	Program Title	Sponsor Name	Sponsor N	lumber	<b>Deadline Date</b>	Funding Amount
	Synopsis	The HD Human Biology Project provides understanding the biology of Huntingto from them should have the potential to for HD. The HD Human Biology Project two years) for new clinical or translatio disease in the hope that the results can	n's disease (HD) in humar directly impact the lives of Fellowships are provided nal research projects that	ns. The research of patients or h as "seed monie are directly rela	n projects and obse elp guide future dru es" (up to \$75,000 p ated to understand	rvations resulting ug development er year for up to
	Applicant Types					
	Funding Limit	75,000.00 per year				
	Limited Submission	No				
023519	Britton Chance Biomedical Opt	ics Award	International Society for Photonics	or Optics and	01-Jul-20	22 2,000 USD
	Contact Name					
	Contact Telephone	360-676-3290				
	Contact Email	awards@spie.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2022				
	Synopsis	The Britton Chance Biomedical Optics A contributions to the field of biomedical				
	Applicant Types					
	Funding Limit	2,000.00 maximum				
	Limited Submission	No				
041826	Biophotonics Technology Innov	vator Award	International Society fo Photonics	or Optics and	01-Jul-20	22 2,000 USD



SPIN ID	Program Title		Sponsor Name	!	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Name									
	Contact Telephone	360-676-3290								
	Contact Email	awards@spie.o	rg							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u> </u>							
	Deadline Dates (ALL)	01-Jul-2022								
	Synopsis		otonics Technology Innovat elopment that show strong ists of \$2,000.	•		•	•			
	Applicant Types									
	Funding Limit	2,000.00 maxim	num							
	Limited Submission	No								
093722	Senior Fellowships			International Kulturwissen	es Forschungszentrum schaften	04-Jul-20	9,765 USD			
	Contact Name									
	Contact Telephone	+43-1-504 11 26	5							
	Contact Email	fellows@ifk.ac.a	<u>at</u>							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	<u>ı URL</u>							
	Deadline Dates (ALL)	04-Jul-2022								
	Synopsis	The IFK's Senior careers.	Fellowships are designed t	to support ex	cellent scholars, who are	well advanced in t	heir academic			
	Applicant Types									



SPIN ID Program Title		Sponsor Name		Sponsor Number	Deadline Date F	unding Amount
	ing Limit 2,325.	00 per month				
095169 Educational Grants I	nfectious Diseas	ses and Vaccines	Janssen Bic	otech, Inc.	31-May-20	Not Specified
Conta	ct Name					
Contact Te	lephone					
Conta	act Email <u>jtgrant</u>	cinfo@its.jnj.com				
Sponsor	Website Link to	sponsor website				
Prog	ram URL Link to	program URL				
Deadline Da	tes (ALL) 31-Ma	y-2022 , 31-Jul-2022 , 30-Se	p-2022 , 15-Nov-20	22		
	Synopsis patien knowle	n provides grants to suppor ts. Priority is given for activi edge, practice and performa area of Infectious Diseases.	ties within Janssen'	s areas of scientific interest	t that contribute to in	nproved
Applica	nt Types					
Fund	ing Limit 0.00 n	ot provided				
Limited Sul	omission No					
081724 Therapeutic Area Cont	ributions - Infec	ctious Diseases Program	Janssen Ph	armaceuticals, Inc.	31-May-20	Not Specified
Conta	ct Name					
Contact Te	lephone 908-21	18-6095				
Conta	act Email					
Sponsor	Website Link to	sponsor website				



SPIN ID	Program Title		Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	31-May-2022 , 3	31-Jul-2022 , 30-Sep-2022 , 1	5-Nov-202	22		
	Synopsis	evaluated comp disparities or un	oceuticals, Inc. makes charital petitively with emphasis giver nmet needs. The Infectious Di piratory Infections; and Vacci	n to innov iseases ar	ative programs with measu	urable outcomes th	at address
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
108507	New Program		La	ffin (John	and Maria) Trust	31-Jul-202	Not Specified
	Contact Name						
	Contact Telephone	888-235-4351 x	235799				
	Contact Email	https://www.w	ellsfargo.com/private-founda	itions/laff	in-trust/		
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)	31-Jul-2022					
	Synopsis	The Laffin Trust research, and h	provides grants to qualified ! uman services.	501(c)(3)	organizations supporting e	ducation, animal w	elfare, medical
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Fundi	ng Amount
077770	Emerging Leader Award		Mark Foundation for Cancer Research	02-May-2		750,000
				[LOI/Pre-	App]	USD
	Contact Name					
	Contact Telephone	646-866-5950				
	Contact Email	info@themarkfoundation.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	25-Jul-2022				
	Synopsis	The Mark Foundation Emerging Leader Avleaders. These grants are awarded to outs that are distinct from their current research	standing early career investigators to sup	_		
	Applicant Types					
	Funding Limit	250,000.00 per year				
	Limited Submission	No				
067187	Neuroanesthesiology Fellowshi	p (Minnesota)	Mayo Clinic College of Medicine and Sc	ience 31-Jul-20	22	Not Specified
	Contact Name	Sandra K. Marzolf, Education Coordinator				
	Contact Telephone	507-255-8731				
	Contact Email	marzolf.sandra@mayo.edu				
	Sponsor Website	Link to sponsor website				
	·	Link to program URL				
	1.108.4					



SPIN ID Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount				
Synopsis	Mayo Clinic offers a one-year fellowship of Minnesota. This clinical fellowship has a garantees strongly rooted in Mayo's commitment to	great deal of flexibility to accommodate	varied interests am					
Applicant Types								
Funding Limit	Funding Limit 0.00 see detail							
Limited Submission	No							
044094 Research Grants		McGovern (Jack) Coats Disease Found (JMCDF)	ation 01-Jul-202 [LOI/Pre-A	25 000 LISD				
Contact Name	Deborah Marron							
Contact Telephone	888-314-8853							
Contact Email	deborahmarron@curecoats.org							
Sponsor Website	<u>Link to sponsor website</u>							
Program URL	Link to program URL							
Deadline Dates (ALL)	01-Jul-2022 [LOI/Pre-App], 01-Oct-2022							
Synopsis	The Jack McGovern Coats' Disease Found diseases which may lead to a cure or imp Disease.	·						
Applicant Types								
Funding Limit	25,000.00 maximum							
Limited Submission	No							
068239 Grants Program - Health & Med	dical Research	McGowan (William G.) Charitable Fund	d, Inc. 01-Jul-202 [LOI/Pre-A					
Contact Name								



SPIN ID	Program Title	Sponsor Nar	ne	Sponsor Number	<b>Deadline Date</b>	Funding Amount				
	Contact Telephone	312-761-9503								
	Contact Email	info@williamgmcgowanfund	.org							
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	01-Jul-2022 [LOI/Pre-App], 0:	-Jul-2022 [LOI/Pre-App], 01-Aug-2022 , 01-Nov-2022 [LOI/Pre-App], 01-Dec-2022							
	Synopsis	The McGowan Charitable Fur that build healthy communiti	e McGowan Charitable Fund partners with institutions that advance cardiac-disease research and organizations t build healthy communities through innovative heart disease prevention programs.							
	Applicant Types									
	Funding Limit	0.00 not provided								
	Limited Submission	No								
079514	BrainStorm Neuroscience Pitch	Competition	Mind Science	ce Foundation	09-May-2	022 40,000 USD				
	Contact Name	Mindy Cohen, Program & Co	mmunications Director							
	Contact Telephone	210-821-6094								
	Contact Email	mcohen@mindscience.org								
	Sponsor Website	Link to sponsor website								
	Program URL	Link to program URL								
	Deadline Dates (ALL)	09-May-2022 , 27-Jul-2022								
	Synopsis	The BrainStorm Neuroscience Pitch Competitio is the vehicle used by Mind Science to fund early-career researchers teamed with senior primary investigators, working on pilot studies to help them obtain grants for further research, with an additional element of a pitch video designed to incentivize the building of skills in translating complex neuroscience for a general audience.								
	Applicant Types									
	Funding Limit	40,000.00 maximum								



SPIN ID Program Title	Sponsor Name	Sponsor Num	ber Deadline Date	Funding Amount
Limited Submission	No			
110489 Request for ProposalsStudy of	of Doberman Hepatitis	Morris Animal Foundation	01-Jul-2	200,000 USD
Contact Name				
Contact Telephone	800-243-2345			
Contact Email	grantapplications@morrisanimalfo	oundation.org		
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2022			
Synopsis	The sponsor is pleased to accept p include chronic hepatitis, chronic a hepatopathy. The etiology and specific this request for proposals is using Foundation, to be restricted to restrocusing on other topics, canine br for Proposals (RFP).	active hepatitis, copper storage disc ecific pathologic mechanisms of Do funding donated to Morris Animal earch focused on the health of the	ease, copper toxicosis and co berman hepatitis have not be Foundation by the Doberma Doberman pinscher breed. F	pper storage een clearly defined. n Pinscher Health Research proposals
Applicant Types	;			
Funding Limit	200,000.00 maximum			
Limited Submission	No			
110720 Request for ProposalsFeline I	Nonsurgical Spay Grant	Morris Animal Foundation	01-Jul-2	.022 75,000 USD
Contact Name				
Contact Telephone	800-243-2345			
Contact Email	grantapplications@morrisanimalfo	oundation.org		



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Fundi	ng Amount
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Jul-2022					
	Synopsis	The sponsor is pleased to accept propos roaming cats that may be receiving vary community cats, stray or feral, may be in be applicable to owned cats. The sponso populations that these cats contribute to add to already-funded programs of resealternatives to animal use in exploring in	ing levels of hacluded allowing welcomes bo. Projects march. Studies i	uman care or no care at al ing for various internationa asic or applied research w ay include proof-of-concep	I. Overlapping populal definitions; technoith the goal of reducent studies, or compo	lations ologies ing sh nents	s known as s may also elter that will
	Applicant Types						
	Funding Limit	75,000.00 maximum					
	Limited Submission	No					
102571	Request for ApplicationsGlob	al Seed Investigator Grants	Multiple Sy	stem Atrophy Coalition	02-May-2 [LOI/Pre-A		100,000 USD
	Contact Name	Nicki Mehall					
	Contact Telephone	1-866-737-4999					
	Contact Email	nmehall@staff.msacoalition.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	08-Jul-2022					
	Synopsis	The Multiple System Atrophy Coalition r improved treatment of Multiple System	equests pre-p Atrophy.	roposal grant applications	for research relevan	nt to th	ne
	Applicant Types						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Funding Limit Limited Submission	50,000.00 per year No				
059563	Barancik Prize for Innovation in	n MS Research	National M	ultiple Sclerosis Society	15-Jul-202	100,000 USD
	Contact Telephone Contact Email Sponsor Website	Barancik.Prize@nmss.org Link to sponsor website Link to program URL				
	Synopsis	The Barancik Prize for Innovation scientists whose work in MS rese made possible by the generosity discretion of the recipient.	arch has demonstrat	ed outstanding innovation	and originality. This	annual prize,
	Applicant Types Funding Limit Limited Submission	100,000.00 maximum				
060162	Psychosocial Research		Neilsen (Cra	aig H.) Foundation	12-Jul-202	Not Specified
	Contact Telephone Contact Email	Constanza Svidler 818-925-1245 constanza@chnfoundation.org Link to sponsor website				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding	g Amount
	Program URL	Link to program URL					
	Deadline Dates (ALL)	12-Jul-2022					
	Synopsis	Craig H. Neilsen Foundation's funding is de the quality of life for those affected by and data to inform and disseminate best pract living with SCI. This research explores the i participation, health practice, lifestyle, and	d living with sices that produced in the side of the s	spinal cord injury. The good duce better outcomes, im of behavioral, social and	al of the portfolio in proving quality of psychological factors.	s to devel life for pe	lop sound eople
	Applicant Types	,					
	Funding Limit	0.00 see detail					
	Limited Submission	No					
074733	Accelerator Award		Neuroendoc	rine Tumor Research Fou	ndation 18-Jul-2	11//	1,200,000 JSD
	Contact Name	,					
	Contact Telephone	617-946-1780					
	Contact Email	grants@netrf.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	18-Jul-2022					
	Synopsis	The Neuroendocrine Tumor Research Four neuroendocrine cancers in innovative and					tudy
	Applicant Types	,					
	Funding Limit	1,200,000.00 maximum					
	Limited Submission	No					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
074738	Pilot Project Award		Neuroend	docrine Tumor Research Fo	undation 18-Jul-20	022 100,000 USD
	Contact Name					
	Contact Telephone	617-946-1780				
	Contact Email	grants@netrf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jul-2022				
	Synopsis	NETRF is seeking investigators a neuroendocrine cancers in new bring the field closer to more ef research applications, and encovery interested in grant proposa in bioinformatics, bio-nanotech transferable mechanisms and/oresearch, are highly desirable, a	ways. We invite innomer ways. We invite innomer ways. We invite the rapies. We invite the control of the release which in the release which ways. We invite the release which was a sure of the release which was a sure ways.	ovative and transformative e are equally interested in l between investigators wit nary groups comprised of b vant disciplines. Proposals h have been applied succes	research proposals basic, translational a h expertise in differ basic scientists, clinio that cover promisin ssfully to other area	in NETs to help and clinical ent fields. We are cians, and experts g and potentially
	Applicant Types					
	Funding Limit	100,000.00 maximum				
	Limited Submission	No				
074735	Investigator Award		Neuroend	docrine Tumor Research Fo	undation 18-Jul-20	300,000 USD
	Contact Name					
	Contact Telephone	617-946-1780				
	Contact Email	grants@netrf.org				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	18-Jul-2022				
	Synopsis	NETRF is seeking investigators and teams neuroendocrine cancers in new ways. We bring the field closer to more effective the research applications, and encourage colvery interested in grant proposals from noin bioinformatics, bio-nanotechnology, of transferable mechanisms and/or technologies research, are highly desirable, and will be	e invite innovanerapies. We allaborations be multidisciplinal or other releval	ative and transformative re tre equally interested in bace etween investigators with try groups comprised of bace ant disciplines. Proposals the mave been applied successf	esearch proposals in sic, translational a expertise in differe sic scientists, clinicitat at cover promising fully to other areas	n NETs to help nd clinical ent fields. We are ians, and experts gand potentially
	Applicant Types					
	Funding Limit	300,000.00 maximum				
	Limited Submission	No				
11441114	NASPGHAN Foundation AstraZothe Upper Gastrointestinal Trace	eneca Research Award for Disorders of ct		ican Society for Pediatric llogy, Hepatology and Nuti	rition 01-Jul-20	150,000 USD
	Contact Name					
	Contact Telephone	215-641-9800				
	Contact Email	naspghan@naspghan.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	_	<u>Link to program URL</u>				
	Deadline Dates (ALL)	01-Jul-2022				



SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		1				
	Synopsis	The NASPGHAN Foundation Astra provide \$75,000 annually for two natural history, genetics, diagnosi gastrointestinal tract in children.	years (total \$150,00	0) for studies focused on	the epidemiology,	pathogenesis,
	Applicant Types					
	Funding Limit	75,000.00 per year				
	Limited Submission	No				
099011 <u>N</u>	IASPGHAN Foundation Innova	ations in Clinical Care Grant		rican Society for Pediatric ology, Hepatology and N		2022 5,000 USD
	Contact Name					
	Contact Telephone	215-641-9800				
	Contact Email	naspghan@naspghan.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2022				
	Synopsis	The NASPGHAN Foundation Innov of innovative approaches to optin by the clinically focused pediatric \$2,000 to \$5,000 for a one-year p	nize the quality of ca gastroenterologist. •	re and health care delive	ry to children with	digestive diseases
	Applicant Types					
	Funding Limit	5,000.00 maximum				
	Limited Submission	Yes				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
088368	NASPGHAN Foundation/Georg Award	e Ferry Young Investigator Development	North American Society for Pediatric Gastoenterology, Hepatology and Nut Foundation	rition 01-Jul-20	150,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2022			
	Synopsis	The NASPGHAN Foundation/NASPGHAN a meritorious clinical, quality improveme gastrointestinal tract, liver, pancreas or n	nt, translational or basic science resear	•	• • •
	Applicant Types				
	Funding Limit	75,000.00 per year			
	Limited Submission	No			
103653		Medical Research Award For the Study of ohydrate Maldigestion/Malabsorption in	North American Society for Pediatric Gastoenterology, Hepatology and Nut Foundation	rition 01-Jul-20	150,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	'	•			



SPIN ID Program Title		Sponsor Name		Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
Deadline Dates (ALI	.) 01-Jul-2022					
Synops	s Maldigestion/N	Malabsorption in Children	will provide \$	ward For the Study of Disc 375,000 annually for two y tion/malabsorption in chil	ears (total \$150,00	00) for studies
Applicant Type	S					
Funding Lim	it 75,000.00 per y	year				
Limited Submissio	n No					
099010 NASPGHAN Foundation CPNP	Nutrition Resear	rch Grant		rican Society for Pediatric ology, Hepatology and Nu	trition 01-Jul-20	022 5,000 USD
Contact Nam	e					
Contact Telephon	e 215-641-9800					
Contact Ema	il naspghan@nas	pghan.org				
Sponsor Websit	e Link to sponsor	website				
Program UR	Link to program	n URL				
Deadline Dates (ALI	.) 01-Jul-2022					
Synops	s support researc	ch activities that have the	potential to a	Grant is a one-year award advance the nutrition care nutrition care will award grants ranging	of patients and far	milies of children
Applicant Type	S					
Funding Lim	it 5,000.00 maxin	num				
Limited Submissio	n No					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
001986	NASPGHAN Foundation/APGNI	N Susan Moyer Nursing Research Grant	North American Society for Pediatric Gastoenterology, Hepatology and Nut Foundation	rition 01-Jul-20	022 5,000 USD
	Contact Name		roundation		
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jul-2022			
	Synopsis	This one-year grant is available to pediat activities that have the potential to adva hepatobiliary, pancreatic or nutritional d to study the nursing care of families and nutritional disorders.	nce nursing care of patients and families lisorders. Monies are awarded in suppor	s of children with g t of a meritorious	gastrointestinal, research projects
	Applicant Types				
	Funding Limit	5,000.00 maximum			
	Limited Submission	No			
099007	NASPGHAN Foundation Mid-Le	evel Career Development Award	North American Society for Pediatric Gastoenterology, Hepatology and Nut Foundation	rition 01-Jul-20	100,000 USD
	Contact Name				
	Contact Telephone	215-641-9800			
	Contact Email	naspghan@naspghan.org			
		Link to sponsor website			



SPIN ID Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
Program URI	Link to program URL				
Deadline Dates (ALL)	01-Jul-2022				
Synopsis	The NASPGHAN Foundation Mi pediatric gastroenterology, hep to \$100,000 in direct funding fo	oatology and nutrition	and are at a mid-level in th	•	-
Applicant Types	,				
Funding Limit	50,000.00 per year				
Limited Submissior	No				
038084 Seed Grants		Pablove Fo	undation	12-Jul-20	Not Specified
Contact Name					
Contact Telephone	323-657-5557				
Contact Emai	grants@pablove.org				
Sponsor Website	Link to sponsor website				
Program URI	Link to program URL				
Deadline Dates (ALL	12-Jul-2022				
Synopsis	The Pablove Foundation invites Program, which provides funds common childhood cancers. In considered. The seed grants se clinical trial.	to conduct innovative addition, projects that	, cutting edge investigation focus on Opsoclonus-Myc	ns, with preferences oclonus Syndrome (0	s going toward less DMS) will be
Applicant Types	,				
Funding Limit	50,000.00 per year				
Limited Submission	No				



SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	<b>Deadline Date</b>	Funding Amour
001069 <u>Po</u>	ostdoctoral Fellowships Progr	<u>am</u>	Paralyzed	Veterans of America	01-Jul-20	22 100,000 USD
	Contact Name	Cheryl Vines, M.S. Director of	Research and Education	on		
	Contact Telephone	805-439-2804				
	Contact Email	cherylv@pva.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2022				
		David		f	anticological and a constant and anticological ant	
	Synopsis	Paralyzed Veterans of America design and development, inte sponsor provides up to \$100,0	nded to encourage tra	•		
	Synopsis	design and development, inte sponsor provides up to \$100,0	nded to encourage tra	•		
	Synopsis Applicant Types	design and development, inte sponsor provides up to \$100,0	nded to encourage tra	•		
	Synopsis Applicant Types	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum	nded to encourage tra	•		
001563 <u>Ba</u>	Synopsis Applicant Types Funding Limit	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum	nded to encourage tra	•		rd research. The
001563 <u>Ba</u>	Synopsis  Applicant Types Funding Limit Limited Submission  asic Science Research Grants	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum	nded to encourage tra	ining and specialization i	n the field of spinal cor	150,000
001563 <u>Ba</u>	Synopsis  Applicant Types Funding Limit Limited Submission  asic Science Research Grants	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum No Lindsay Perlman	nded to encourage tra	ining and specialization i	n the field of spinal cor	150,000
001563 <u>Ba</u>	Synopsis  Applicant Types Funding Limit Limited Submission  asic Science Research Grants  Contact Name Contact Telephone	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum No Lindsay Perlman	nded to encourage tra	ining and specialization i	n the field of spinal cor	150,000
001563 <u>Ba</u>	Synopsis  Applicant Types Funding Limit Limited Submission  asic Science Research Grants  Contact Name Contact Telephone Contact Email	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum No Lindsay Perlman 202-416-7611	nded to encourage tra	ining and specialization i	n the field of spinal cor	150,000
001563 <u>Ba</u>	Synopsis  Applicant Types Funding Limit Limited Submission  asic Science Research Grants  Contact Name Contact Telephone Contact Email Sponsor Website	design and development, inte sponsor provides up to \$100,0 100,000.00 maximum  No  Lindsay Perlman 202-416-7611  LindsayP@pva.org	nded to encourage tra	ining and specialization i	n the field of spinal cor	150,000



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date Fur	nding Amount
	I			
Synopsis	Basic Science research grants fund laborisease. The sponsor will provide up to	oratory research in the basic sciences re \$75,000 per year or up to \$150,000 for	lated to spinal cord injury 2 years.	or
Applicant Types				
Funding Limit	75,000.00 per year			
Limited Submission	No			
001067 Design and Development/Assis	tive Technology Grants	Paralyzed Veterans of America	01-Jul-2022	Not Specified
Contact Name	Lindsay Perlman, Associate Director			
Contact Telephone	202-416-7611			
Contact Email	LindsayP@pva.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	01-Jul-2022			
Synopsis	rehabilitative and assistive technology	es funding to aid in the design and develong the series for people with SCI/D to improvand utilization of these devices. The spoons	ve function, which also in	cludes
Applicant Types				
Funding Limit	0.00 see detail			
Limited Submission	No			
Medical Education Grant: Loca 102065 Increase Awareness & Underst Cardiomyopathy (ATTR-CM)	l Level Educational Grants Program to anding of Transthyretin Amyloid	Pfizer Pharmaceuticals	27-May-2022	20,000 USD



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Name	Amanda Stein, Grant Officer							
	Contact Telephone								
	Contact Email	amanda.j.stein@pfizer.com							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL	program URL						
	Deadline Dates (ALL)	27-May-2022 , 29-Jul-2022 , 30-Sep-2022	, 28-Oct-202	2					
	Synopsis	Pfizer is issuing this Request for Proposals level with Transthyretin Cardiomyopathy		ojects focused on improvir	ng the care of patier	nts on the local			
	Applicant Types								
	Funding Limit	20,000.00 maximum							
	Limited Submission	No							
110126	ASTRO-Myovant Sciences-Pfize Challenge	er Alliance New Combination Therapy	Pfizer Pharr	maceuticals	18-Jul-202	500,000 USD			
	Contact Name								
	Contact Telephone								
	Contact Email	science@astro.org							
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	18-Jul-2022							
	Synopsis	The American Society of Radiation Oncolonew collaborative research opportunities the Myovant Sciences-Pfizer Alliance in thindividual project grant is up to US\$500,0	, and to facili ne space of m	itate radiation oncology lea	adership in scientific	discovery with			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types				
	Funding Limit	500,000.00 see detail			
	Limited Submission	No			
		prove the Treatment of Advanced or	Pfizer Pharmaceuticals	07-Jul-202	300,000
	Metastatic Bladder Cancer Pati	ients Request for Proposals (RFP)	1 Hzer i Harmaceuticais	07 341 202	USD
	Contact Name	Jacqueline Waldrop, Grant Officer			
	Contact Telephone				
	Contact Email	Jacqueline.Waldrop@pfizer.com			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	07-Jul-2022 , 18-Aug-2022			
	Synopsis	The National Comprehensive Cancer Net opportunity to support Quality Improver concordant care, and best practices arou	nent projects that will advance t	he quality of care, including	guideline
	Applicant Types				
	Funding Limit	300,000.00 see detail			
	Limited Submission	No			
077263	Medical Research Grant		Progeria Research Foundation	01-Jul-202 [LOI/Pre-A	75 000 HSD
	Contact Name				
	Contact Telephone	978- 535-2594			
	Contact Email	researchgrants@progeriaresearch.org			
	Sponsor Website	<u>Link to sponsor website</u>			



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2022 [LOI/Pre-App], 03-Oct-2022				
	Synopsis	The Progeria Research Foundation (PRF) is and its aging-related disorders, including for the equivalent to submit applications for \$75,000 per year.	neart disease	e. The PRF invites qualified	scientists with fact	ulty appointments
	Applicant Types	,				
	Funding Limit	75,000.00 see detail				
	Limited Submission	No				
035362	PCF Challenge Award		Prostate Ca	ncer Foundation	01-Jul-20	1,000,000 USD
	Contact Name					
	Contact Telephone	310-570-4700				
	Contact Email	applications@pcf.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jul-2022				
	Synopsis	The Prostate Cancer Foundation (PCF) is p Challenge Awards for investigations of me the level of innovation in applications rece institutions around the world.	tastatic, leth	nal prostate cancer. These	awards will be fund	ded depending on
	Applicant Types	;				
	Funding Limit	1,000,000.00 maximum				
	Limited Submission	No				



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	unding Amour
058301 Research Grants		PSC Partners Seeking a Cure	16-May-20	Not Specified
Contact Name				
Contact Telephone	303-771-5227			
Contact Emai	contactus@pscpartners.org			
Sponsor Website	Link to sponsor website			
Program URI	Link to program URL			
Deadline Dates (ALL)	16-May-2022 , 18-Jul-2022			
	DCC Dartners offers grants to conduc		and novel basic or clinic	al research
Synopsis	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal t	et research that addresses an important associated diseases (such as inflammato Grants Program seeks to encourage inv that data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso	nd earch in
Applicant Types	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to	associated diseases (such as inflammato Grants Program seeks to encourage inv	ory bowel diseases (IBD) a estigators to conduct reso	nd earch in
Applicant Types	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal t	associated diseases (such as inflammato Grants Program seeks to encourage inv	ory bowel diseases (IBD) a estigators to conduct reso	nd earch in
Applicant Types	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail	associated diseases (such as inflammato Grants Program seeks to encourage inv	ory bowel diseases (IBD) a estigators to conduct reso	nd earch in
Applicant Types Funding Limit Limited Submission	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail	associated diseases (such as inflammato Grants Program seeks to encourage inv	ory bowel diseases (IBD) a estigators to conduct reso	earch in ional funding.
Applicant Types Funding Limit Limited Submission	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail	associated diseases (such as inflammato Grants Program seeks to encourage inv hat data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso (NIH) or external internat 15-Jun-202	earch in ional funding.
Applicant Types Funding Limit Limited Submission 070888 RPB Stein Innovation Awards	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail  No  Pattie Moran	associated diseases (such as inflammato Grants Program seeks to encourage inv hat data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso (NIH) or external internat 15-Jun-202	earch in ional funding.
Applicant Types Funding Limit Limited Submission 070888 RPB Stein Innovation Awards Contact Name	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail  No  Pattie Moran	associated diseases (such as inflammato Grants Program seeks to encourage inv hat data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso (NIH) or external internat 15-Jun-202	earch in ional funding.
Applicant Types Funding Limit Limited Submission  070888 RPB Stein Innovation Awards  Contact Name Contact Telephone Contact Email	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail No  Pattie Moran 646-892-9566	associated diseases (such as inflammato Grants Program seeks to encourage inv hat data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso (NIH) or external internat 15-Jun-202	earch in ional funding.
Applicant Types Funding Limit Limited Submission  070888 RPB Stein Innovation Awards  Contact Name Contact Telephone Contact Email	question related to PSC and closely a cholangiocarcinoma). The Research promising new areas, with the goal to 0.00 see detail No  Pattie Moran 646-892-9566 pmoran@rpbusa.org	associated diseases (such as inflammato Grants Program seeks to encourage inv hat data generated will lead to federal	ory bowel diseases (IBD) a estigators to conduct reso (NIH) or external internat 15-Jun-202	earch in ional funding.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Fund	ing Amount
	Synopsis	The RPB Stein Innovation (SI) Awards provide understanding the visual system and the disc provide seed money to proposed high-risk/h demonstrates out-of-the-box thinking.	eases that compromise its function.	These SI Awards are	e inter	nded to
	Applicant Types					
	Funding Limit	300,000.00 maximum				
	Limited Submission	No				
006942 <u>Ca</u>	reer Development Awards	Re	esearch to Prevent Blindness	15-Jun-20 [LOI/Pre-		350,000 USD
	Contact Name	Pattie Moran, Director of Grants Administrat	tion			
	Contact Telephone	646-892-9566				
	Contact Email	pmoran@rpbusa.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Jun-2022 [LOI/Pre-App], 01-Jul-2022				
	Synopsis	The RPB Career Development Award helps R ophthalmology faculty who have demonstra payable for up to four years upon approval of the second sec	ted their potential for independent	research. The \$350,	•	
	Applicant Types					
	Funding Limit	350,000.00 maximum				
	Limited Submission	No				
002115 <u>lnv</u>	vestigator Award	Rh	neumatology Research Foundation	01-Jun-20 [LOI/Pre-		375,000 USD



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Fundii	ng Amount
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rh	eumatology.org					
	Sponsor Website	Link to sponsor	<u>website</u>					
	Program URL	Link to program	<u>ı URL</u>					
	Deadline Dates (ALL)	01-Jun-2022 [L0	OI/Pre-App], 01-Jul-2022					
	Synopsis	developing a pr postdoctoral fe engaged in rese	oject that will be competi llowship. The purpose is to	tive for NIH a o provide sup matic disease	with a faculty appointmen ind/or equivalent funding. iport for basic science, trail is for the period between ent investigator.	It is not intended to nslational, and clinic	be a scal inve	second estigators
	Applicant Types							
	Funding Limit	375,000.00 max	ximum					
	Limited Submission	No						
000622	Scientist Development Award			Rheumatolo	ogy Research Foundation	01-Jun-20 [LOI/Pre-/		Not Specified
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	foundation@rh	eumatology.org					



Sponsor Website
Program URL
Link to sponsor website
Link to program URL

Deadline Dates (ALL) 01-Jun-2022 [LOI/Pre-App], 01-Jul-2022

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline	Date Fund	ing Amount
	Synopsis	This award is designed for individuals in prior research experience who plan to e provide support for a structured research rheumatology.	mbark on careers in rheumatic diseases.	The purpo	ose of this awa	rd is to
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
095001 <u>I</u>	nnovative Research Award		Rheumatology Research Foundation		01-Jun-2022 [LOI/Pre-App]	400,000 USD
	Contact Name					
	Contact Telephone	404-365-1373				
	Contact Email	foundation@rheumatology.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Jun-2022 [LOI/Pre-App], 01-Jul-2022				
	Synopsis	The Innovative Research Award provide into the cause, progression, treatment, is up to \$400,000 for two years (maximu	and outcomes of rheumatic and musculc		•	•
	Applicant Types					
	Funding Limit	400,000.00 maximum				
	Limited Submission	No				
048368	Royal-Mach-Gaensslen Prize fo	or Mental Health Research	Royal's Institute of Mental Health Res	earch 1	15-Jul-2022	77,000 USD
	Contact Name					



SPIN ID	Program Title		Sponsor Name	S	ponsor Number	<b>Deadline Date</b>	Funding Amount
	Contact Telephone	613-722-6521					
	Contact Email	research.award	s@theroyal.ca				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	15-Jul-2022					
	Synopsis	rising star researesearch intere researchers wit imagination and	Royal-Mach-Gaensslen Prize for ircher in the field of mental hearsts and goals. The annual nation had demonstrated track record doriginality; and a clear ability institution with which they are	alth, to rec nal prize p in researc to work in	cognize, encourage and so provides \$100,000 in functions; ch; excellence in scientifi partnership with other	support them as the ding to Canadian eactive to crigor, innovative t	ey pursue their arly-career thinking,
	Applicant Types						
	Funding Limit	100,000.00 max	kimum				
	Limited Submission	No					
046418	Science & SciLifeLab Prize for Y	oung Scientists	Scie	nce		15-Jul-20	22 30,000 USD
	Contact Name						
	Contact Telephone	202-326-6417					
	Contact Email	<u>SciLifeLabPrize(</u>	@aaas.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	ı URL				
	Deadline Dates (ALL)						
	Synopsis	This prize is awa	arded annually to one young so a doctoral degree in the previo	ientist for us two yea	outstanding life science or s. The topic of the entr	research for which ant's thesis researc	they ch must be in one



SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date F	unding Amount
	of the following categories: Cell and Mole approaches; Ecology and Environment; ar		and Systems Biology	
Applicant Types				
Funding Limit	30,000.00 maximum			
Limited Submission	No			
084126 <u>Travel Scholarships</u>		Society for Advancement of Chicanos Native Americans in Science	and 24-May-20	Not Specified
Contact Name				
Contact Telephone	831-459-0170			
Contact Email	travelscholarships@sacnas.org			
Sponsor Website	Link to sponsor website			
Program URL	Link to program URL			
Deadline Dates (ALL)	24-May-2022 , 08-Jul-2022 , 22-Aug-2022			
Synopsis	SACNAS-provided conference scholarship SACNAS National Diversity in STEM Confe support from SACNAS, as well as specializ	rence. Accepted awardees will have ac	cess to conference re	gistration
Applicant Types				
Funding Limit	0.00 not provided			
Limited Submission	No			
066849 Mentored Clinical Scientist Res	search Career Development Award (K08)	Society for Vascular Surgery	12-Jun-202	Not Specified
Contact Name	Jane D. Scott			
Contact Telephone	301-435-0535			



SPIN ID Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
Contact Emai	l scottj2@nhlbi.r	nih.gov					
Sponsor Website	Link to sponsor	<u>website</u>					
Program UR	Link to program	<u>ı URL</u>					
Deadline Dates (ALL	) 12-Jun-2022 , 1	2-Jul-2022 , 12-Oct-2022 , 12-No	v-2022				
Synopsi	development o	he SVS Foundation offers this award in partnership with the NHLBI as a means to facilitate the research career evelopment of individuals pursuing a career in vascular research. This award provides financial support over and bove that offered by the NHLBI KO8 mechanism.					
Applicant Type	s						
Funding Limi	t 0.00 see detail						
Limited Submission	n No						
001382 St. Baldrick's Scholars (Career	Development Aw	vard) St. Ba	ldrick's Foundation	08-Jul-20 [LOI/Pre-/	,		
Contact Name	Laura Chung, D	irector of Grants Administration					
Contact Telephone	626-792-8247 x	(236					
Contact Emai	l <u>Laura@StBaldri</u>	icks.org					
Sponsor Website	Link to sponsor	<u>website</u>					
Program UR	Link to program	<u>ı URL</u>					
Deadline Dates (ALL	) 08-Jul-2022 [LO	01/Pre-App], 26-Aug-2022					
Synopsi	research of high post-fellowship	's Scholars program is a career de hly-qualified individuals still early ). This is an early-career award. The careers of highly qualified inves	in their careers (no more than he Scholar award is intended to	seven years as a factor develop the indepe	ulty member, endent pediatric		
Applicant Type	s						
Funding Limi	t 110,000.00 per	year					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Limited Submission	Yes			
024280	SFIAR Award		Swiss Forum for International Agricult Research	tural 14-Jul-202	2 Not Specified
	Contact Name				
	Contact Telephone	+41(0)31 910 21 91			
	Contact Email	info@sfiar.ch			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	14-Jul-2022			
	Synopsis	The Swiss Forum for International Agricultural research carried out at or in close collaboration windividuals) located in developing countries.	for development. Eligible for the SFIAR vith a Swiss institution and has involved	Award is research th	at has been
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
067677 <u>(</u>	Grants Program		The Gibbs Family Foundation	01-Jul-202 [LOI/Pre-A	10 000 1150
	Contact Name				
	Contact Telephone	773-332-0323			
		info@thegibbsfamilyfoundation.org			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			



Deadline Dates (ALL) 01-Jul-2022 [LOI/Pre-App], 01-Oct-2022  Currently, TGFF seeks to expand its services to the community, in particular individuals at risk of contracting or developing rare diseases such as infectious diseases, certain cancers, and neurological conditions (see a sample list of diseases funded by the organization). TGFF is implementing an outreach and educational program targeting that population in the Midwest: IL, IN, WI, MN, OH, and MI.  Applicant Types Funding Limit 10,000.00 maximum  Limited Submission No  University of Alabama at Birmingham 18-Jul-2022 Not Specified  Contact Name Contact Telephone 205-934-4993 Contact Email norwoodawd@uab.edu Sponsor Website Link to sponsor website Program URL Link to program URL Deadline Dates (ALL) 18-Jul-2022 The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit 0.00 see detail Limited Submission No	SPIN ID	Program Title	Sponsor Nam	e	Sponsor Number	<b>Deadline Date</b>	Funding Amount
developing rare diseases such as infectious diseases, certain cancers, and neurological conditions (see a sample list of diseases funded by the organization). TGFF is implementing an outreach and educational program targeting that population in the Midwest: IL, IN, WI, MN, OH, and MI.  Applicant Types Funding Limit Limited Submission No  University of Alabama at Birmingham 18-Jul-2022  Contact Name Contact Telephone Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) 18-Jul-2022 The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a swoman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit 0.00 see detail		Deadline Dates (ALL)	01-Jul-2022 [LOI/Pre-App], 01-	Oct-2022			
Funding Limit 10,000.00 maximum   No   No   No   No   No   No   No   N		Synopsis	developing rare diseases such as infectious diseases, certain cancers, and neurological conditions (see a sample list of diseases funded by the organization). TGFF is implementing an outreach and educational program targeting that				
Limited Submission No  013748 Janet L. Norwood Award  Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis Synopsis Funding Limit  Limit to Sponsor Website Link to program URL Synopsis Synopsis Synopsis Funding Limit  Limit to program URL Synopsis Synopsis Synopsis Synopsis Funding Limit  O.00 see detail		Applicant Types					
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis Funding Limit  O.00 see detail  Deadline Dates (ALL)  Applicant Types Funding Limit  O.00 see detail		Funding Limit	10,000.00 maximum				
Contact Name Contact Telephone Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis  Synopsis  Applicant Types Funding Limit  Oniversity of Alabama at Birmingham  18-Jul-2022 Specified  Specified  Specified  Specified  Oniversity of Alabama at Birmingham  18-Jul-2022 Specified  Specified  Specified  Specified  Oniversity of Alabama at Birmingham  18-Jul-2022 Specified  Specified  Oniversity of Alabama at Birmingham  18-Jul-2022 Specified  Specified  Oniversity of Alabama at Birmingham  18-Jul-2022 Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Oniversity of Alabama at Birmingham  In It alies of Specified  Oniversity of Alabama at Birmingham  Oniversity of Specified  Oniversity of Alabama at Birmingham		Limited Submission	No				
Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis  Synopsis  Applicant Types Funding Limit  205-934-4993  norwoodawd@uab.edu Link to sponsor website Link to sponsor website Link to program URL Link to program URL  18-Jul-2022  The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  O.00 see detail	013748	lanet L. Norwood Award		University o	of Alabama at Birmingham	18-Jul-20	122
Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis Synopsis  Applicant Types Funding Limit  Deadwig@uab.edu Link to sponsor website Link to program URL Link to program URL 18-Jul-2022 The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  0.00 see detail		Contact Name					
Sponsor Website Program URL Deadline Dates (ALL) Synopsis Synopsis Synopsis Applicant Types Funding Limit  Link to sponsor website Link to program URL 18-Jul-2022 The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit		Contact Telephone	205-934-4993				
Program URL Deadline Dates (ALL)  The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit  O.00 see detail		Contact Email	norwoodawd@uab.edu				
Deadline Dates (ALL)  18-Jul-2022  The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types  Funding Limit  0.00 see detail		Sponsor Website	Link to sponsor website				
The School of Public Health is pleased to present the Janet L. Norwood Award for outstanding achievement by a woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit  O.00 see detail	Program URL		Link to program URL				
Synopsis woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also to recognize the contribution of all women to the statistical sciences.  Applicant Types Funding Limit 0.00 see detail	Deadline Dates (ALL)		18-Jul-2022				
Funding Limit 0.00 see detail		Synopsis woman in the statistical sciences. The school wishes not only to recognize Dr. Norwood's achievements, but also t					
		Applicant Types					
Limited Submission No		Funding Limit	0.00 see detail				
		Limited Submission	No				

